<SEC-DOCUMENT>0001104659-24-053089.txt : 20240426
<SEC-HEADER>0001104659-24-053089.hdr.sgml : 20240426
<ACCEPTANCE-DATETIME>20240426171415
ACCESSION NUMBER:		0001104659-24-053089
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20240611
FILED AS OF DATE:		20240426
DATE AS OF CHANGE:		20240426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MAXCYTE, INC.
		CENTRAL INDEX KEY:			0001287098
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				522210438
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40674
		FILM NUMBER:		24885228

	BUSINESS ADDRESS:	
		STREET 1:		9713 KEY WEST AVENUE,
		STREET 2:		SUITE 400
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-517-5556

	MAIL ADDRESS:	
		STREET 1:		9713 KEY WEST AVENUE,
		STREET 2:		SUITE 400
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MAXCYTE INC
		DATE OF NAME CHANGE:	20040415
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>tm242951-1_def14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<html>
  <head>
    <title>tm242951-1_def14a - none - 10.1250388s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">UNITED STATES </font>
          <br >
          <font style="letter-spacing:-0.28pt;">SECURITIES AND EXCHANGE COMMISSION </font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Washington, D.C. 20549</font><font style="font-weight:normal;font-size:14pt;">&#8203;<font style="letter-spacing:0.28pt;"> </font></font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">SCHEDULE 14A</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proxy Statement Pursuant to Section&#160;14(a) of the </font>
          <br >
          <font style="letter-spacing:-0.2pt;">Securities Exchange Act of 1934</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Filed by the Registrant&nbsp;&nbsp;&nbsp;&#9746; </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Filed by a Party other than the Registrant&nbsp;&nbsp;&nbsp;&#9744; </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Check the appropriate box: </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9744;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Preliminary Proxy Statement </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9744;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Confidential, for Use of the Commission Only (as permitted by Rule&#160;14a-6(e)(2)) </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9746;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Definitive Proxy Statement </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9744;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Definitive Additional Materials </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9744;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Soliciting Material under &#167;240.14a-12 </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:20pt;font-weight:bold;font-size:18pt;">
          <font style="letter-spacing:-0.36pt;">MaxCyte, Inc.</font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(Name of Registrant as Specified In Its Charter)</font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Payment of Filing Fee (Check all boxes that apply): </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9746;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">No fee required </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9744;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Fee paid previously with preliminary materials </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#9744;</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Fee computed on table in exhibit required by Item&#160;25(b) per Exchange Act Rules 14a-6(i)(1) and 0- 11</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">MAXCYTE, INC. </font>
          <br >
          <font style="letter-spacing:0.2pt;">9713 Key West Avenue, Suite 400 </font>
          <br >
          <font style="letter-spacing:0.2pt;">Rockville, Maryland 20850 </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTICE OF ANNUAL MEETING OF STOCKHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">To Be Held On June&#160;11, 2024</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Dear Stockholder:</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">You are cordially invited to attend the 2024 Annual Meeting of Stockholders (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Annual Meeting</font><font style="letter-spacing:0.2pt;">&#8221;) of </font><font style="font-weight:bold;text-transform:uppercase;letter-spacing:-0.2pt;">M<font style="font-size:7pt;">ax</font>C<font style="font-size:7pt;">yte</font>, I<font style="font-size:7pt;">nc</font>.</font><font style="letter-spacing:0.2pt;">, a Delaware corporation (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">&#8221;). The Annual Meeting will be held on Tuesday, June&#160;11, 2024 at 11:00&#160;a.m. Eastern Time at 9713 Key West Avenue, Suite 400, Rockville, Maryland 20850. The meeting will be held for the following purposes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">1.</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To elect the Board&#8217;s three nominees as identified in the accompanying Proxy Statement as Class&#160;III directors: Will Brooke, John Johnston, and Richard Douglas. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To approve an amendment to the MaxCyte, Inc. 2022 Equity Incentive Plan to increase the shares of the Company&#8217;s common stock issuable thereunder by 2,300,000 shares. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">3.</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To ratify the Audit Committee&#8217;s selection of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December&#160;31, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">4.</font>
          <br >
        </div>
        <div style=" margin-top:7.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To conduct any other business properly brought before the meeting. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These items of business are more fully described in the Proxy Statement accompanying this Notice. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The record date for the Annual Meeting is April&#160;15, 2024. Only stockholders of record at the close of business on that date may vote at the meeting or any adjournment thereof. </font>
        </div>
        <table style="width:456pt;margin-top:10pt;border-collapse: collapse;border:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:12pt;white-space:normal;text-align:justify;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 1.333pt 0pt; width:450pt;">
              <div style="text-align:justify;">
                <font style="letter-spacing:-0.2pt;">Important Notice Regarding the Availability of Proxy Materials for the Stockholders&#8217; Meeting to Be Held on Thursday, June&#160;11, 2024 at 9713 Key West Avenue, Suite 400, Rockville, Maryland, 20850:</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:25.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:3pt;">&#8203;</td>
            <td style="border-bottom:0.75pt solid #000000; ;padding:9pt 0pt 8pt 0pt; width:450pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">The proxy statement and annual report to stockholders are available at www.proxyvote.com.</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:19.4pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">By Order of the Board of Directors </font>
        </div>
        <div style="position:relative;margin-top:9.9pt; width:456pt;">
          <img src="sg_davidsandoval-bw.jpg" alt="[MISSING IMAGE: sg_davidsandoval-bw.jpg]" height="63" width="227" >
        </div>
        <div style="margin-top:4.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">David Sandoval </font> <br ><font style="letter-spacing:0.2pt;">Senior Vice President, General </font> <br ><font style="letter-spacing:0.2pt;">Counsel and Corporate Secretary </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Rockville, Maryland </font> <br ><font style="letter-spacing:0.2pt;">April&#160;26, 2024 </font></div>
        <table style="width:456pt;margin-bottom:5.5pt;margin-top:10pt;border-collapse: collapse;border:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:12pt;min-height:94pt;white-space:normal;text-align:justify;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:3pt;">&#8203;</td>
            <td style="border-bottom:0.75pt solid #000000; ;padding:4.167pt 0pt 6pt 0pt; width:450pt;">
              <div style="margin-top:3.667pt; text-align:justify;">
                <font style="letter-spacing:-0.2pt;">You are cordially invited to attend the Annual Meeting in person. Whether or not you expect to attend the Annual Meeting, please complete, date, sign and return the enclosed proxy, or vote by telephone or the internet as instructed in these materials, as promptly as possible in order to ensure your representation at the meeting. A return envelope (which is postage prepaid if mailed in the United States) has been provided for your convenience. Even if you have voted by proxy, you may still vote in person if you attend the meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you must obtain a proxy issued in your name from that record holder.</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:0.75pt solid #000000; ; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRSU">&#8203;</a><a name="tMEEGA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:176.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">MAXCYTE, INC. </font>
          <br >
          <font style="letter-spacing:0.2pt;">9713 Key West Avenue, Suite 400 </font>
          <br >
          <font style="letter-spacing:0.2pt;">Rockville, Maryland 20850 </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROXY STATEMENT </font>
          <br >
          <font style="letter-spacing:-0.2pt;">FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">To Be Held On June&#160;11, 2024</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROXY SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In this Proxy Statement, we refer to MaxCyte, Inc. as the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">,&#8221; &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">MaxCyte</font><font style="letter-spacing:0.2pt;">,&#8221; &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">we</font><font style="letter-spacing:0.2pt;">,&#8221; or &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">us</font><font style="letter-spacing:0.2pt;">&#8221; and the Board of Directors as our &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Board</font><font style="letter-spacing:0.2pt;">.&#8221; This Proxy Summary highlights information contained elsewhere in this Proxy Statement in connection with the Company&#8217;s 2024 Annual Meeting of Stockholders (the </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">&#8220;Annual Meeting&#8221;</font><font style="letter-spacing:0.2pt;">). This Proxy Summary does not contain all of the information you should consider and you should read the entire Proxy Statement before voting. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">OVERVIEW OF PROPOSALS TO BE PRESENTED AT THE ANNUAL MEETING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;min-height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:165.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Proposals </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:16.67pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:165.59pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Voting Standard </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:72.15pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Board </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Recommendation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:47.25pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 8.833pt 0pt; width:165.59pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Election of the three Class&#160;III directors named in this Proxy Statement </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 8.833pt 0pt; width:16.67pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">6 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 8.833pt 0pt; width:165.59pt;text-align:justify;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">Plurality of shares present in person or represented by proxy and entitled to vote on the matter </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 8.833pt 0pt; width:72.15pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">FOR</font><font style="letter-spacing:0.2pt;">&#8221; each </font>
                <br >
                <font style="letter-spacing:0.2pt;">director nominee </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:10.167pt 0pt 8.833pt 0pt; width:165.59pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Approval of an amendment to the MaxCyte, Inc. 2022 Equity Incentive Plan (the </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">&#8220;2022 Plan&#8221;</font><font style="letter-spacing:0.2pt;">) to increase the number of shares of the Company&#8217;s common stock issuable thereunder by 2,300,000 shares. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:10.167pt 0pt 8.833pt 0pt; width:16.67pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">17</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:10.167pt 0pt 8.833pt 0pt; width:165.59pt;text-align:justify;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">Majority of shares present in person or represented by proxy and entitled to vote on the matter </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:10.167pt 0pt 8.833pt 0pt; width:72.15pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">FOR</font><font style="letter-spacing:0.2pt;">&#8221; </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:63pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:10.167pt 0pt 8.833pt 0pt; width:165.59pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Ratification of the selection of CohnReznick LLP as the Company&#8217;s independent registered public accounting firm for fiscal year 2024 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:10.167pt 0pt 8.833pt 0pt; width:16.67pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">27</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:10.167pt 0pt 8.833pt 0pt; width:165.59pt;text-align:justify;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">Majority of shares present in person or represented by proxy and entitled to vote on the matter </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:10.167pt 0pt 8.833pt 0pt; width:72.15pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">FOR</font><font style="letter-spacing:0.2pt;">&#8221;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:66.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:524.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRSU"><font style="letter-spacing:0.2pt;">PROXY SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPRSU">ii</a></font> <a href="#tPRSU"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMEEGA"><font style="letter-spacing:0.2pt;">MEETING AGENDA </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMEEGA">ii</a></font>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tQAAA"><font style="letter-spacing:0.2pt;">QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tQAAA">1</a></font> <a href="#tQAAA"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPR1"><font style="letter-spacing:0.2pt;">PROPOSAL 1 ELECTION OF DIRECTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPR1">6</a></font> <a href="#tPR1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:427.33pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tIRTB"><font style="letter-spacing:0.2pt;">INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIRTB">10</a></font> <a href="#tIRTB"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIOTB"><font style="letter-spacing:0.2pt;">Independence of the Board of Directors </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIOTB">10</a></font> <a href="#tIOTB"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tBLS"><font style="letter-spacing:0.2pt;">Board Leadership Structure </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tBLS">10</a></font> <a href="#tBLS"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tROTB"><font style="letter-spacing:0.2pt;">Role of the Board in Risk Oversight </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tROTB">10</a></font> <a href="#tROTB"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMOTB"><font style="letter-spacing:0.2pt;">Meetings of the Board of Directors </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMOTB">11</a></font> <a href="#tMOTB"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIRCO"><font style="letter-spacing:0.2pt;">Information Regarding Committees of the Board of Directors </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIRCO">11</a></font> <a href="#tIRCO"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tAUCO"><font style="letter-spacing:0.2pt;">Audit Committee </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tAUCO">11</a></font> <a href="#tAUCO"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tROTA"><font style="letter-spacing:0.2pt;">Report of the Audit Committee of the Board of Directors </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tROTA">12</a></font> <a href="#tROTA"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCOCO"><font style="letter-spacing:0.2pt;">Compensation Committee </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCOCO">12</a></font> <a href="#tCOCO"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tNACG"><font style="letter-spacing:0.2pt;">Nominating and Corporate Governance Committee </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tNACG">14</a></font> <a href="#tNACG"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCWTB"><font style="letter-spacing:0.2pt;">Communications With the Board of Directors </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCWTB">15</a></font> <a href="#tCWTB"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCOE"><font style="letter-spacing:0.2pt;">Code of Ethics </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCOE">15</a></font> <a href="#tCOE"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCGG"><font style="letter-spacing:0.2pt;">Corporate Governance Guidelines </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCGG">15</a></font> <a href="#tCGG"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tHEPO"><font style="letter-spacing:0.2pt;">Hedging Policy </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tHEPO">16</a></font> <a href="#tHEPO"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tPR2"><font style="letter-spacing:0.2pt;">PROPOSAL 2 APPROVAL OF AN AMENDMENT TO THE 2022 EQUITY INCENTIVE </font>
                  <br >
                  <font style="letter-spacing:0.2pt;">PLAN </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPR2">17</a></font> <a href="#tPR2"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSAFI"><font style="letter-spacing:0.2pt;">Securities Authorized for Issuance Under Equity Compensation Plans </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSAFI">26</a></font> <a href="#tSAFI"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:427.33pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tPR3"><font style="letter-spacing:0.2pt;">PROPOSAL 3 RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPR3">27</a></font> <a href="#tPR3"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXOF"><font style="letter-spacing:0.2pt;">EXECUTIVE OFFICERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXOF">28</a></font> <a href="#tEXOF"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDS1R"><font style="letter-spacing:0.2pt;">DELINQUENT SECTION 16(A) REPORTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDS1R">29</a></font> <a href="#tDS1R"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSOOC"><font style="letter-spacing:0.2pt;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSOOC">30</a></font> <a href="#tSOOC"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXCO"><font style="letter-spacing:0.2pt;">EXECUTIVE COMPENSATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXCO">32</a></font> <a href="#tEXCO"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDICO"><font style="letter-spacing:0.2pt;">Director Compensation </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDICO">37</a></font> <a href="#tDICO"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTWRP"><font style="letter-spacing:0.2pt;">TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTWRP">39</a></font> <a href="#tTWRP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRTPA"><font style="letter-spacing:0.2pt;">Related-Person Transactions Policy and Procedures </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRTPA">39</a></font> <a href="#tRTPA"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCRT"><font style="letter-spacing:0.2pt;">Certain Related-Person Transactions </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCRT">39</a></font> <a href="#tCRT"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tINAG"><font style="letter-spacing:0.2pt;">Indemnification Agreements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tINAG">40</a></font> <a href="#tINAG"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tHOPM"><font style="letter-spacing:0.2pt;">HOUSEHOLDING OF PROXY MATERIALS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tHOPM">41</a></font> <a href="#tHOPM"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tOTMA"><font style="letter-spacing:0.2pt;">OTHER MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tOTMA">42</a></font>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">iii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tQAAA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Why am I receiving these materials?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have sent you these proxy materials because the Board is soliciting your proxy to vote at the Annual Meeting, including at any adjournments or postponements thereof. You are invited to attend the Annual Meeting to vote on the proposals described in this Proxy Statement. However, you do not need to attend the Annual Meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed proxy card, or follow the instructions below to submit your proxy by telephone or on the internet. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We intend to mail these proxy materials on or about April&#160;26, 2024 to all stockholders of record entitled to vote at the Annual Meeting. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How do I attend the Annual Meeting?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The meeting will be held on Tuesday, June&#160;11, 2024 at 11:00&#160;a.m. Eastern Time at 9713 Key West Avenue, Suite 400, Rockville, Maryland 20850. Information on how to vote in person at the Annual Meeting is discussed below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Who can vote at the Annual Meeting?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Only stockholders of record at the close of business on April&#160;15, 2024 will be entitled to vote at the Annual Meeting. On the record date, there were 104,518,803 shares of common stock outstanding and entitled to vote. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Stockholder of Record: Shares Registered in Your Name</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If on April&#160;15, 2024 your shares were registered directly in your name with MaxCyte&#8217;s transfer agent, Computershare Trust Company N.A., then you are a stockholder of record. As a stockholder of record, you may vote in person at the meeting or vote by proxy. Whether or not you plan to attend the meeting, we urge you to fill out and return the enclosed proxy card or vote by proxy by telephone or on the internet as instructed below to ensure your vote is counted. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Beneficial Owner: Shares Registered in the Name of a Broker or Bank</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If on April&#160;15, 2024 your shares were held, not in your name, but rather in an account at a brokerage firm, bank or other similar organization, then you are the beneficial owner of shares held in &#8220;street name&#8221; and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker, bank, or other agent regarding how to vote the shares in your account. You are also invited to attend the Annual Meeting. However, since you are not the stockholder of record, you may not vote your shares in person at the meeting unless you request and obtain a valid proxy from your broker, bank, or other agent. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What am I voting on?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There are three matters scheduled for a vote: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Election of the three Class&#160;III directors named in this Proxy Statement (Proposal 1); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Approval of an amendment to the 2022 Plan to increase the number of shares of the Company&#8217;s common stock issuable thereunder by 2,300,000 shares (Proposal 2); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Ratification of the Audit Committee&#8217;s selection of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December&#160;31, 2024 (Proposal 3). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What if another matter is properly brought before the meeting?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on those matters in accordance with their best judgment. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How do I vote?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">You may either vote &#8220;For&#8221; all the nominees to the Board or you may &#8220;Withhold&#8221; your vote for any nominee you specify. For each of the other matters to be voted on, you may vote &#8220;For&#8221; or &#8220;Against&#8221; the applicable proposal or abstain from voting. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The procedures for voting are as follows: </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Stockholder of Record: Shares Registered in Your Name</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you are a stockholder of record, you may vote at the Annual Meeting, vote by proxy using the enclosed proxy card, vote by proxy over the telephone or vote by proxy on the internet. Whether or not you plan to attend the meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the meeting and vote at the meeting even if you have already voted by proxy. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To vote in person, come to the Annual Meeting and we will give you a ballot when you arrive. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To vote </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">prior</font><font style="letter-spacing:0.2pt;"> to the Annual Meeting (until 11:59&#160;p.m. Eastern Time on Monday, June&#160;10, 2024), you may vote on the internet, by telephone or by completing and returning the proxy card or voting instruction form, each as described below. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:50pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To vote on the </font><font style="font-weight:bold;letter-spacing:-0.2pt;">internet</font><font style="letter-spacing:0.2pt;"> prior to the meeting, go to www.proxyvote.com and follow the instructions to submit your vote on an electronic proxy card. You will be asked to provide the company number and Control Number from the Notice. Your internet vote must be received by 11:59&#160;p.m. Eastern Time on Monday, June&#160;10, 2024 to be counted. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:50pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To vote by </font><font style="font-weight:bold;letter-spacing:-0.2pt;">telephone</font><font style="letter-spacing:0.2pt;">, dial toll-free 1-800-690-6903 using a touch-tone phone and follow the recorded instructions. You will be asked to provide the company number and Control Number from the </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Notice</font><font style="letter-spacing:0.2pt;">. Your telephone vote must be received by 11:59&#160;p.m. Eastern Time on Monday, June&#160;10, 2024 to be counted. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:50pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To vote using the </font><font style="font-weight:bold;letter-spacing:-0.2pt;">proxy card</font><font style="letter-spacing:0.2pt;">, simply complete, sign and date the enclosed proxy card and return it promptly in the envelope provided. If you return your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct. You should mail your signed proxy card sufficiently in advance for it to be received by Monday, June&#160;10, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Beneficial Owner: Shares Registered in the Name of Broker or Bank</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you should have received a voting instruction form with these proxy materials from that organization rather than from MaxCyte. Simply complete and mail the voting instruction form to ensure that your vote is counted. Alternatively, you may vote by telephone or on the internet as instructed by your broker or bank. To vote at the Annual Meeting, you may be required to obtain a valid proxy from your broker, bank, or other agent. Follow the instructions from your broker, bank, or other agent included with these proxy materials, or contact that organization to request a proxy form. </font>
        </div>
        <table style="width:456pt;height:56pt;margin-top:10pt;border-collapse: collapse;border-top:0.75pt solid #000000; border-left:0.75pt solid #000000; border-right:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:12pt;white-space:normal;text-align:justify;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:4.167pt 0pt 1.583pt 0pt; width:450pt;">
              <div style="text-align:justify;">
                <font style="letter-spacing:-0.2pt;">Internet proxy voting is provided to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies.</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:3pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How many votes do I have?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On each matter to be voted upon, you have one vote for each share of common stock you owned as of April&#160;15, 2024, which is the record date for the Annual Meeting. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If I am a stockholder of record and I do not vote, or if I return a proxy card or otherwise vote without giving specific voting instructions, what happens?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you are a stockholder of record and do not vote by completing your proxy card, by telephone, on the internet or in person at the Annual Meeting, your shares will not be voted. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, &#8220;For&#8221; the election of all three nominees for director (Proposal 1), &#8220;For&#8221; the approval of an amendment to the 2022 Plan (Proposal 2) and &#8220;For&#8221; the ratification of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December&#160;31, 2024 (Proposal 3). If any other matter is properly presented at the meeting, your proxyholder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If I am a beneficial owner of shares held in street name and I do not provide my broker or bank with voting instructions, what happens, and what is a &#8220;broker non-vote&#8221;?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you are a beneficial owner of shares held in street name and you do not instruct your broker, bank, or other agent how to vote your shares, your broker, bank, or other agent may still be able to vote your shares in its discretion. In this regard, under applicable rules, brokers, banks and other securities intermediaries may use their discretion to vote your &#8220;uninstructed&#8221; shares with respect to matters considered to be &#8220;routine&#8221; under such rules, but not with respect to &#8220;non-routine&#8221; matters. Proposals 1 and 2 are considered to be &#8220;non- routine&#8221; under such rules, meaning that your broker may not vote your shares on these proposals in the absence of your voting instructions. However, Proposal 3 is considered to be &#8220;routine&#8221; under such rules, meaning that if you do not return voting instructions to your broker by its deadline, your shares may be voted by your broker in its discretion on Proposal 3 and a &#8220;broker non-vote&#8221; will occur as to the other proposals. Broker non-votes will have no impact on the voting results. Because Proposal 3 is considered &#8220;routine,&#8221; there will not be any broker non-votes on this proposal. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If you are a beneficial owner of shares held in street name, and you do not plan to attend the meeting, in order to ensure your shares are voted in the way you would prefer, you </font><font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">must</font><font style="letter-spacing:-0.2pt;"> provide voting instructions to your broker, bank, or other agent by the deadline provided in the materials you receive from your broker, bank or other agent.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Who is paying for this proxy solicitation?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will pay for the entire cost of soliciting proxies. In addition to these proxy materials, our directors and employees may also solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have engaged D.F. King &amp; Co., Inc. </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">(&#8220;D.F. King&#8221;)</font><font style="letter-spacing:0.2pt;"> to assist us in the solicitation of proxies for the Annual Meeting. We expect to pay D.F. King a fee of approximately $25,000 plus out-of-pocket expenses. You may contact D.F. King at: </font>
        </div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">United Kingdom</font><font style="letter-spacing:0.2pt;">: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">United States</font><font style="letter-spacing:0.2pt;">: </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 1pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">D.F. King Ltd </font>
              <br >
              <font style="letter-spacing:0.2pt;">65 Gresham St, </font>
              <br >
              <font style="letter-spacing:0.2pt;">London EC2V 7NQ, United Kingdom </font>
              <br >
              <font style="letter-spacing:0.2pt;">Email: proxy@dfkingltd.com </font>
              <br >
              <font style="letter-spacing:0.2pt;">Telephone: +44 20 7920 9700 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 1pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">D.F. King &amp; Co., Inc. </font>
              <br >
              <font style="letter-spacing:0.2pt;">48 Wall Street, 22nd Floor </font>
              <br >
              <font style="letter-spacing:0.2pt;">New York, NY 10005 </font>
              <br >
              <font style="letter-spacing:0.2pt;">Email: mxct@dfking.com </font>
              <br >
              <font style="letter-spacing:0.2pt;">Telephone: +1 212 269 5550</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.9pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What does it mean if I receive more than one set of proxy materials?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you receive more than one set of proxy materials, your shares may be registered in more than one name or in different accounts. Please follow the voting instructions on the proxy cards in the proxy materials to ensure that all of your shares are voted. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Can I change my vote after submitting my proxy?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Stockholder of Record: Shares Registered in Your Name</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Yes. You can revoke your proxy at any time before the final vote at the Annual Meeting. If you are the record holder of your shares, you may revoke your proxy in any one of the following ways: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">You may submit another properly completed proxy card with a later date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">You may grant a subsequent proxy by telephone or on the internet. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">You may send a timely written notice that you are revoking your proxy to MaxCyte&#8217;s Corporate Secretary at 9713 Key West Avenue, Suite 400, Rockville, Maryland 20850. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">You may attend the Annual Meeting and vote in person. Simply attending the meeting will not, by itself, revoke your proxy. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:7.12pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Your most current proxy card or telephone or internet proxy is the one that is counted. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Beneficial Owner: Shares Registered in the Name of Broker or Bank</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If your shares are held by your broker, bank, or other agent, you should follow the instructions provided by that organization. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">When are stockholder proposals and director nominations due for next year&#8217;s Annual Meeting?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For a stockholder proposal to be considered for inclusion in next year&#8217;s proxy materials, your proposal must be submitted in writing by December&#160;27, 2024, to our Corporate Secretary at 9713 Key West Avenue, Suite 400, Rockville, Maryland 20850, and must otherwise comply with the requirements set forth in Rule&#160;14a-8. If you wish to nominate an individual for election at, or bring business other than through a stockholder proposal before, the 2025 Annual Meeting of Stockholders, you must deliver your notice to our Corporate Secretary at the address above between February&#160;11, 2025 and March&#160;13, 2025. Your notice to the Corporate Secretary must set forth information specified in our Amended and Restated Bylaws (the </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">&#8220;Bylaws&#8221;</font><font style="letter-spacing:0.2pt;">). In addition, stockholders who intend to solicit proxies in support of director nominees other than our Board&#8217;s nominees must also comply with the additional requirements of the SEC&#8217;s Rule&#160;14a-19(b) and provide the applicable notice by April&#160;14, 2025. Your notice to the Corporate Secretary must set forth information specified in our Bylaws, including your name and address and the number of shares of our stock that you beneficially own. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For more information, and for more detailed requirements, please refer to our Bylaws, filed as an exhibit to our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">SEC</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How are votes counted?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Votes will be counted by the inspector of election appointed for the meeting, who will be from American Election Services, LLC. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How many votes are needed to approve each proposal?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For the election of directors (Proposal 1), the three nominees receiving the most &#8220;For&#8221; votes from the holders of shares present in person or represented by proxy and entitled to vote on the election of directors will be elected. Only votes &#8220;For&#8221; will affect the outcome. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To be approved, Proposal 2 (approval of an amendment to the 2022 Plan to increase the number of shares of the Company&#8217;s common stock issuable thereunder) must receive &#8220;For&#8221; votes from the holders of a majority of shares present in person or represented by proxy and entitled to vote on the matter. If you mark your proxy to &#8220;Abstain&#8221; from voting, it will have the same effect as an &#8220;Against&#8221; vote. Broker non-votes will have no effect. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To be approved, Proposal 3 (ratification of the selection of CohnReznick LLP as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2024) must receive &#8220;For&#8221; votes from the holders of a majority of shares present in person or represented by proxy and entitled to vote on the matter. If you mark your proxy to &#8220;Abstain&#8221; from voting, it will have the same effect as an &#8220;Against&#8221; vote. Since brokers have authority to vote on your behalf with respect to Proposal 3, there will not be any broker non-votes on this proposal. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What is the quorum requirement?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding at least a majority of the outstanding shares entitled to vote are present at the meeting or represented </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:424pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">by proxy. On the record date, there were 104,518,803 shares outstanding and entitled to vote. Thus, the holders of 52,259,402 shares must be present in person or represented by proxy at the meeting to have a quorum. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote at the meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum, either the chairperson of the meeting or the holders of a majority of shares present at the meeting or represented by proxy may adjourn the meeting to another date. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How can I find out the results of the voting at the Annual Meeting?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a Current Report on Form 8-K that we expect to file within four business days after the Annual Meeting. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What proxy materials are available on the internet?</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Proxy Statement and annual report to stockholders are available at www.proxyvote.com.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPR1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROPOSAL 1</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ELECTION OF DIRECTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">MaxCyte&#8217;s Board is divided into three classes. Each class has a three-year term. Vacancies on the Board may be filled only by persons elected by a majority of the remaining directors. A director elected by the Board to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director&#8217;s successor is duly elected and qualified. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Board presently has nine members. There are three directors in Class&#160;III whose term of office expires in 2024. Each of the three nominees listed below is currently a director of the Company, and each of whom was previously elected by stockholders. If elected at the Annual Meeting, each of these three nominees would serve until the 2027 annual meeting and until his successor has been duly elected and qualified, or, if sooner, until the director&#8217;s death, resignation or removal. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Directors are elected by a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote on the election of directors. Accordingly, the three nominees receiving the highest number of affirmative votes will be elected. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the three nominees named below. If any nominee becomes unavailable for election as a result of an unexpected occurrence, shares that would have been voted for that nominee will instead be voted for the election of a substitute nominee proposed by the Board. Each person nominated for election has agreed to serve if elected. The Company&#8217;s management has no reason to believe that any nominee will be unable to serve. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following is a brief biography of each nominee for director and each director whose term will continue after the Annual Meeting, including a discussion of the specific experience, qualifications, attributes or skills of each nominee and continuing director that led the Nominating and Corporate Governance Committee (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">N&amp;CG Committee</font><font style="letter-spacing:0.2pt;">&#8221;) of the Board to recommend that person as a nominee for director or that describes the reasons as to why the Company believes that the director should continue to serve on the Board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The N&amp;CG Committee seeks to assemble a board that, as a whole, possesses the appropriate balance of professional and industry knowledge, financial expertise, and high-level management experience necessary to oversee and direct the Company&#8217;s business. To that end, the N&amp;CG Committee has identified and evaluated nominees in the broader context of the Board&#8217;s overall composition, with the goal of recruiting members who complement and strengthen the skills of other members and who also exhibit integrity, collegiality, sound business judgment, and other qualities that the N&amp;CG Committee views as critical to effective functioning of the Board. To provide a mix of experience and perspective on the Board, the N&amp;CG Committee also takes into account gender, age and ethnic diversity. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Nominees for Election for a Three-Year Term Expiring at the 2027 Annual Meeting</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Richard Douglas, PhD</font><font style="font-weight:normal;letter-spacing:0.2pt;">, age 71</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Richard Douglas has served on our Board since 2018 and as our Non-Executive Chairman since October&#160;2021. Dr.&#160;Douglas served as the senior vice president of corporate development of Genzyme Corporation where he worked from 1989 until 2011 when Genzyme was acquired by Sanofi. Prior to joining Genzyme, Dr.&#160;Douglas served in science and corporate development capacities at Integrated Genetics prior to its acquisition by Genzyme in 1989. Since 2011, Dr.&#160;Douglas has served as an adviser to RedSky Partners, a biotechnology-focused advisory firm, and also as executive director of Labyrinth Choir, Inc. He is chairman of the board of directors of the publicly held company Aldeyra Therapeutics, Inc., which he joined in 2016, and has been a board member of Novavax, Inc. since 2010. He has a B.S. in chemistry from the University of Michigan, where he now serves on the National Advisory Board, and a Ph.D. in biochemistry from the University of California, Berkeley. Our Board believes that Dr.&#160;Douglas&#8217;s significant business experience and scientific background qualify him to serve as a director. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Will Brooke</font><font style="font-weight:normal;letter-spacing:0.2pt;">, age 68</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Will Brooke has served on our Board since 2004. Mr.&#160;Brooke retired from Harbert Management Corporation (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">HMC</font><font style="letter-spacing:0.2pt;">&#8221;), a U.S. investment management company, in December&#160;2021, having served in various capacities since co-founding HMC in 1993. He most recently served as Executive Vice President and Limited Partner prior to his retirement from HMC and also served as Managing Partner of HMC&#8217;s venture capital funds family from 2003 to 2014. Mr.&#160;Brooke has been advising and investing in early-stage and growth companies for more than 30&#160;years, and previously served on the boards of numerous pharmaceutical and medical equipment companies such as nContact, Inc., NovaMin Technology, Inc. and Emageon Corporation. Since December&#160;2018 he has also served as a board member of KPX, LLC, an environmental, social and governance advisory firm serving the investment and advisory sectors. Prior to joining HMC, Mr.&#160;Brooke practiced law for a decade. Mr.&#160;Brooke received a B.S. in Business Management and a J.D. from the University of Alabama. Our Board believes Mr.&#160;Brooke&#8217;s extensive business experience and deep financial knowledge qualify him to serve as a director. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">John Johnston</font><font style="font-weight:normal;letter-spacing:0.2pt;">, age 65</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">John Johnston has served on our Board since 2016. From 2011 until his retirement from his financial career in 2013, Mr.&#160;Johnston served as managing director of institutional sales at Nomura Code Securities Ltd, a brokerage company, and from 2008 to 2011, he was director of sales and trading at the investment bank Seymour Pierce. In 2003, Mr.&#160;Johnston founded Revera Asset Management, where he oversaw an investment trust, a unit trust and a hedge fund, which he ran until 2007. Mr.&#160;Johnston began his investment career at the Royal Bank of Scotland and previously held positions at investment firms Legg Mason Investors and Murray Johnstone. Within the past five&#160;years, Mr.&#160;Johnston served as a non-executive director of the publicly held company Midatech Pharma plc (now Biodexa Pharmaceuticals plc). Mr.&#160;Johnston received his B.A. in commerce from Abertay University and his M.B.A. from the University of Dundee. Our Board believes Mr.&#160;Johnston&#8217;s executive leadership and operational experience qualify him to serve as a director. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THE BOARD OF DIRECTORS RECOMMENDS A VOTE IN FAVOR OF EACH NAMED NOMINEE.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Directors Continuing in Office Until the 2025 Annual Meeting</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Maher Masoud</font><font style="font-weight:normal;letter-spacing:0.2pt;">, age 49</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Maher Masoud was named President and Chief Executive Officer of MaxCyte in January&#160;2024. He brings more than 25&#160;years of experience in the biopharmaceutical industry, most recently through his service as Executive Vice President, Head of Global Development, and Chief Counsel to MaxCyte from January&#160;2020 to January&#160;2024. He also served as MaxCyte&#8217;s Vice President of Legal from 2017 to January&#160;2020 and as our Corporate Secretary from July&#160;2021 to December&#160;2023. During his tenure, MaxCyte&#8217;s Strategic Platform License Partnerships grew to include 24 partners (as of January&#160;2024). Mr.&#160;Masoud started his biopharmaceutical career as a research associate at Glen Research, a Maravai company, before joining Human Genome Sciences as a director and Corporate Counsel, overseeing legal activities for the company&#8217;s global clinical trials, until its acquisition by GlaxoSmithKline in August&#160;2012. Prior to joining MaxCyte, he oversaw the operations of six business subsidiaries at Wellstat, a life science holding company. During his tenure at Human Genome Sciences and Wellstat, Mr.&#160;Masoud supported the launch of three therapies approved by the U.S. Food and Drug Administration, Benlysta</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Vistogard</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> and Xuriden</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">. Mr.&#160;Masoud earned his Juris Doctor degree from Michigan State University College of Law after completing his Bachelor of Science degree in cell and molecular biology and genetics at the University of Maryland </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Yasir Al-Wakeel, BM BCh</font><font style="font-weight:normal;letter-spacing:0.2pt;">, age 42</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Yasir Al-Wakeel has served on our Board since 2021. Dr.&#160;Al-Wakeel served as Chief Financial Officer and Head of Corporate Development of Kronos Bio, Inc., a clinical-stage biopharmaceutical company developing therapeutics that target the dysregulated transcription that causes cancer, from August&#160;2020 to September&#160;2023, before leaving to become chief executive officer of a new formed biotechnology company. Dr.&#160;Al-Wakeel previously served as the Chief Financial Officer of Neon Therapeutics, Inc., a biotechnology company developing novel neoantigen-based T-cell therapies, from 2017 to May&#160;2020. Previously, Dr.&#160;Al-Wakeel served as the Chief Financial Officer and Head of Corporate Development at Merrimack </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pharmaceuticals, Inc. from 2015 until 2017. Dr.&#160;Al-Wakeel previously served in various capacities at Credit Suisse, an investment banking firm, from 2008 to 2015. While at Credit Suisse, Dr.&#160;Al-Wakeel was Director of Healthcare Investment Banking, focused on biotechnology, and, prior to that role, he was an Equity Research Analyst covering the biotechnology and specialty pharmaceuticals sectors. Before joining Credit Suisse, Dr. Al-Wakeel was a practicing physician, holding both clinical and academic medical posts. Dr.&#160;Al-Wakeel received his BM BCh (Doctor of Medicine and Surgery) from Oxford University and his M.A. in theology from Cambridge University. Our Board believes that Dr.&#160;Al-Wakeel&#8217;s significant scientific and finance background qualifies him to serve as a director. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rekha Hemrajani</font><font style="font-weight:normal;letter-spacing:0.2pt;">, age 54</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Rekha Hemrajani has served on our Board since 2021. Ms.&#160;Hemrajani served as Chief Executive Officer and a director of Jiya Acquisition Corporation, a publicly held special purpose acquisition company, from its inception in August&#160;2020 until November&#160;2022. She previously served as President and Chief Executive Officer and a director of Aravive, Inc., a publicly held clinical-stage biotechnology company, from January&#160;2020 to April&#160;2020. From March&#160;2019 to September&#160;2019, Ms.&#160;Hemrajani served as the Chief Operating Officer and Chief Financial Officer of Arcus Biosciences, a biotechnology company. From 2016 to March&#160;2019, she served as Chief Operating Officer of FLX Bio, Inc. (now RAPT Therapeutics, Inc.), a biotechnology company. From 2015 to 2016, Ms.&#160;Hemrajani served as Chief Financial Officer and Senior Vice President of Business and Financial Operations at 3-V Biosciences, Inc. (now Sagimet Biosciences, Inc.), a biotechnology company. From 2013 to 2015, Ms.&#160;Hemrajani advised privately held companies on strategic corporate development and financing activities at Ravinia Consulting, a consulting firm she founded. Ms.&#160;Hemrajani currently serves as a director of the publicly held company ALX Oncology Holdings Inc. and within the past five&#160;years also served as a director of the publicly held company Adverum Biotechnologies, Inc. She holds a B.S. in Economics and Computer Science from the University of Michigan and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University. Our Board believes Ms.&#160;Hemrajani is qualified to serve as a director due to her executive and financial experience at multiple companies in the biopharmaceutical and biotechnology industries. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Directors Continuing in Office Until the 2026 Annual Meeting</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Art Mandell</font><font style="font-weight:normal;letter-spacing:0.2pt;">, age 71</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Art Mandell has served on our Board since 2006. Since 2008, Mr.&#160;Mandell has been an advisor to companies in the healthcare and technology industries. Mr.&#160;Mandell served as president and chief operating officer of Prestwick Pharmaceuticals, Inc. from 2005 to 2007. Prior to Prestwick, Mr.&#160;Mandell was president and chief executive officer and a director of Cellective Therapeutics, Inc. from 2004 to 2005, when it was acquired by Astra Zeneca/MedImmune. Before Cellective, Mr.&#160;Mandell served as president and chief executive officer and director of Stemron Corporation from 2001 to 2003, and as senior vice president and chief business officer of Human Genome Sciences, Inc. from 1997 to 2001. Mr.&#160;Mandell began his healthcare career at Syntex Pharmaceutical Corporation where he spent 14&#160;years in various senior management positions both domestically and abroad. Mr.&#160;Mandell received his B.S. from San Jose State University and his M.B.A. from Santa Clara University. Our Board believes Mr.&#160;Mandell&#8217;s extensive knowledge and experience in the pharmaceuticals and biotechnology industries qualify him to serve as a director. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stanley C. Erck</font><font style="font-weight:normal;letter-spacing:0.2pt;">, age 76</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Stanley Erck has served on our Board since 2005. Mr.&#160;Erck served as president and chief executive officer of Novavax, Inc., a biotechnology company that develops vaccines to counter serious infectious diseases, from 2011, and as a director of Novavax from 2009, until his retirement from these positions in January&#160;2023. Mr.&#160;Erck previously served as executive chairman of Novavax from 2010 to 2011 and interim chief financial officer from 2017 to 2018. From 2000 to 2008, Mr.&#160;Erck served as president and chief executive officer of Iomai Corporation, a developer of vaccines and immune system therapies, which was acquired in 2008 by Intercell AG. He also previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now Sanofi Genzyme and Baxter International. Mr.&#160;Erck received a B.S. in economics from the University of Illinois and an M.B.A. from the University of Chicago. During his tenure as chief executive officer of Novavax, Mr.&#160;Erck led the company from preclinical development through global </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:58pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">commercialization with first year revenues of over $2&#160;billion. Our Board believes Mr.&#160;Erck&#8217;s public company board experience and extensive knowledge and experience in the biotechnology industry qualify him to serve as a director. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Patrick J. Balthrop</font><font style="font-weight:normal;letter-spacing:0.2pt;">, age 67</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Patrick Balthrop has served on our Board since 2022. Mr.&#160;Balthrop has more than three decades of experience in the healthcare sector, particularly in diagnostics, life science tools and medical devices. From 2004 until his retirement in 2014, Mr.&#160;Balthrop was President, Chief Executive Officer and a director of Luminex Corporation, a publicly held life science tools and molecular diagnostics company. From 2002 to 2004, he served as president of Fisher Healthcare, now a division of Thermo Fisher Scientific, Inc. He previously served for more than 20&#160;years in roles of increasing responsibility with Abbott Laboratories, including as head of Abbott Vascular and Corporate VP of Worldwide Operations for Abbott Diagnostics. He currently serves as chairman of the board of the privately held life sciences companies Agendia, Inc. and Discovery Life Sciences, as director of the privately held contract research and manufacturing company Ascential Technologies, and as director of the privately held life sciences company Pattern Biosciences. Within the past five&#160;years, he served as a director of the publicly held diagnostics company Oxford Immunotec Global PLC, including as its chairman from June&#160;2019 until March&#160;2021. He also served as a member of the board of directors of Personalis, Inc., a publicly held cancer genomics company, from 2015 until March&#160;2021. In 2015, Mr.&#160;Balthrop founded and has since served as Principal of Apalachee Ventures, LLC (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Apalachee</font><font style="letter-spacing:0.2pt;">&#8221;), an investment and advisory firm. He also serves as executive adviser to Water Street Healthcare Partners, a healthcare- focused private equity firm. Mr.&#160;Balthrop holds a B.S. in Biology from Spring Hill College and an M.B.A. from the Kellogg School of Management at Northwestern University. Our Board believes Mr.&#160;Balthrop&#8217;s public company board experience and extensive knowledge and experience in the biotechnology industry qualify him to serve as a director. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Board Diversity</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Board Diversity Matrix below provides the diversity statistics for our Board. Last year&#8217;s Board Diversity Matrix is available in our 2023 proxy statement filed with the SEC on April&#160;28, 2023. The Board Diversity Matrix sets forth certain self-identified personal demographic characteristics of our directors. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Board Diversity Matrix (as of April&#160;26, 2024)*</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:97pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:390.64pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Total Number of Directors:</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">9 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:390.64pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Female </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Male </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:390.64pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Gender Identity</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:390.64pt;text-align:left;">
              <div style="font-style:italic;">
                <font style="letter-spacing:0.2pt;">Totals</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:6.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">8</td>
            <td style="padding:0pt;padding-left:3.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:390.64pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Demographic Background</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:390.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Asian </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:6.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:390.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">White </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">8<font style="position:absolute;">*</font></td>
            <td style="padding:0pt;padding-left:3.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Although Nasdaq&#8217;s classification system does not include Middle Eastern individuals as an underrepresented demographic group, other classification systems and our Board consider them to be diverse. Under the ISS definition, &#8220;Middle Eastern&#8221; is defined as a person with origins in any of the Persian or Arab countries in the Middle East or North Africa. Two of our directors self-identify as &#8220;Middle Eastern&#8221; based on this definition. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIRTB">&#8203;</a><a name="tIOTB">&#8203;</a><a name="tBLS">&#8203;</a><a name="tROTB">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Independence of the Board of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As required under The Nasdaq Stock Market, LLC (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Nasdaq</font><font style="letter-spacing:0.2pt;">&#8221;) listing standards, a majority of the members of a listed company&#8217;s board of directors must qualify as &#8220;independent,&#8221; as affirmatively determined by the board of directors. The Board consults with the Company&#8217;s counsel to ensure that the Board&#8217;s determinations are consistent with relevant securities and other laws and regulations regarding the definition of &#8220;independent,&#8221; including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and the Company, its senior management and its independent auditors, the Board has affirmatively determined that the following eight directors are independent directors within the meaning of the applicable Nasdaq listing standards: Dr.&#160;Al-Wakeel, Mr.&#160;Brooke, Dr.&#160;Douglas, Ms.&#160;Hemrajani, Mr.&#160;Erck, Mr.&#160;Johnston, Mr.&#160;Mandell and Mr.&#160;Balthrop. In making this determination, the Board found that none of these directors or nominees for director had a material or other disqualifying relationship with the Company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Board Leadership Structure</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Board has an independent chairman, Dr.&#160;Douglas, who has authority, among other things, to call and preside over Board meetings, including meetings of the independent directors, to set meeting agendas and to determine materials to be distributed to the Board. Accordingly, the Chairman has substantial ability to shape the work of the Board. The Company believes that separation of the positions of Chairman and Chief Executive Officer reinforces the independence of the Board in its oversight of the business and affairs of the Company. In addition, the Company believes that having an independent Chairman creates an environment that is more conducive to objective evaluation and oversight of management&#8217;s performance, increasing management accountability, and improving the ability of the Board to monitor whether management&#8217;s actions are in the best interests of the Company and its stockholders. As a result, the Company believes that having an independent Chairman can enhance the effectiveness of the Board as a whole. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Role of the Board in Risk Oversight</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">One of the Board&#8217;s key functions is informed oversight of the Company&#8217;s risk management process. The Board does not have a standing risk management committee, but rather administers this oversight function directly through the Board as a whole, as well as through various Board standing committees that address risks inherent in their respective areas of oversight. In particular, our Board is responsible for monitoring and assessing strategic risk exposure, including a determination of the nature and level of risk appropriate for the Company. The Audit Committee of our Board (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Audit Committee</font><font style="letter-spacing:0.2pt;">&#8221;) has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The Audit Committee also monitors compliance with legal and regulatory requirements, in addition to oversight of the performance of our internal audit function. Audit Committee responsibilities also include oversight of cybersecurity risk management, and, to that end, the Audit Committee typically meets twice annually with both IT and business personnel responsible for cybersecurity risk management and receives periodic reports from the head of cybersecurity risk management, as well as incidental reports as matters arise. Our N&amp;CG Committee monitors the effectiveness of our corporate governance guidelines, including whether they are successful in preventing illegal or improper liability-creating conduct. The Compensation Committee of our Board (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Compensation Committee</font><font style="letter-spacing:0.2pt;">&#8221;) assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. Typically, the entire Board meets with the head of the Company&#8217;s risk management group at least annually, and the applicable Board committees meet at least annually with the employees responsible for risk management in the committees&#8217; respective areas of oversight. Both the Board as a whole and the various standing committees receive periodic reports from the head of risk management, as well as incidental reports as matters may arise. It is the responsibility of the committee chairs to report findings regarding material risk exposures to the Board as quickly as possible. The Board has delegated to the Board&#8217;s independent Chairman </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMOTB">&#8203;</a><a name="tIRCO">&#8203;</a><a name="tAUCO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">the responsibility of coordinating between the Board and management with regard to the determination and implementation of responses to any problematic risk management issues. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">For more information on cybersecurity oversight, please refer to Item&#160;1C, &#8220;Cybersecurity&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2023, filed with the SEC on March&#160;12, 2024. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Meetings of the Board of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The Board met five times during the last fiscal year. Each Board member attended 75% or more of the aggregate number of meetings of the Board and of the committees on which he or she served, held during the portion of the last fiscal year for which he or she was a director or committee member. It is the Company&#8217;s policy to encourage directors and nominees for director to attend each annual meeting of stockholders, in person or telephonically. All of our directors attended the 2023 annual meeting of stockholders (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">2023 Annual Meeting</font><font style="letter-spacing:0.2pt;">&#8221;). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Information Regarding Committees of the Board of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The Board has three committees: the Audit Committee, the Compensation Committee, and the N&amp;CG Committee. The following table provides membership and meeting information for each of the Board committees: </font>
        </div>
        <table style="width:456pt;height:155.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:282.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Audit</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Committee </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Compensation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Committee </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Nominating and </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Corporate </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Governance </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Committee </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:282.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dr.&#160;Yasir Al-Wakeel </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">X</td>
            <td style="padding:0pt;padding-left:14.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Mr.&#160;Patrick Balthrop </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">X</td>
            <td style="padding:0pt;padding-left:22.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Mr.&#160;Will Brooke </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">X<font style="position:absolute;">*</font></td>
            <td style="padding:0pt;padding-left:14.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">X</td>
            <td style="padding:0pt;padding-left:19.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dr.&#160;Richard Douglas </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">X</td>
            <td style="padding:0pt;padding-left:22.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Mr.&#160;Stanley C. Erck </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">X</td>
            <td style="padding:0pt;padding-left:19.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">X</td>
            <td style="padding:0pt;padding-left:22.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Ms.&#160;Rekha Hemrajani </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">X<font style="position:absolute;">*</font></td>
            <td style="padding:0pt;padding-left:19.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Mr.&#160;John Johnston </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">X</td>
            <td style="padding:0pt;padding-left:14.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Mr.&#160;Art Mandell </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">X</td>
            <td style="padding:0pt;padding-left:14.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; white-space:nowrap;">X<font style="position:absolute;">*</font></td>
            <td style="padding:0pt;padding-left:22.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.9pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Committee Chairperson </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Each of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities. The Board has determined that each member of each committee meets the applicable Nasdaq rules and regulations regarding &#8220;independence&#8221; and each member is free of any relationship that would impair his or her individual exercise of independent judgment with regard to the Company. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Below is a description of each committee of the Board. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Audit Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The Audit Committee was established by the Board in accordance with Section&#160;3(a)(58)(A) of the Securities and Exchange Act of 1934, as amended (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Exchange Act</font><font style="letter-spacing:0.2pt;">&#8221;), to oversee the Company&#8217;s corporate accounting and financial reporting processes and audits of its financial statements. Specific responsibilities of our Audit Committee include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">helping our Board oversee our corporate accounting and financial reporting processes; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">managing the selection, engagement, qualifications, independence, and performance of a qualified firm to serve as the independent registered public accounting firm to audit our financial statements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, our interim and year-end operating results; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tROTA">&#8203;</a><a name="tCOCO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reviewing related person transactions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">obtaining and reviewing a report by the independent registered public accounting firm at least annually that describes our internal quality control procedures, any material issues with such procedures and any steps taken to deal with such issues when required by applicable law; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">approving or, as permitted, pre-approving, audit and permissible non-audit services to be performed by the independent registered public accounting firm. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Audit Committee is currently comprised of four directors: Dr.&#160;Al-Wakeel and Messrs. Brooke, Johnston and Mandell, with Mr.&#160;Brooke serving as chairman. The Audit Committee met five times during the fiscal year ended December&#160;31, 2023. The Board has adopted a written Audit Committee charter that is available to stockholders on the Company&#8217;s website at https://investors.maxcyte.com/corporate-governance/</font>&#8203;<font style="letter-spacing:0.2pt;">documents-charters. </font></div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Board reviews the Nasdaq listing standards definition of independence for Audit Committee members on an annual basis and has determined that all members of the Company&#8217;s Audit Committee are independent (as independence is currently defined in Rule&#160;5605(c)(2)(A)(i) and (ii)&#160;of the Nasdaq listing standards). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Board has also determined that Mr.&#160;Brooke and Dr.&#160;Al-Wakeel each qualify as an &#8220;audit committee financial expert,&#8221; as defined in applicable SEC rules. The Board made a qualitative assessment of each of Mr.&#160;Brooke&#8217;s and Dr.&#160;Al-Wakeel&#8217;s level of knowledge and experience based on a number of factors, including their formal education and experience. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Report of the Audit Committee of the Board of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The material in the following report is not &#8220;soliciting material,&#8221; is not deemed &#8220;filed&#8221; with the SEC and is not to be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, unless and only to the extent that the Company specifically incorporates it by reference. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Audit Committee has reviewed and discussed the audited financial statements for the fiscal year ended December&#160;31, 2023 with management of the Company and CohnReznick LLP. The Audit Committee has discussed with the independent registered public accounting firm the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">PCAOB</font><font style="letter-spacing:0.2pt;">&#8221;) and the SEC. The Audit Committee has also received the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the PCAOB regarding the independent accountants&#8217; communications with the Audit Committee concerning independence, and has discussed with the independent registered public accounting firm the accounting firm&#8217;s independence. Based on the foregoing, the Audit Committee has recommended to the Board that the audited consolidated financial statements be included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2023. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Audit Committee:</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Mr.&#160;Will Brooke, Chair </font> <br ><font style="letter-spacing:0.2pt;">Mr.&#160;John Johnston </font> <br ><font style="letter-spacing:0.2pt;">Mr.&#160;Art Mandell </font> <br ><font style="letter-spacing:0.2pt;">Dr.&#160;Yasir Al-Wakeel </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensation Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Compensation Committee is currently comprised of three directors: Messrs. Brooke and Erck and Ms.&#160;Hemrajani, with Ms.&#160;Hemrajani serving as the chairperson. Each member of the Compensation Committee meets the compensation committee independence requirements of Nasdaq and the rules under the Exchange Act. The Compensation Committee met five times during the fiscal year ended December&#160;31, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2023. The Board has adopted a written Compensation Committee charter that is available to stockholders on the Company&#8217;s website at https://investors.maxcyte.com/corporate-governance/documents-charters. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Compensation Committee acts on behalf of the Board to review, adopt, and oversee the Company&#8217;s compensation strategy, policies, plans, and programs. Specific responsibilities of our Compensation Committee include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reviewing and approving the compensation of our chief executive officer, other executive officers and senior management; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reviewing and recommending to our Board the compensation paid to our non-executive directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">administering our equity incentive plans and other company benefit programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reviewing, adopting, amending and terminating incentive compensation and equity plans, severance agreements, profit sharing plans, bonus plans, change-of-control protections, and any other compensatory arrangements for our executive officers and other senior management; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reviewing and establishing general policies relating to compensation and benefits of our employees, including our overall compensation philosophy. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Once required by SEC rules, the Compensation Committee will review with management the Company&#8217;s Compensation Discussion and Analysis and consider whether to recommend that it be included in proxy statements and other filings. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Compensation Committee Processes and Procedures</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Typically, the Compensation Committee meets at least four times annually and with greater frequency if deemed necessary. The agenda for each meeting is usually developed by the chairperson in consultation with the Company&#8217;s Chief Executive Officer and other executives, the Chair of the Board, and the Company&#8217;s compensation consultant. The Compensation Committee meets regularly in executive session. Various members of management and other employees as well as outside advisors or consultants may be invited by the Compensation Committee to make presentations, to provide data and other background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer may not participate in, or be present during, any deliberations or determinations of the Compensation Committee regarding his compensation. The charter of the Compensation Committee grants the Compensation Committee full access to all books, records, facilities and personnel of the Company. In addition, under the charter, the Compensation Committee has the authority to obtain, at the expense of the Company, advice and assistance from compensation consultants and internal and external legal, accounting or other advisors and other external resources that the Compensation Committee considers necessary or appropriate in the performance of its duties. The Compensation Committee has direct responsibility for the oversight of the work of any consultants or advisers engaged for the purpose of advising the Compensation Committee. In particular, the Compensation Committee has the sole authority to retain, in its sole discretion, compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve the consultant&#8217;s reasonable fees and other retention terms. Under the charter, the Compensation Committee may select, or receive advice from, a compensation consultant, legal counsel or other adviser to the Compensation Committee, other than in-house legal counsel and certain other types of advisers, only after taking into consideration six factors, prescribed by the SEC and Nasdaq, that bear upon the adviser&#8217;s independence; however, there is no requirement that any adviser be independent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During 2023, after taking into consideration the six factors prescribed by the SEC and Nasdaq, the Compensation Committee initially engaged Arnosti Consulting, Inc. (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Arnosti</font><font style="letter-spacing:0.2pt;">&#8221;) and then subsequently engaged Pearl Meyer and Partners, LLC (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Pearl Meyer</font><font style="letter-spacing:0.2pt;">&#8221;) as compensation consultants. The Compensation Committee requested that Arnosti and Pearl Meyer: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">evaluate the efficacy of the Company&#8217;s existing compensation strategy and practices in supporting and reinforcing the Company&#8217;s long-term strategic goals; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">assist in refining the Company&#8217;s compensation strategy and in developing and implementing an executive compensation program to execute that strategy. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tNACG">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As part of their engagement, Arnosti and Pearl Meyer were requested by the Compensation Committee to develop a comparative group of companies and to perform analyses of competitive performance and compensation levels for that group. Arnosti and Pearl Meyer provided data and guidance in developing recommendations for compensation of executives, and made direct recommendations to the Compensation Committee with regards to compensation of non-executive directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Generally, the Compensation Committee&#8217;s process comprises two related elements: the determination of compensation levels and the establishment of performance objectives for the current year. For executives other than the Chief Executive Officer, the Compensation Committee solicits and considers evaluations and recommendations submitted to the Compensation Committee by the Chief Executive Officer. In the case of the Chief Executive Officer, the evaluation of his performance is conducted by the Compensation Committee for recommendation to the full Board, which determines any adjustments to his compensation as well as equity awards to be granted. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Nominating and Corporate Governance Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The N&amp;CG Committee of the Board is responsible for identifying, reviewing and evaluating candidates to serve as directors of the Company (consistent with criteria approved by the Board), reviewing and evaluating incumbent directors, recommending to the Board for selection candidates for election to the Board, making recommendations to the Board regarding the membership of the committees of the Board, assessing the performance of management and the Board, and developing a set of corporate governance principles for the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The N&amp;CG Committee is currently comprised of four directors: Messrs. Mandell, Erck and Balthrop and Dr.&#160;Douglas, with Mr.&#160;Mandell serving as chairman. All members of the N&amp;CG Committee are independent (as independence is currently defined in Rule&#160;5605(a)(2) of the Nasdaq listing standards). The N&amp;CG Committee met five times during the fiscal year ended December&#160;31, 2023. The Board has adopted a written N&amp;CG Committee charter that is available to stockholders on the Company&#8217;s website at https://investors.maxcyte.com/corporate-governance/documents-charters. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The N&amp;CG Committee believes that candidates for director should have certain minimum qualifications, including the ability to read and understand basic financial statements, being over 21&#160;years of age and having the highest personal integrity and ethics. The N&amp;CG Committee also considers such factors as possessing relevant expertise upon which to be able to offer advice and guidance to management, having sufficient time to devote to the affairs of the Company, demonstrated excellence in his or her field, having the ability to exercise sound business judgment and having the commitment to rigorously represent the long-term interests of the Company&#8217;s stockholders. However, the N&amp;CG Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the Board, the operating requirements of the Company and the long-term interests of stockholders. In conducting this assessment, the N&amp;CG Committee typically considers diversity (including gender, racial and ethnic diversity), age, skills and such other factors as it deems appropriate, given the current needs of the Board and the Company, to maintain a balance of knowledge, experience and capability. We have no formal policy regarding board diversity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The N&amp;CG Committee appreciates the value of thoughtful Board refreshment, and regularly identifies and considers qualities, skills and other director attributes that would enhance the composition of the Board. In the case of incumbent directors whose terms of office are set to expire, the N&amp;CG Committee reviews these directors&#8217; overall service to the Company during their terms, including the number of meetings attended, level of participation, quality of performance and any other relationships and transactions that might impair the directors&#8217; independence. The N&amp;CG Committee will also take into account the results of the Board&#8217;s self- evaluation, conducted annually on a group and individual basis. In the case of new director candidates, the N&amp;CG Committee also determines whether the nominee is independent for Nasdaq purposes, which determination is based upon applicable Nasdaq listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. The N&amp;CG Committee then uses its network of contacts to compile a list of potential candidates, but may also engage, if it deems appropriate, a professional search firm. The N&amp;CG Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCWTB">&#8203;</a><a name="tCOE">&#8203;</a><a name="tCGG">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">possible candidates after considering the function and needs of the Board. The N&amp;CG Committee meets to discuss and consider the candidates&#8217; qualifications and then selects a nominee for recommendation to the Board by majority vote. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The N&amp;CG Committee will consider director candidates recommended by the Company&#8217;s stockholders. The N&amp;CG Committee does not intend to alter the manner in which it evaluates a candidate for nomination to the Board based on whether or not the candidate was recommended by a stockholder of the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Stockholders who wish to recommend individuals for consideration by the N&amp;CG Committee to become nominees for election to the Board at an annual meeting of stockholders must do so by delivering a written recommendation to the Nominating and Corporate Governance Committee c/o&#160;MaxCyte, Inc., 9713 Key West Avenue, Suite 400, Rockville, Maryland 20850, Attn: General Counsel. Each submission must set forth: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the name and address of the stockholder on whose behalf the submission is made; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the number of shares of the Company&#8217;s common stock that are owned beneficially by such stockholder as of the date of the submission; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the full name of the proposed candidate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a description of the proposed candidate&#8217;s business experience for at least the previous five&#160;years; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">complete biographical information for the proposed candidate; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a description of the proposed candidate&#8217;s qualifications as a director. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any such submission must be accompanied by the written consent of the proposed candidate to be named as a nominee and to serve as a director if elected. All written submissions received from stockholders that include the information described above will be reviewed by the N&amp;CG Committee at its next appropriate meeting. If a stockholder wishes the N&amp;CG Committee to consider a director candidate for nomination at an annual meeting of stockholders, then the recommendation must be provided at least 90&#160;days, but not more than 120&#160;days, prior to the anniversary date of the preceding year&#8217;s annual meeting of stockholders. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Communications With the Board of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Board has adopted a process by which stockholders may communicate with the Board or any of its directors. Stockholders who wish to communicate with the Board may do so by sending written communications addressed to the Board or such director c/o&#160;MaxCyte, Inc., 9713 Key West Avenue, Suite&#160;400, Rockville, Maryland 20850, Attn: General Counsel. Each communication must set forth: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the name and address of the stockholder on whose behalf the communication is sent; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the number of shares of the Company&#8217;s common stock that are owned beneficially by such stockholder as of the date of the communication. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The General Counsel will review each communication. The General Counsel will forward such communication to the Board or to any individual director to whom the communication is addressed unless the communication contains advertisements or solicitations or is unduly hostile, threatening or similarly inappropriate, in which case the General Counsel will discard the communication. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Code of Ethics</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has adopted the MaxCyte, Inc. Code of Conduct and Ethics that applies to all officers, directors and employees. The Code of Business Conduct and Ethics is available on the Company&#8217;s website at https://investors.maxcyte.com/corporate-governance/documents-charters. If the Company makes any substantive amendments to the Code of Business Conduct and Ethics or grants any waiver from a provision of the Code of Business Conduct and Ethics to any executive officer or director, the Company will promptly disclose the nature of the amendment or waiver on its website. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Corporate Governance Guidelines</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2021, the Board documented the governance practices to be followed by the Company by adopting Corporate Governance Guidelines to assure that the Board will have the necessary authority and practices in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tHEPO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:500pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">place to review and evaluate the Company&#8217;s business operations as needed and to make decisions that are independent of the Company&#8217;s management. The guidelines are also intended to align the interests of directors and management with those of the Company&#8217;s stockholders. The Corporate Governance Guidelines set forth the practices the Board intends to follow with respect to board composition and selection including diversity, board meetings and involvement of senior management, Chief Executive Officer performance evaluation, succession planning and board committees and compensation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Hedging Policy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We do not currently have any practices or policies regarding hedging or offsetting any decrease in the market value of our equity securities.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPR2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROPOSAL 2</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">APPROVAL OF AN AMENDMENT TO THE 2022 EQUITY INCENTIVE PLAN</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Background</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In April&#160;2024, our Board approved an amendment (the </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">&#8220;Amendment&#8221;)</font><font style="letter-spacing:0.2pt;"> of the MaxCyte, Inc. 2022 Equity Incentive Plan, as amended and restated (the </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">&#8220;2022 Plan&#8221;),</font><font style="letter-spacing:0.2pt;"> subject to approval by our stockholders at the Annual Meeting, to increase the available shares under the 2022 Plan by 2,300,000 shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Approval of the Amendment by our stockholders will allow us to continue to grant stock options, restricted stock unit awards and other awards at levels determined appropriate by our Board or Compensation Committee. The Amendment will allow us to continue to grant a broad array of equity incentives and performance cash incentives in order to secure and retain the services of our employees, consultants, and directors, and to provide long-term incentives that align the interests of our employees, consultants, and directors with the interests of our stockholders. Our Board believes that the Amendment is an integral part of our long-term compensation philosophy and is necessary to continue providing the appropriate levels and types of equity compensation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">A summary of the material features of the 2022 Plan is set forth below. This summary is, however, qualified in its entirely by and subject to the full text of the 2022 Plan, as proposed to be amended by the Amendment, which is attached as Appendix&#160;A-1. For ease of reference, the marked copy of the 2022 Plan in Appendix&#160;A-2 shows the proposed changes of the Amendment with the added text underlined. If our stockholders approve the Amendment, we will file with the SEC a registration statement on Form S-8, as soon as reasonably practicable after the approval, to register the additional shares available for issuance under the 2022 Plan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Requested Shares</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to adjustment for certain changes in our capitalization, if the Amendment is approved by our stockholders, the aggregate number of shares of common stock that may be issued under the 2022 Plan will not exceed the sum of (i)&#160;2,300,000 new shares available pursuant to the Amendment, plus (ii)&#160;6,069,000 shares approved by our stockholders at our 2023 Annual Meeting, plus (iii)&#160;the 1,928,000 shares originally reserved under the 2022 Plan, plus (iv)&#160;the number of unallocated shares remaining available for grant under the MaxCyte, Inc. Long-Term Incentive Plan (the </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">&#8220;LTIP&#8221;)</font><font style="letter-spacing:0.2pt;"> as of the original effective date of the 2022 Plan, plus (v)&#160;the Prior Plans&#8217; Returning Shares (as defined below), as such shares become available from time to time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The term &#8220;Prior Plans&#8217; Returning Shares&#8221; refers to the following shares of our common stock subject to any outstanding award granted under the LTIP or the MaxCyte, Inc. 2021 Inducement Plan (the </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">&#8220;Inducement Plan&#8221;),</font><font style="letter-spacing:0.2pt;"> as of the effective date of the 2022 Plan, and that following the effective date of the 2022 Plan: (i)&#160;are not issued because the stock award or any portion thereof expires or otherwise terminates without all of the shares covered by such stock award having been issued; (ii)&#160;are not issued because such stock award or any portion thereof is settled in cash; or (iii)&#160;are forfeited back to or repurchased by us because of the failure to meet a contingency or condition required for the vesting of such shares. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Why We Believe It Is Important to Vote to Approve the Amendment to the 2022 Plan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity Awards Are an Important Part of Our Compensation Philosophy</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our Board believes that our future success depends, in large part, on our ability to maintain a competitive position in retaining and motivating our employees, consultants, and directors and that the issuance of equity awards is a key element in accomplishing these goals. The Amendment will allow us to continue to provide equity-based incentives to our eligible employees. Therefore, the Board believes that the Amendment is in the best interests of the Company and its stockholders and recommends a vote in favor of this Proposal 2. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Size of Our Share Reserve Request Is Reasonable</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of April&#160;15, 2024, we had 4,353,262 shares available for grant under the 2022 Plan. If the Amendment is approved by our stockholders, we will have 6,653,262 shares available for grant under the 2022 Plan immediately after the Annual Meeting (based on shares available as of April&#160;15, 2024). We anticipate this to be a pool of shares necessary for retaining and motivating employees, consultants, and directors. If the Amendment is not approved by our stockholders, the 2022 Plan will continue in effect, but we will be extremely limited in the grants that we will be able to make, which could place us in a disadvantageous position as compared with our competitors, potentially resulting in challenges with employee retention, difficulty recruiting key positions and a need to increase cash compensation in order to deliver a competitive total compensation program. Based on our Company&#8217;s current stock price and estimated use of equity awards, we expect our shares available, if this Proposal 2 is not approved, will be exhausted within two&#160;years. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We Manage Our Equity Incentive Award Use Carefully, and Dilution Is Reasonable</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We continue to believe that equity awards are a vital part of our overall compensation program. However, we recognize that equity awards dilute existing stockholders, and, therefore, we must responsibly manage the growth of our equity compensation program. We are committed to effectively monitoring our equity compensation share reserve, including our &#8220;burn rate,&#8221; to maximize stockholders&#8217; value by granting the appropriate number of equity incentive awards deemed necessary to attract, reward, and retain employees. The tables below show our overhang and burn rate information. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overhang</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table provides certain additional information regarding our equity incentive program. </font>
        </div>
        <table style="width:456pt;height:122.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:376.78pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of April&#160;15, 2024 </font>
                <br >
                <font style="letter-spacing:-0.16pt;">(Record Date) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:376.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total number of shares subject to outstanding stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.405pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">15,416,420</td>
            <td style="padding:0pt;padding-left:8.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:376.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted-average exercise price of outstanding stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.405pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5.78</td>
            <td style="padding:0pt;padding-left:8.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:376.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted-average remaining term of outstanding stock options (years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.405pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">6.9</td>
            <td style="padding:0pt;padding-left:8.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:376.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total number of shares subject to outstanding full value awards</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.405pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,509,373</td>
            <td style="padding:0pt;padding-left:8.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:376.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total number of shares available for grant under the 2022 Plan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.405pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,353,262</td>
            <td style="padding:0pt;padding-left:8.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:376.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total number of shares outstanding </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.405pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">17,925,793</td>
            <td style="padding:0pt;padding-left:8.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:376.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Per-share closing price of common stock as reported on Nasdaq Global Market </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.405pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4.19</td>
            <td style="padding:0pt;padding-left:8.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Includes 688,551 shares subject to performance awards with vesting tied to target revenues for the three-year performance period ending December&#160;31, 2026 and which were granted on March&#160;15, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Burn Rate</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table provides detailed information regarding the activity related to our equity incentive plans for fiscal&#160;years 2023, 2022 and 2021. </font>
        </div>
        <table style="width:456pt;height:82pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:273.76pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fiscal Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:273.76pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:273.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total number of shares subject to stock options granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">2,713,395</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">4,408,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,117,956</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total number of shares subject to full value awards granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">1,043,150</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">662,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted-average number of shares outstanding </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">103,268,502</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">101,702,664</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">90,619,057</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Gross Burn Rate</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">3.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">5.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4.5<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Calculated as the total number of shares subject to stock options granted plus the total number of shares subject to full value awards granted, divided by weighted-average common shares. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Key Plan&#160;Features</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 2022 Plan includes provisions that are designed to protect our stockholders&#8217; interests and to reflect corporate governance best practices including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Repricing is not allowed without stockholder approval</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The 2022 Plan prohibits the repricing of outstanding stock options and stock appreciation rights and the cancelation of any outstanding stock options or stock appreciation rights that have an exercise or strike price greater than the then-current fair market value of our shares in exchange for cash or other awards under the 2022 Plan without prior stockholder approval. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Stockholder approval is required for additional shares</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The 2022 Plan does not contain an annual &#8220;evergreen&#8221; provision. The 2022 Plan authorizes a fixed number of shares, so that stockholder approval is required to issue any additional shares, allowing our stockholders to have direct input on our equity compensation programs. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Fungible share counting structure</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The 2022 Plan contains a &#8220;fungible share counting&#8221; structure, whereby the number of shares of our common stock available for issuance under the 2022 Plan will be reduced by: (i)&#160;one share for each share issued pursuant to an Appreciation Award; and (ii)&#160;1.14 shares for each share issued pursuant to a Full Value Award. This structure allows us to use the share reserve more effectively with regard to the value of each type of award. Under the 2022 Plan, Appreciation Awards consist of stock options and stock appreciation rights, with an exercise price equal to at least 100% of the fair market value on the date of grant, and Full Value Awards consist of all other types of equity-based awards under the 2022 Plan. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">No liberal share counting</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The following shares will not become available again for issuance under the 2022 Plan: (i)&#160;shares that are reacquired or withheld (or not issued) by us to satisfy the exercise or strike price of an Appreciation Award or the purchase price of a Full Value Award; (ii)&#160;shares that are reacquired or withheld (or not issued) by us to satisfy a tax withholding obligation in connection with an Appreciation Award or Full Value Award; (iii)&#160;shares repurchased by us on the open market with the proceeds of the exercise or strike price of an Appreciation Award or the purchase price of a Full Value Award; and (iv)&#160;in the event that a stock appreciation right is settled in shares of common stock, the gross number of shares of common stock subject to the award. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Minimum vesting provision</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;No award may vest (and/or, if applicable, be exercisable) until at least 12&#160;months following the date of grant of the award; provided, however, that up to 5% of the share reserve may be subject to awards that do not meet such vesting (and/or, if applicable, exercisability) requirements. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Restrictions on dividends</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The 2022 Plan provides that (i)&#160;no dividends or dividend equivalents may be paid with respect to any shares of our common stock subject to an equity award before the date such shares have vested, (ii)&#160;any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares under the terms of the applicable equity award agreement (including any vesting conditions), and (iii)&#160;any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to us on the date such shares are forfeited to or repurchased by us due to a failure to vest. Dividends or dividend equivalents may not be paid or credited with respect to stock options and stock appreciation rights. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Equity award vesting for failure to assume employee awards in a corporate transaction or change in control.</font><font style="letter-spacing:0.2pt;"> The 2022 Plan specifically provides that in the event of a corporate transaction or change in control of the Company if the surviving or acquiring corporation (or its parent company) does not assume or continue outstanding equity awards held by employees under the 2022 Plan, or substitute similar equity awards for such outstanding equity awards, then with respect to any such employee equity award that have not been assumed, continued or substituted and that are held by employees whose continuous service has not terminated prior to a Transaction, as defined below, the vesting of such equity awards will be accelerated in full (and with respect to any performance-based equity awards, vesting will be deemed to be satisfied at the target level of performance). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Limit on non-employee director compensation</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The aggregate value of all cash and equity-based compensation paid or granted by us to any individual for service as a non-employee director of our </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; text-align:justify; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Board with respect to any fiscal year of the Company will not exceed (i)&#160;$900,000 in total value or (ii)&#160;in the event such non-employee director is first appointed or elected to the Board during such fiscal year, $1,400,000 in total value, in each case, calculating the value of any equity awards based on the grant date fair value of such equity awards for financial reporting purposes. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">No discounted stock options or stock appreciation rights</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;All stock options and stock appreciation rights must have an exercise price equal to or greater than the fair market value of our shares on the date the stock option or stock appreciation right is granted. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Awards subject to forfeiture/clawback</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Awards granted under the 2022 Plan are subject to recoupment in accordance with the Amended and Restated Incentive Compensation Recoupment Policy that we adopted in November&#160;2023, which policy is designed to comply with Section&#160;10D of the Exchange Act, Rule&#160;10D-1 promulgated thereunder and Nasdaq Listing Rule&#160;5608. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Administration by independent committee</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The 2022 Plan will be administered by the members of our Compensation Committee, all of whom are &#8220;non-employee directors&#8221; within the meaning of Rule&#160;16b-3 under the Exchange Act and &#8220;independent&#8221; within the meaning of the Nasdaq listing standards. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Description of the 2022 Plan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The material features of the 2022 Plan, as amended by the Amendment, are described below. This summary is, however, qualified in its entirely by and subject to the full text of the 2022 Plan, as proposed to be amended by the Amendment, which is attached as Appendix&#160;A-1. For ease of reference, the marked copy of the 2022 Plan attached as Appendix&#160;A-2 shows the proposed changes of the Amendment with the added text underlined. Stockholders are urged to read the actual text of the 2022 Plan and the Amendment in its entirety. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">General.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The 2022 Plan provides for the grant of incentive stock options to our employees and employees of certain affiliates, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards, and other forms of stock awards to our employees, directors and consultants and the employees and consultants of our affiliates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Eligibility.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Participants in the 2022 Plan consist of such employees, non-employee directors, and consultants of the Company and its affiliates as selected by the plan administrator. As of March&#160;31, 2024, we had 130 employees, five consultants and eight non-employee directors who would be eligible to receive grants under the 2022 Plan if selected by the plan administrator. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Authorized Shares and Share Counting Provisions.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Subject to adjustment for certain changes in our capitalization, the aggregate number of shares of our common stock that may be issued under the 2022 Plan, as amended by the Amendment, will not exceed the sum of (i)&#160;2,300,000 new shares, plus (ii)&#160;6,069,000 shares approved by our stockholders at our 2023 Annual Meeting, plus (iii)&#160;the 1,928,000 shares originally reserved under the 2022 Plan, plus (iv)&#160;the number of unallocated shares remaining available for grant under the LTIP as of the original effective date of the 2022 Plan, plus (v)&#160;the Prior Plans&#8217; Returning Shares, as such shares become available from time to time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The number of shares available for issuance under the 2022 Plan will be reduced by: (a)&#160;one share for each share issued pursuant to an Appreciation Award; and (b)&#160;1.14 shares for each share issued pursuant to a Full Value Award. The number of shares available for issuance under the 2022 Plan will be increased by: (A)&#160;one share for each share subject to an Appreciation Award that returns from the LTIP, Inducement Plan or 2022 Plan; and (B)&#160;1.14 shares for each Prior Plans&#8217; Returning Share or the 2022 Plan&#160;Returning Share (as defined below) subject to a Full Value Award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is 37,200,000 shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following actions will not result in an issuance of shares under the 2022 Plan and accordingly do not reduce the number of shares subject to the share reserve and available for issuance under the 2022 Plan: (i)&#160;the expiration or termination of any portion of an award without the shares covered by such portion of the award having been issued; or (ii)&#160;the settlement of any portion of an award granted under the 2022 Plan in cash. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following shares of our common stock (collectively, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">2022 Plan&#160;Returning Shares&#8221;</font><font style="letter-spacing:0.2pt;">) will become available again for issuance under the 2022 Plan: any shares that are forfeited back to or repurchased by the Company because of a failure to meet a contingency or condition required for the vesting of such shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following shares of our common stock will not become available again for issuance under the 2022 Plan: (1)&#160;any shares that are reacquired or withheld (or not issued) by the Company to satisfy the exercise or strike price of an Appreciation Award or the purchase price of a Full Value Award; (2)&#160;any shares that are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with an Appreciation Award or a Full Value Award; (3)&#160;any shares repurchased by us on the open market with the proceeds of the exercise or strike price of an Appreciation Award or the purchase price of a Full Value Award; and (4)&#160;in the event that a stock appreciation right is settled in shares of common stock, the gross number of shares of common stock subject to such award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Plan&#160;Administration.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our Board, or a duly authorized committee of our Board, administers the 2022 Plan. Our Board may also delegate to one or more of our officers the authority to (1)&#160;designate employees (other than officers) to receive specified stock awards and (2)&#160;determine the number of shares subject to such stock awards. Under the 2022 Plan, our Board has the authority to determine the terms of awards, including recipients, the exercise, purchase or strike price of stock awards, if any, the number of shares subject to each stock award, the fair market value of a share, the vesting schedule applicable to the awards, together with any vesting acceleration, the form of consideration, if any, payable upon exercise or settlement of the award and the terms of the award agreements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">No Repricing Without Stockholder Approval</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under the 2022 Plan, the plan administrator does not have the authority to reprice any outstanding stock option or stock appreciation right by reducing the exercise or strike price of the stock option or stock appreciation right or to cancel any outstanding stock option or stock appreciation right that has an exercise or strike price greater than the then-current fair market value of our common stock in exchange for cash or other stock awards without obtaining the approval of our stockholders. Such approval must be obtained within 12&#160;months prior to such an event. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Minimum Vesting Requirements.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Under the 2022 Plan, no award may vest (and/or, if applicable, be exercisable) until at least 12&#160;months following the date of grant of the award; provided, however, that up to 5% of the share reserve may be subject to awards that do not meet such vesting (and/or, if applicable, exercisability) requirements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Dividends and Dividend Equivalents.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The 2022 Plan provides that dividends or dividend equivalents may be paid or credited with respect to any shares of our common stock subject to an award, as determined by the plan administrator and contained in the applicable award agreement; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided, however</font><font style="letter-spacing:0.2pt;">, that (i)&#160;no dividends or dividend equivalents may be paid with respect to any such shares before the date such shares have vested, (ii)&#160;any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares under the terms of the applicable award agreement (including any vesting conditions), and (iii)&#160;any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to us on the date such shares are forfeited to or repurchased by us due to a failure to vest. Dividends or dividend equivalents may not be paid or credited with respect to stock options and stock appreciation rights. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Stock Options.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Incentive stock options and nonstatutory stock options are granted pursuant to stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for stock options, within the terms and conditions of the 2022 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of a share on the date of grant. Options granted under the 2022 Plan vest at the rate specified in the stock option agreement as determined by the plan administrator. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Restricted Stock Unit Awards.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Restricted stock unit awards are granted pursuant to restricted stock unit award agreements adopted by the plan administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our Board, or a duly authorized committee of our Board, and permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator or in any other form of consideration set forth in the restricted stock unit award agreement. Except as otherwise </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">provided in the applicable award agreement, restricted stock&#160;units that have not vested will be forfeited upon the participant&#8217;s cessation of continuous service for any reason. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Restricted Stock Awards.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Restricted stock awards are granted pursuant to restricted stock award agreements adopted by the plan administrator. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past services to us or any other form of legal consideration that may be acceptable to our Board, or a duly authorized committee of our Board, and permissible under applicable law. The plan administrator determines the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a participant&#8217;s service relationship with us ceases for any reason, we may receive through a forfeiture condition or a repurchase right any or all of the shares held by the participant that have not vested as of the date the participant terminates service with us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Stock Appreciation Rights.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Stock appreciation rights are granted pursuant to stock appreciation grant agreements adopted by the plan administrator. The plan administrator determines the purchase price or strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of a share on the date of grant. A stock appreciation right granted under the 2022 Plan vests at the rate specified in the stock appreciation right agreement as determined by the plan administrator. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Performance Awards.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The 2022 Plan permits the grant of performance-based stock and cash awards. Our Compensation Committee may structure awards so that the stock or cash will be issued or paid only following the achievement of certain pre-established performance goals during a designated performance period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Other Stock Awards.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The plan administrator may grant other awards based in whole or in part by reference to our shares. The plan administrator will set the number of shares under the stock award and all other terms and conditions of such awards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Changes to Capital Structure.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split or recapitalization, appropriate adjustments will be made to (1)&#160;the class and maximum number of shares reserved for issuance under the 2022 Plan, (2)&#160;the class and maximum number of shares that may be issued upon the exercise of incentive stock options, and (3)&#160;the class and number of shares and exercise price, strike price or purchase price, if applicable, of all outstanding stock awards. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Corporate Transaction and Change in Control</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following provisions will apply to outstanding awards under the 2022 Plan in the event of a corporate transaction (as defined in the 2022 Plan and described below) or a change in control (as defined in the 2022 Plan and described below) (each, a &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Transaction</font><font style="letter-spacing:0.2pt;">&#8221;), unless otherwise provided in the instrument evidencing the award, in any other written agreement between us or one of our affiliates and the participant, or in our director compensation policy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event of a Transaction, any surviving or acquiring corporation (or its parent company) may assume or continue any or all outstanding awards under the 2022 Plan, or may substitute similar stock awards for such outstanding awards (including, but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Transaction), and any reacquisition or repurchase rights held by the Company in respect of shares issued pursuant to any outstanding awards under the 2022 Plan may be assigned by the Company to the surviving or acquiring corporation (or its parent company). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event of a Transaction in which the surviving or acquiring corporation (or its parent company) does not assume or continue outstanding awards under the 2022 Plan, or substitute similar stock awards for such outstanding awards, then with respect to any such awards that have not been assumed, continued or substituted and that are held by participants whose continuous service has not terminated prior to the effective time of the Transaction (the </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">&#8220;Current Participants</font><font style="letter-spacing:0.2pt;">&#8221;), the vesting (and exercisability, if applicable) of such awards will be accelerated in full (and with respect to any such awards that are subject to performance-based vesting conditions or requirements, vesting will be deemed to be satisfied at the target level of performance to a date prior to the effective time of the Transaction (contingent upon the closing or completion of the Transaction)) as the plan administrator will determine, and such awards will terminate if not exercised (if applicable) prior to the effective time of the Transaction in accordance with the exercise procedures determined </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">by the plan administrator, and any reacquisition or repurchase rights held by the Company with respect to such awards will lapse (contingent upon the closing or completion of the Transaction). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event of a Transaction in which the surviving or acquiring corporation (or its parent company) does not assume or continue outstanding awards under the 2022 Plan, or substitute similar stock awards for such outstanding awards, then with respect to any such awards that have not been assumed, continued or substituted and that are held by participants other than the Current Participants, such awards will terminate if not exercised (if applicable) prior to the effective time of the Transaction; provided, however, that any reacquisition or repurchase rights held by the Company with respect to such awards will not terminate and may continue to be exercised notwithstanding the Transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event any outstanding award under the 2022 Plan held by a participant will terminate if not exercised prior to the effective time of a Transaction, the plan administrator may provide that the participant may not exercise such award but instead will receive a payment, in such form as may be determined by the plan administrator, equal in value to the excess, if any, of (i)&#160;the value of the property the participant would have received upon the exercise of such award immediately prior to the effective time of the Transaction, over (ii)&#160;any exercise price payable by the participant in connection with such exercise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For purposes of the 2022 Plan, a &#8220;corporate transaction&#8221; generally will be deemed to occur in the event of the consummation of: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a sale or other disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a sale or other disposition of at least 50% of the outstanding securities of the Company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of common stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For purposes of the 2022 Plan, a &#8220;change in control&#8221; generally will be deemed to occur in the event: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a person, entity or group acquires, directly or indirectly, our securities representing more than 50% of the combined voting power of our then outstanding securities, other than by virtue of a merger, consolidation, or similar transaction; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">there is consummated a merger, consolidation, or similar transaction and, immediately after the consummation of such transaction, our stockholders immediately prior thereto do not own, directly or indirectly, more than 50% of the combined outstanding voting power of the surviving entity or the parent of the surviving entity in substantially the same proportions as their ownership of our outstanding voting securities immediately prior to such transaction; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">there is consummated a sale or other disposition of all or substantially all of our consolidated assets, other than a sale or other disposition to an entity in which more than 50% of the entity&#8217;s combined voting power is owned by our stockholders in substantially the same proportions as their ownership of our outstanding voting securities immediately prior to such sale or other disposition; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a majority of our Board becomes comprised of individuals whose nomination, appointment, or election was not approved by a majority of the Board members or their approved successors. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Transferability.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;A participant may not transfer a stock option or stock appreciation right under the 2022 Plan other than by will, the laws of descent and distribution or as otherwise provided under the 2022 Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Plan&#160;Amendment or Termination.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our Board has the authority to amend, suspend or terminate the 2022 Plan, provided that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. Certain material amendments also require the approval of our stockholders </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">under Nasdaq listing rules. No incentive stock options may be granted after the tenth anniversary of the date our Board initially adopted the 2022 Plan. No stock awards may be granted under the 2022 Plan while it is suspended or after it is terminated. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">U.S. Federal Income Tax Consequences</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The information set forth below is a summary only and does not purport to be complete. The information is based upon current federal income tax rules and therefore is subject to change when those rules change. Because the tax consequences to any recipient may depend on his or her particular situation, each recipient should consult the recipient&#8217;s tax adviser regarding the federal, state, local, and other tax consequences of the grant or exercise of an award or the disposition of stock acquired as a result of an award. The 2022 Plan is not qualified under the provisions of Section&#160;401(a) of the Internal Revenue Code of 1986, as amended (the </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">&#8220;Code&#8221;</font><font style="letter-spacing:0.2pt;">) and is not subject to any of the provisions of the Employee Retirement Income Security Act of 1974, as amended. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Nonstatutory Stock Options</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Generally, there is no taxation upon the grant of a nonstatutory stock option if the stock option is granted with an exercise price equal to the fair market value of the underlying stock on the grant date. On exercise, an optionholder will recognize ordinary income equal to the excess, if any, of the fair market value on the date of exercise of the stock over the exercise price. If the optionholder is employed by us or one of our affiliates, that income will be subject to withholding taxes. We (or the affiliated employer) will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the optionholder, subject to any applicable deduction limitations under Section&#160;162(m) of the Code. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Incentive Stock Options</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 2022 Plan provides for the grant of stock options that qualify as &#8220;incentive stock options,&#8221; as defined in Section&#160;422 of the Code. Under the Code, an optionholder generally is not subject to ordinary income tax upon the grant or exercise of an incentive stock option (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">ISO</font><font style="letter-spacing:0.2pt;">&#8221;) (although, in certain circumstances, there may be an item of adjustment included for alternative minimum tax purposes). If the optionholder holds a share received on exercise of an ISO for more than two&#160;years from the date the stock option was granted and more than one year from the date the stock option was exercised, which is referred to as the required holding period, the difference, if any, between the amount realized on a sale or other taxable disposition of that share and the holder&#8217;s tax basis in that share will be long-term capital gain or loss. If, however, an optionholder disposes of a share acquired on exercise of an ISO before the end of the required holding period, which is referred to as a disqualifying disposition, the optionholder generally will recognize ordinary income in the year of the disqualifying disposition equal to the excess, if any, of the fair market value of the share on the date the ISO&#160;was exercised over the exercise price. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are not allowed an income tax deduction with respect to the grant or exercise of an ISO or the disposition of a share acquired on exercise of an ISO after the required holding period. If there is a disqualifying disposition of a share, however, we (or the affiliated employer) are generally allowed a deduction in an amount equal to the ordinary income includible in income by the optionholder, subject to any applicable deduction limitations under Section&#160;162(m) of the Code. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Restricted Stock Awards</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Generally, the recipient of a restricted stock award (i.e., stock subject to a substantial risk of forfeiture, such as a vesting requirement that the employee work for a period of time in order to have the right to sell the stock) will not recognize income until the substantial risk of forfeiture&#160;lapses, at which time the recipient will recognize ordinary income equal to the excess, if any, of the fair market value of the stock on the date the substantial risk of forfeiture lapses over any amount paid by the recipient in exchange for the stock. A recipient may, however, file an election with the Internal Revenue Service under Section&#160;83(b) of the Code within 30&#160;days following his or her receipt of the stock award, to recognize ordinary income, as of the date the recipient receives the award, equal to the excess, if any, of the fair market value of the stock on the date the award is granted over any amount paid by the recipient for the stock. We (or the affiliated employer) will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the stock award </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(upon grant or lapse of the substantial risk of forfeiture), subject to any applicable deduction limitations under Section&#160;162(m) of the Code. </font>
        </div>
        <div style="margin-top:9.63pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Restricted Stock Unit Awards</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Generally, the recipient of a stock unit structured to conform to the requirements of Section&#160;409A of the Code or an exception to Section&#160;409A of the Code will recognize ordinary income at the time the stock is delivered equal to the excess, if any, of any cash received or the fair market value of the shares received over any amount paid by the recipient in exchange for the shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We (or the affiliated employer) will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the stock award, subject to the deduction limitations under Section&#160;162(m) of the Code. </font>
        </div>
        <div style="margin-top:9.62pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stock Appreciation Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may grant under the 2022 Plan stock appreciation rights separate from any other award or in tandem with other awards under the 2022 Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Where the stock appreciation rights are granted with a strike price equal to the fair market value of the underlying stock on the grant date, the recipient will recognize ordinary income equal to the fair market value of the stock or net cash received upon such exercise. We (or the affiliated employer) will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the stock appreciation right, subject to any applicable deduction limitations under Section&#160;162(m) of the Code. </font>
        </div>
        <div style="margin-top:9.63pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Section&#160;162(m) Limitations</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under Section&#160;162(m) of the Code (</font><font style="font-weight:bold;letter-spacing:-0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Section&#160;162(m)</font><font style="font-weight:bold;letter-spacing:-0.2pt;">&#8221;</font><font style="letter-spacing:0.2pt;">), compensation paid to each of the Company&#8217;s &#8220;covered employees&#8221; that exceeds $1&#160;million per taxable year is generally non-deductible. </font>
        </div>
        <div style="margin-top:9.63pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">New Plan&#160;Benefits</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot currently determine the benefits or number of shares subject to awards that may be granted in the future to executive officers, directors, and employees under the 2022 Plan. We do not presently have any current plans, proposals or arrangements, written or otherwise, to issue any of the newly available authorized shares under the 2022 Plan. </font>
        </div>
        <div style="margin-top:9.62pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Plan&#160;Benefits under 2022 Plan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table shows, for each of the named executive officers and the various groups indicated, the number of (i)&#160;stock options underlying shares of common stock that have been granted, (ii)&#160;restricted stock&#160;units granted, and (iii)&#160;performance stock&#160;units granted, (even if not currently outstanding) under the 2022 Plan since its approval by stockholders in June&#160;2022. </font>
        </div>
        <table style="width:456pt;height:197.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:273.44pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name and position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Stock </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Options </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Restricted </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stock </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Units </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Performance </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stock Units </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:273.44pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Doug Doerfler </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">400,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.19</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.86pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:273.44pt;">
              <font style="letter-spacing:0.2pt;">Former President, Chief Executive Officer</font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:273.44pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Maher Masoud </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">520,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.37</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.86pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">400,000</td>
            <td style="padding:0pt;padding-left:4.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:273.44pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:0.2pt;">President, Chief Executive Officer, Former Vice President and General Counsel</font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:273.44pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Douglas Swirsky </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">575,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.19</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">81,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.86pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">31,250</td>
            <td style="padding:0pt;padding-left:4.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:273.44pt;">
              <font style="letter-spacing:0.2pt;">Chief Financial Officer</font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:273.44pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">All current executive officers as a group (4 persons) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,402,625</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.31</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">152,163</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.86pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">460,163</td>
            <td style="padding:0pt;padding-left:4.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:273.44pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">All current directors who are not executive officers as a group (8 persons </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">768,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.78</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:273.44pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">All employees, including all current officers who are not executive officers, as a group (approximately 166 persons) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,035,720</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.59</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,423,105</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">90,675</td>
            <td style="padding:0pt;padding-left:4.86pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSAFI">&#8203;</a><a name="StartOfCellsToJoin">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:78pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No awards have been granted under the 2022 Plan over its lifetime to the following categories of persons:&#160;(i)&#160;any associates of our non-employee directors, executive officers or nominees; or (ii)&#160;any other person who received or who is to receive 5% of such options, warrants or rights. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Securities Authorized for Issuance Under Equity Compensation Plans</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table provides certain information with respect to all of the Company&#8217;s equity compensation plans in effect as of December&#160;31, 2023. </font>
        </div>
        <table style="width:456pt;height:189pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:216.82pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of securities </font>
                <br >
                <font style="letter-spacing:-0.16pt;">to be issued upon </font>
                <br >
                <font style="letter-spacing:-0.16pt;">exercise of outstanding </font>
                <br >
                <font style="letter-spacing:-0.16pt;">options, warrants and </font>
                <br >
                <font style="letter-spacing:-0.16pt;">rights</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(a) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted average </font>
                <br >
                <font style="letter-spacing:-0.16pt;">exercise price of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">outstanding options, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">warrants and rights</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(b) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">securities </font>
                <br >
                <font style="letter-spacing:-0.16pt;">remaining available for </font>
                <br >
                <font style="letter-spacing:-0.16pt;">issuance under equity </font>
                <br >
                <font style="letter-spacing:-0.16pt;">compensation plans </font>
                <br >
                <font style="letter-spacing:-0.16pt;">(excluding securities </font>
                <br >
                <font style="letter-spacing:-0.16pt;">reflected in column </font>
                <br >
                <font style="letter-spacing:-0.16pt;">(a)) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:216.82pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Equity compensation plans approved by security holders </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216.82pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">2022 Equity Incentive Plan </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.2pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,355,595</td>
            <td style="padding:0pt;padding-left:15.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.54</td>
            <td style="padding:0pt;padding-left:21.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.655pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">6,202,089</td>
            <td style="padding:0pt;padding-left:17.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216.82pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Long-Term Incentive Plan </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.2pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,540,171</td>
            <td style="padding:0pt;padding-left:15.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.28</td>
            <td style="padding:0pt;padding-left:21.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.655pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:17.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216.82pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Equity compensation plans not approved by </font>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216.82pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">security holders </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:216.82pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Inducement Plan</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.2pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">818,400</td>
            <td style="padding:0pt;padding-left:15.2pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.97pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">5.69</td>
            <td style="padding:0pt;padding-left:21.97pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.655pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:17.655pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:216.82pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.2pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">In December&#160;2021, the Board adopted the Inducement Plan, which is a non-stockholder approved stock plan adopted pursuant to the &#8220;inducement exception&#8221; provided under Nasdaq listing rules. Simultaneous with approval of the 2022 Plan, we retired the Inducement Plan. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Required Vote</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The affirmative vote of the holders of a majority of the shares present in person or represented by proxy and entitled to vote on the matter at the Annual Meeting will be required to approve the Amendment to the 2022 Plan. Broker non-votes will have no effect and will not be counted towards the vote total for this proposal. Abstentions on this proposal will be counted towards the vote total and will have the same effect as an &#8220;Against&#8221; vote. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proposed Resolutions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">It is proposed that at the Annual Meeting the following resolution be adopted: </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; text-align:justify; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;RESOLVED, that the Amendment to the MaxCyte, Inc. 2022 Equity Incentive Plan, as amended and restated, in the form attached as Appendix&#160;A-2 to this Proxy Statement, dated April&#160;26, 2024, relating to the 2024 Annual Meeting of Stockholders, be, and hereby is, approved.&#8221; </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THE BOARD OF DIRECTORS RECOMMENDS A VOTE IN FAVOR OF PROPOSAL 2.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPR3">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROPOSAL 3</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC </font>
          <br >
          <font style="letter-spacing:-0.2pt;">ACCOUNTING FIRM</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Audit Committee has selected CohnReznick LLP as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2024 and has further directed that management submit the selection of its independent registered public accounting firm for ratification by the stockholders at the Annual Meeting. CohnReznick LLP has audited the Company&#8217;s financial statements since the fiscal year ended December&#160;31, 2019. Representatives of CohnReznick LLP are expected to be present at the Annual Meeting. They will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither the Company&#8217;s Bylaws nor other governing documents or law require stockholder ratification of the selection of CohnReznick LLP as the Company&#8217;s independent registered public accounting firm. However, the Audit Committee is submitting the selection of CohnReznick LLP to the stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit Committee will reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit Committee in its discretion may direct the appointment of different independent auditors at any time during the year if they determine that such a change would be in the best interests of the Company and its stockholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The affirmative vote of the holders of a majority of the shares present in person or represented by proxy and entitled to vote on the matter at the Annual Meeting will be required to ratify the selection of CohnReznick&#160;LLP. Abstentions on this proposal will be counted towards the vote total and will have the same effect as an &#8220;Against&#8221; vote. Since brokers have authority to vote on your behalf with respect to this proposal, we do not expect broker non-votes on this proposal. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Principal Accountant Fees And Services</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table represents aggregate fees billed to the Company for the fiscal&#160;years ended December&#160;31, 2023 and 2022 by CohnReznick LLP, the Company&#8217;s principal accountant. </font>
        </div>
        <table style="width:456pt;height:71pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.23pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fiscal Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336.23pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:336.23pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:336.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Audit Fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.945pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">420</td>
            <td style="padding:0pt;padding-left:13.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.945pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">306</td>
            <td style="padding:0pt;padding-left:13.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:336.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Tax Fees </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.945pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:14.25pt; text-align:right; white-space:nowrap;">45</td>
            <td style="padding:0pt;padding-left:13.945pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.945pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">33</td>
            <td style="padding:0pt;padding-left:13.945pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 1.5pt 0pt; width:336.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Total Fees</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.945pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">465</td>
            <td style="padding:0pt;padding-left:13.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.945pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">339</td>
            <td style="padding:0pt;padding-left:13.945pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:5pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Audit fees</font><font style="letter-spacing:0.2pt;"> consist of fees billed for professional services provided in connection with the audit of our annual financial statements, the review of our quarterly financial statements, and audit services that are normally provided by the independent registered public accounting firm in connection with regulatory filings. </font>
        </div>
        <div style="margin-left:20pt; margin-top:5pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Tax fees</font><font style="letter-spacing:0.2pt;"> consist of fees for tax compliance, consultation, and related matters</font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All fees described above were pre-approved by the Audit Committee in accordance with its pre-approval policy. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Pre-Approval Policy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The pre-approval policy requires services provided by the independent registered public accounting firm to be pre-approved by the Audit Committee, which may be delegated to one or more of the Audit Committee&#8217;s members, so long as any such pre-approval decisions are presented to the full Audit Committee at the next scheduled meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Audit Committee has determined that the rendering of services other than audit services by CohnReznick LLP is compatible with maintaining the principal accountant&#8217;s independence. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THE BOARD OF DIRECTORS RECOMMENDS </font>
          <br >
          <font style="letter-spacing:-0.2pt;">A VOTE &#8220;FOR&#8221; PROPOSAL 3. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tEXOF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXECUTIVE OFFICERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth information for our executive officers, including their ages as of March&#160;31, 2024: </font>
        </div>
        <table style="width:456pt;height:68.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:145.74pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Age </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:273.01pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:145.74pt;">
              <font style="letter-spacing:0.2pt;">Maher Masoud </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; white-space:nowrap;text-align:center;">49</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:273.01pt;">
              <font style="letter-spacing:0.2pt;">President, Chief Executive Officer and Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:145.74pt;">
              <font style="letter-spacing:0.2pt;">Douglas Swirsky </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; white-space:nowrap;text-align:center;">54</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.01pt;">
              <font style="letter-spacing:0.2pt;">Chief Financial Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:145.74pt;">
              <font style="letter-spacing:0.2pt;">Thomas M. Ross </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; white-space:nowrap;text-align:center;">63</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.01pt;">
              <font style="letter-spacing:0.2pt;">Executive Vice President, Global Sales </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:145.74pt;">
              <font style="letter-spacing:0.2pt;">David Sandoval </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; white-space:nowrap;text-align:center;">46</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.01pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Senior Vice President, General Counsel and Corporate Secretary</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The biography of Mr.&#160;Masoud is set forth in &#8220;Proposal 1: Election of Directors&#8221; above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Douglas Swirsky</font><font style="letter-spacing:0.2pt;"> has served as our Chief Financial Officer since March&#160;2023. Prior to joining MaxCyte, Mr.&#160;Swirsky served as Chief Financial Officer and Treasurer of Aavantibio, Inc., a gene therapy company, from February&#160;2021 until its acquisition by Solid Biosciences, Inc. in December&#160;2022, initially joining AavantiBio as its Interim President and a director in May&#160;2020. Mr.&#160;Swirsky served as President, Chief Executive Officer and a director of the publicly held company Rexahn Pharmaceuticals, Inc., a biotechnology company, beginning in November&#160;2018, where he led that company&#8217;s merger with Ocuphire Pharma, Inc. in November&#160;2020. Prior to joining Rexahn as its President and Chief Financial Officer in January&#160;2018, Mr.&#160;Swirsky served as President, Chief Executive Officer and a director of GenVec, Inc., a publicly traded biotechnology company, a position he held from 2013 through the sale of the company in 2017 to Intrexon Corporation (now known as Precigen, Inc.). He joined GenVec in 2006 as its Chief Financial Officer. Prior to GenVec, Mr.&#160;Swirsky was a Managing Director and the Head of Life Sciences Investment Banking at Stifel Nicolaus from 2005 to 2006 and held investment banking positions at Legg Mason from 2002 until Stifel Financial&#8217;s acquisition of the Legg Mason Capital Markets business in 2005. He also previously held investment banking positions at UBS, PaineWebber and Morgan Stanley. Mr.&#160;Swirsky currently serves as the Chairman of the Board of the publicly traded company Cellectar Biosciences, Inc. Within the last five&#160;years, Mr.&#160;Swirsky served on the board of directors of NeuroBo Pharmaceuticals, Inc. and also served on the board of directors of then-publicly traded life sciences companies Pernix Therapeutics Holdings, Inc. and Fibrocell Science, Inc. Mr.&#160;Swirsky is a certified public accountant and a CFA&#174; charterholder. He received his B.S. in Business Administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Thomas M. Ross</font><font style="letter-spacing:0.2pt;"> has served as our Executive Vice President of Global Sales since 2014. Prior to joining MaxCyte, Mr.&#160;Ross was senior vice president of commercial operations at OpGen from 2012 to 2014. Mr.&#160;Ross also served as chief commercial officer at Predictive BioScience and vice president of North America medical diagnostics sales at Qiagen/Digene Corporation. Prior to working at Digene Corporation, Mr.&#160;Ross held several senior leadership roles in manufacturing operations at Life Technologies Corporation and Cambrex. Mr.&#160;Ross received his B.A. in business administration from The Citadel </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">David Sandoval</font><font style="letter-spacing:0.2pt;"> has served as our Senior Vice President, General Counsel and Corporate Secretary since February&#160;2024. Previously, Mr.&#160;Sandoval served as our Senior Vice President, Legal and Deputy General Counsel from November&#160;2023 to February&#160;2024. From 2010 to 2023, Mr.&#160;Sandoval served as the Head of Legal Affairs/Chief Legal Officer and Chief Compliance Officer at Leadiant Biosciences, Inc., a research-based pharmaceutical company that seeks to develop novel and effective therapies for patients affected by rare disease, and from 2007 to 2010, as Assistant General Counsel and Assistant Compliance Officer at Enzon Pharmaceuticals, Inc. Mr.&#160;Sandoval also served as a member of the advisory board to The Microbial, LLC, a probiotic startup, from August&#160;2018 to September&#160;2021. Mr.&#160;Sandoval began his legal career working at major U.S. law firms. Mr.&#160;Sandoval is a member of the New York and New Jersey Bars and earned his J.D. from New&#160;York University School of Law after receiving his Bachelor of Arts from Cornell University. Mr.&#160;Sandoval also holds a Certificate of Business Administration from Georgetown University. Mr.&#160;Sandoval has been a guest lecturer at Cornell University on Pharmaceutical Policy and is a Board Member of the Cornell Latino Alumni Association. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDS1R">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:492pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DELINQUENT SECTION 16(A) REPORTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;16(a) of the Exchange Act requires the Company&#8217;s directors and executive officers, and persons who own more than ten&#160;percent of a registered class of the Company&#8217;s equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and other equity securities of the Company. Officers, directors and greater than ten&#160;percent stockholders are required by SEC regulation to furnish the Company with copies of all Section&#160;16(a) forms they file. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the Company&#8217;s knowledge, based solely on a review of the copies of such reports filed on the SEC&#8217;s EDGAR system and written representations that no other reports were required, during the fiscal year ended December&#160;31, 2023, all Section&#160;16(a) filing requirements applicable to its officers, directors and greater than ten&#160;percent beneficial owners were complied with. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSOOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SECURITY OWNERSHIP OF </font>
          <br >
          <font style="letter-spacing:-0.2pt;">CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth certain information regarding the ownership of the Company&#8217;s common stock as of April&#160;15, 2024 by: (i)&#160;each director; (ii)&#160;each of the Company&#8217;s named executive officers; (iii)&#160;all current executive officers and directors of the Company as a group; and (iv)&#160;all those known by the Company to be beneficial owners of more than five&#160;percent of its common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have determined beneficial ownership in accordance with the rules and regulations of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect to all shares that they beneficially own, subject to applicable community property laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This table is based upon information supplied by officers, directors and principal stockholders. Applicable&#160;percentage ownership is based on 104,518,803 shares of common stock outstanding as of April&#160;15, 2024. In computing the number of shares beneficially owned by a person and the&#160;percentage ownership of such person, we include all shares subject to options held by the person that are currently exercisable, or would be exercisable or would vest based on service-based vesting conditions as of June&#160;14, 2024, which is 60&#160;days after April&#160;15, 2024. However, except as described above, we do not deem such shares outstanding for the purpose of computing the&#160;percentage ownership of any other person. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise indicated, the address for each beneficial owner listed in the table below is c/o&#160;MaxCyte, Inc. 9713 Key West Avenue, Suite 400, Rockville, Maryland 20850. </font>
        </div>
        <table style="width:456pt;height:296.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:304.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name of Beneficial Owner </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of Shares </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Beneficially Owned </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares Beneficially </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:304.24pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">5% Stockholders:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">BlackRock, Inc.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">8,264,933</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">7.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Integrated Core Strategies (US) LLC</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5,749,015</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">5.5<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cadian Capital Management, LP</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5,644,898</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">5.4<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">The Vanguard Group</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5,282,108</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">5.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.24pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Directors and Named Executive Officers:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Doug Doerfler</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,798,298</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">2.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Yasir Al-Wakeel</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">154,683</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Will Brooke</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">212,785</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Richard Douglas, PhD</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(8)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">255,583</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Stanley Erck</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(9)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">573,701</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Rekha Hemrajani</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(10)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">154,683</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">John Johnston</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">229,883</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Art Mandell</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(12)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">557,367</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Patrick J. Balthrop</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(13)</font><font style="letter-spacing:0.2pt;">. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Maher Masoud</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(14)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">458,700</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Douglas Swirsky</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(15)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">102,083</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.24pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">All directors and current executive officers as a group (12 persons)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(16)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,213,586</td>
            <td style="padding:0pt;padding-left:12.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">3.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:25.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.31pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents beneficial ownership of less than 1%. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.5pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:3.5pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Based solely on a Schedule&#160;13G/A filed with the SEC on January&#160;26, 2024, BlackRock, Inc., a Delaware corporation, located at 50 Hudson Yards, New York, NY 10001 (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">BlackRock</font><font style="letter-spacing:0.2pt;">&#8221;), reported aggregate beneficial ownership of 8,264,933 shares of our common stock. BlackRock reported that it possessed sole voting power of 8,109,060 shares and sole dispositive power of 8,264,933 shares. BlackRock also reported that it did not possess shared voting or dispositive power over any shares beneficially owned. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:80pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Based solely on a Schedule&#160;13G filed with the SEC on March&#160;25, 2024, Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander (collectively, &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Integrated Core Strategies</font><font style="letter-spacing:0.2pt;">&#8221;) reported shared ownership of 5,749,015 shares of our common stock. Integrated Core Strategies (US) LLC reported shared voting and dispositive power over 5,743,954 shares. The other reporting entities and Mr.&#160;Englander reported shared voting and dispositive power over 5,749,015 shares. The address of the foregoing entities and person is c/o&#160;Millennium Management LLC, 399 Park Avenue, New York, NY 10022. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Based solely on a Schedule&#160;13G filed with the SEC on February&#160;14, 2024, Cadian Capital Management, LP, Cadian Capital Management GP, LLC, and Eric Bannasch (collectively, &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Cadian</font><font style="letter-spacing:0.2pt;">&#8221;) reported shared ownership of 5,644,898 shares of our common stock. Cadian reported that it possessed shared voting power of 5,644,898 shares and shared dispositive power of 5,644,898 shares. The address of the foregoing entities and person is 535 Madison Avenue, 36th Floor, New York, NY 10022. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Based solely on a Schedule&#160;13G filed with the SEC on February&#160;13, 2024, The Vanguard Group., a Pennsylvania corporation, located at 100 Vanguard Blvd. Malvern, PA 19355 (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Vanguard</font><font style="letter-spacing:0.2pt;">&#8221;), reported aggregate beneficial ownership of 5,282,108 shares of our common stock. Vanguard reported sole dispositive power over 5,125,864 shares, shared voting power over 59,252 shares and shared dispositive power over 156,244 shares. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;333,197 shares of common stock and (ii)&#160;2,465,101 shares of common stock issuable upon the exercise of options exercisable as of June&#160;14, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 154,683 shares of common stock issuable upon the exercise of options exercisable as of June&#160;14, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;50,302 shares of common stock and (ii)&#160;162,483 shares of common stock issuable upon the exercise of options exercisable as of June&#160;14, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;100,000 shares of common stock and (ii)&#160;155,583 shares of common stock issuable upon the exercise of options exercisable as of June&#160;14, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(9)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;247,751 shares of common stock and (ii)&#160;325,950 shares of common stock issuable upon the exercise of options exercisable as of June&#160;14, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(10)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 154,683 shares of common stock issuable upon the exercise of options exercisable as of June&#160;14, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(11)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;120,583 shares of common stock and (ii)&#160;109,300 shares of common stock issuable upon the exercise of options exercisable as of June&#160;14, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(12)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;374,484 shares of common stock and (ii)&#160;182,883 shares of common stock issuable upon the exercise of options exercisable as of June&#160;14, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(13)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 50,000 shares of common stock issuable upon the exercise of options exercisable as of June&#160;14, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(14)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 458,700 shares of common stock issuable upon the exercise of options exercisable as of June&#160;14, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(15)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of 102,083 shares of common stock issuable upon the exercise of options exercisable as of June&#160;14, 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(16)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;893,120 shares of common stock and (ii)&#160;2,320,466 shares of common stock issuable upon the exercise of options exercisable as of June&#160;14, 2024.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tEXCO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXECUTIVE COMPENSATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our named executive officers (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">NEOs</font><font style="letter-spacing:0.2pt;">&#8221;) for the fiscal year ended December&#160;31, 2023, consisting of our principal executive officer and the next two most highly compensated executive officers serving as of December&#160;31, 2023, were: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Doug Doerfler, our former President and Chief Executive Officer, who served in such position through December&#160;31, 2023; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Maher Masoud, our current President and Chief Executive Officer, effective as of January&#160;1, 2024, who served during 2023 as our Executive Vice President, Head of Global Business Development and General Counsel; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Douglas Swirsky, our Chief Financial Officer. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2023 Summary Compensation Table</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table presents all of the compensation awarded to or earned by or paid to our NEOs for the fiscal&#160;years ended December&#160;31, 2023 and, to the extent required by SEC disclosure rules, December&#160;31, 2022. </font>
        </div>
        <table style="width:456pt;height:140.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:163.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name and Principal Position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Salary</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Non-Equity</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Incentive Plan</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">All Other</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total</font>
                <br >
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7.25pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1pt 0pt; width:163.51pt;text-align:left;" rowspan="2">
              <div style="text-align:justify; line-height:12pt; padding-bottom:0.666666666666667pt;">
                <font style="letter-spacing:0.2pt;">Doug Doerfler</font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">Former President and Chief Executive </font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">Officer</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:15pt; text-align:right; white-space:nowrap;">2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">641,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">797,936</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">572,100</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,124,948</td>
            <td style="padding:0pt;padding-left:3.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,136,284</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:24pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">605,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">375,679</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">576,000</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.46pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">18,638</td>
            <td style="padding:0pt;padding-left:3.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,575,317</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1pt 0pt; width:163.51pt;text-align:left;" rowspan="2">
              <div style="text-align:justify; line-height:12pt; padding-bottom:0.666666666666667pt;">
                <font style="letter-spacing:0.2pt;">Maher Masoud</font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">President and Chief Executive Officer,</font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">former Executive Vice President</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:15pt; text-align:right; white-space:nowrap;">2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">450,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">239,381</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">186,600</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:30.75pt; text-align:right; white-space:nowrap;">14,384</td>
            <td style="padding:0pt;padding-left:3.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:30.75pt; text-align:right; white-space:nowrap;">890,365</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:24pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">412,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">178,806</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">184,800</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.46pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">14,765</td>
            <td style="padding:0pt;padding-left:3.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">790,871</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 9.833pt 0pt; width:163.51pt;text-align:left;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">Douglas Swirsky, </font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">Chief Financial Officer</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 9.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 9.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 9.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 9.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">326,129</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 9.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 9.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">684,923</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 9.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 9.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">161,500</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.46pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 9.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 9.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">17,382</td>
            <td style="padding:0pt;padding-left:3.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 9.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 9.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,189,934</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.4pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Amounts reported represent the aggregate grant date fair value of the stock options granted to our NEOs during the indicated year, computed in accordance with Financial Accounting Standard Board Accounting Standards Codification Topic 718 (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">ASC 718</font><font style="letter-spacing:0.2pt;">&#8221;). The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in Notes 2 and 4 to our audited financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2023. This amount does not reflect the actual economic value that may be realized by the NEOs upon the exercise of the options or the sale of the underlying shares. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents amounts paid pursuant to our annual incentive compensation program, described below. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Consists of matching contributions under our 401(k) plan paid by us during 2023 and 2022 and de minimis incentives provided to all employees based on company-wide sales performance. For 2023, amounts for Mr.&#160;Doerfler also include costs incurred in connection with his retirement and employment transition, consisting of $961,950 in accrued severance payments, $40,069 in accrued post-employment health insurance benefits, $89,409 for accrued but unused vacation that was cashed out, and $15,000 in legal fees reimbursed to him in connection with entering into a transition agreement and consulting agreement with us. See &#8220;Retirement Benefits and Other Compensation&#8201;&#8212;&#8201;Transition Agreement and Consulting Agreement with Doug Doerfler&#8221; for additional information. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Mr.&#160;Swirsky was not employed by our company prior to March&#160;2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Narrative to the 2023 Summary Compensation Table</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Compensation Committee determines the compensation of our executive officers and reviews such compensation on an annual basis. In setting executive base salaries and bonuses and granting equity incentive awards, our Compensation Committee considers compensation for comparable positions in the market, the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">historical compensation levels of our executives, individual performance as compared to our expectations and objectives, our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders and a long-term commitment to our company. We do not target a specific competitive position or a specific mix of compensation among base salary, bonus or long-term incentives. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Compensation Committee typically reviews and discusses management&#8217;s proposed compensation with the Chief Executive Officer for all executives other than the Chief Executive Officer. Our Compensation Committee, without members of management present, discusses and ultimately approves the compensation of our executive officers, with the exception of the Chief Executive Officer&#8217;s compensation, which is recommended to the full Board. The Compensation Committee retained Arnosti and Pearl Meyer, two&#160;compensation consulting firms, to evaluate and make recommendations with respect to our executive compensation program decisions for 2022 (Arnosti only), 2023 and 2024 (both Arnosti and Pearl Meyer). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Annual Performance Bonuses</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each of our executive officers is eligible to receive performance bonus under our annual incentive compensation program. Under our 2023 annual incentive compensation program, each of our NEOs was eligible to receive a cash incentive payment equal to (1)&#160;his target incentive, as a&#160;percentage of annual base salary, multiplied by (2)&#160;the&#160;percentage achievement of certain 2023 corporate goals established by our Compensation Committee in its sole discretion, and approved by our Board, subject to the NEO remaining employed by us through the payment date. In the case of Mr.&#160;Doerfler, in connection with his transition agreement with us we agreed that he would be entitled to receive an annual bonus for 2023 notwithstanding his termination of employment prior to the payment date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Mr.&#160;Doerfler&#8217;s target incentive was set at 85% of his annual base salary, Mr.&#160;Masoud&#8217;s was set at 45% of his annual base salary, and Mr.&#160;Swirsky&#8217;s was set at 45% of his annual base salary The corporate goals used for purposes of the 2023 annual incentive compensation program included revenue, EBITDA, and targets related to product development launches, manufacturing and engineering, and partnership licensing. Our Compensation Committee determined that the&#160;percentage achievement of the applicable corporate goals was 92% for each of the NEOs. As a result, our Compensation Committee approved a cash incentive payment for each NEO in the amounts reflected above in the &#8220;Non-Equity Incentive Plan&#160;Compensation&#8221; column of the 2023 Summary Compensation Table. Each NEO&#8217;s cash incentive payment for 2023 was paid in the first quarter of 2024. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Long-Term Incentives</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In March&#160;2023, we made annual grants of stock options to Mr.&#160;Doerfler and Mr.&#160;Masoud to purchase 400,000 shares and 120,000 shares, respectively. In connection with his appointment as Chief Financial Officer, in March&#160;2023, we granted stock options to Mr.&#160;Swirsky to purchase 350,000 shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">With respect to each of the foregoing stock option grants, 25% of the shares underlying the options vest on the first anniversary of the date of grant and the remaining shares underlying the option vest in 36 equal monthly installments thereafter, subject to each officer&#8217;s continuous service with us at each vesting date. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Retirement Benefits and Other Compensation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Transition Agreement and Consulting Agreement with Doug Doerfler</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As described in our Current Report on Form 8-K filed with the SEC on December&#160;11, 2023, on December&#160;10, 2023, Mr.&#160;Doerfler notified our Board of his decision to retire as an executive officer and director, in each case effective as of December&#160;31, 2023. On December&#160;11, 2023, we entered into a transition agreement (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Transition Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) setting forth the terms of Mr.&#160;Doerfler&#8217;s retirement and employment transition, the terms of which are described in more detail below under &#8220;Potential Payments Upon Termination or Change in Control.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We entered into a separate consulting agreement with Mr.&#160;Doerfler on January&#160;5, 2024, which was effective as of December&#160;31, 2023, under which Mr.&#160;Doerfler will, at the request of our Chief Executive Officer or the Board, or its designee, provide us with consulting services as requested, up to 20 hours per </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">month, through June&#160;30, 2025. In consideration for such services, Mr.&#160;Doerfler will receive a monthly consulting fee of $10,000 per month for the first 15 hours of service in a month, with any additional services in excess of 15 hours to be provided at a rate of $600 per hour. Mr.&#160;Doerfler&#8217;s provision of consulting services constitutes continuous service for purposes of continued vesting of his outstanding stock option awards under our equity incentive plans. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Health and Welfare and Retirement Benefits</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All of our currently serving NEOs are eligible to participate in our employee benefit plans, including our medical, dental, vision, disability and life insurance plans, in each case on the same basis as all of our other employees. We do not provide perquisites or personal benefits to our NEOs other than those provided generally to all employees. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">401(k) Plan</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We maintain a tax-qualified retirement plan, the 401(k) Plan, that provides eligible employees in the United States with an opportunity to save for retirement on a tax-advantaged basis. Under the 401(k) Plan, we may provide matching and other discretionary contributions. We currently match employee contributions equal to 50% of the first 10% of salary deferral contributions, with a maximum company contribution of 5% of the employee&#8217;s eligible compensation. Pre-tax contributions are allocated to each participant&#8217;s individual account and are then invested in selected investment alternatives according to the participants&#8217; directions. The 401(k) Plan is intended to qualify under Sections&#160;401(a) and 501(a) of the Code. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2023 Outstanding Equity Awards at Fiscal Year End</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table presents information regarding outstanding stock options held by our NEOs as of December&#160;31, 2023. None of our NEOs held restricted stock or other stock awards at the end of 2023. </font>
        </div>
        <table style="width:456pt;height:313.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Securities</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Underlying</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unexercised</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Options</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercisable </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:12pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:12pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Securities</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Underlying</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unexercised</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Options</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unexercisable </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:12pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:12pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price ($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:12pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:12pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Expiration</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Doug Doerfler </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">85,080</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.04</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11/11/2024</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">296,000</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.09</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">6/13/2026</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">296,000</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3.17</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7/14/2027</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">296,000</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3.18</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7/18/2028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">390,200</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.35</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3/4/2029</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">382,071</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">8,129<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.25pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.81</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1/20/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">276,392</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">113,808<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.25pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">14.46</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2/16/2031</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,833</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">4,167<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(3</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.25pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">16.63</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">8/9/2031</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">218,750</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">281,250<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(4</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.25pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">7.12</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3/25/2032</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">400,000<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(5</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.25pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4.19</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3/20/2033</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Maher Masoud </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">35,000</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3.18</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7/18/2028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">46,100</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.35</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3/4/2029</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">45,140</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">960<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.25pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.81</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1/20/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">69,792</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">5,208<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(6</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.25pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.13</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2/25/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">70,833</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">29,167<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.25pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">14.46</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2/16/2031</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,833</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">4,167<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(3</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.25pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">16.63</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">8/9/2031</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">45,833</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">54,167<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(7</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.25pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6.32</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2/25/2032</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">62,125</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">79,875<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(4</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.25pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">7.12</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3/25/2032</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">120,000<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(5</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.25pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4.19</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3/20/2033</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:210.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Douglas Swirsky </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">350,000<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(8</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.25pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4.11</td>
            <td style="padding:0pt;padding-left:3.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3/27/2033</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents an option to purchase shares of our common stock granted on January&#160;20, 2020. The shares </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">underlying this option vest as follows: 1/16</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> of the shares vested 90 calendar days following the grant date and the remainder vests monthly in 45 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents an option to purchase shares of our common stock granted on February&#160;16, 2021. The shares underlying this option vest as follows: 1/4</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> of the shares vested one calendar year following the grant date and the remainder vests monthly in 36 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents an option to purchase shares of our common stock granted on August&#160;9, 2021. The shares underlying this option vest as follows: 1/4</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> of the shares vested one calendar year following the grant date and the remainder vests monthly in 36 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents an option to purchase shares of our common stock granted on March&#160;25, 2022. The shares underlying this option vest as follows: 1/4</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> of the shares vested one calendar year following the grant date and the remainder vests monthly in 36 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents an option to purchase shares of our common stock granted on March&#160;20, 2023. The shares underlying this option vest as follows: 1/4</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> of the shares vested one calendar year following the grant date and the remainder vests monthly in 36 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents an option to purchase shares of our common stock granted on February&#160;25, 2020. The shares underlying this option vest as follows: 1/16</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> of the shares vested 90 calendar days following the grant date and the remainder vests monthly in 45 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents an option to purchase shares of our common stock granted on February&#160;25, 2022. The shares underlying this option vest as follows: 1/4</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> of the shares vested one calendar year following the grant date and the remainder vests monthly in 36 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.91pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:3.91pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents an option to purchase shares of our common stock granted on March&#160;27, 2023. The shares underlying this option vest as follows: 1/4</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> of the shares vested one calendar year following the grant date and the remainder vests monthly in 36 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Potential Payments Upon Termination or Change in Control</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have entered into severance agreements with each of the NEOs in connection with his employment with us, which sets forth the terms and conditions of his specified payments and benefits in connection with a termination of employment in certain circumstances. In each case, the officer must sign and not revoke a release of claims in our favor in order to receive these payments and benefits. Our goal in providing these severance and change in control payments and benefits is to offer sufficient cash continuity protection such that the NEOs will focus their full time and attention on the requirements of the business rather than the potential implications of a qualifying employment termination or change in control for their respective positions. We prefer to have certainty regarding the potential severance amounts payable to the NEOs, rather than negotiating severance at the time that an NEO&#8217;s employment terminates. We have also determined that accelerated vesting provisions with respect to outstanding equity awards in connection with a qualifying termination of employment in certain circumstances are appropriate because they encourage our NEOs to stay focused on the business in those circumstances, rather than focusing on the potential implications of the termination of employment for them personally. The material terms of the severance agreements we have entered into with our NEOs are summarized below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Doug Doerfler</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We previously entered into a severance agreement with Mr.&#160;Doerfler on July&#160;20, 2021. As described above, on December&#160;11, 2023, we and Mr.&#160;Doerfler entered into the Transition Agreement, which supersedes the previous severance agreement. Under the Transition Agreement, subject to Mr.&#160;Doerfler executing a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">general release of claims in our favor and allowing it to become effective, Mr.&#160;Doerfler became entitled to the equivalent of 18&#160;months of his base salary in effect as of December&#160;31, 2023, to be paid in 18 equal monthly installments beginning on February&#160;1, 2024, and up to 18-months of Company-paid COBRA coverage for Mr.&#160;Doerfler and his covered dependents. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Maher Masoud</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We and Mr.&#160;Masoud entered into a severance agreement dated January&#160;11, 2021, setting forth the terms of his severance eligibility. Under Mr.&#160;Masoud&#8217;s severance agreement that was in effect on December&#160;31, 2023, if he had been terminated by us other than for &#8220;cause&#8221; &#8203;(as defined in the severance agreement), or if he had resigned for &#8220;good reason&#8221; &#8203;(as defined in the severance agreement), and if such termination or resignation occurred on the date of or within 24&#160;months following a &#8220;change of control&#8221; &#8203;(as defined in the severance agreement), then Mr.&#160;Masoud would have been eligible to receive (i)&#160;payment of his monthly base salary (calculated as his total base salary during the 12 month period prior to his date of termination divided by 12) for the 9&#160;months following his departure (less applicable tax withholdings), (ii)&#160;75% of his &#8220;target bonus&#8221; &#8203;(as defined in the severance agreement) (less applicable tax withholdings) paid in monthly installments over 9&#160;months, (iii)&#160;COBRA premium coverage for up to 9&#160;months, and (iv)&#160;full acceleration of the vesting of the unvested shares subject to his outstanding stock options. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If he had been terminated by us other than for &#8220;cause,&#8221; or if he had resigned for &#8220;good reason,&#8221; and if such termination or resignation occurred at any time prior to a &#8220;change of control,&#8221; then Mr.&#160;Masoud would have been eligible to receive (i)&#160;payment of his monthly base salary (calculated as his total base salary during the 12 month period prior to his date of termination divided by 12) for the nine&#160;months following his departure (less any amounts paid to Mr.&#160;Masoud during such nine month period under our Short Term or Long Term Disability Plan, and less applicable tax withholdings), (ii)&#160;COBRA premium coverage for up to nine&#160;months, and (iii)&#160;if the termination or resignation occurs within 180&#160;days prior to a &#8220;change of control,&#8221; then Mr.&#160;Masoud would also have receive full acceleration of the vesting of the unvested shares subject to his outstanding stock options. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with Mr.&#160;Masoud&#8217;s appointment as our President and Chief Executive Officer effective as of January&#160;1, 2024, the Board approved, at the recommendation of the Compensation Committee, and on December&#160;11, 2023, we and Mr.&#160;Masoud entered into, a letter agreement (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Promotion Letter&#8221;</font><font style="letter-spacing:0.2pt;">) setting forth certain changes to Mr.&#160;Masoud&#8217;s compensation upon the effectiveness of his promotion. The Promotion Letter modifies and amends the terms of Mr.&#160;Masoud&#8217;s severance agreement described above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of the severance agreement, as modified by the Promotion Letter, if Mr.&#160;Masoud is terminated by us other than for &#8220;cause&#8221; or if he resigns for &#8220;good reason&#8221; &#8203;(each such termination, a </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">&#8220;Triggering Event&#8221;),</font><font style="letter-spacing:0.2pt;"> and if such Triggering Event occurs on or within three&#160;months prior to, or 24&#160;months following, a &#8220;change of control,&#8221; then Mr.&#160;Masoud will be eligible to receive a severance amount equal to (a)&#160;18&#160;months of his then current base salary plus (b)&#160;1.5 times his then current &#8220;target bonus,&#8221; which is defined as greater of (i)&#160;the actual bonus amount earned under our annual bonus plan with respect to the calendar year prior to the calendar year in which the termination occurs, (ii)&#160;the actual bonus amount earned under our bonus plan for the calendar year in which the termination occurs, or (iii)&#160;the target bonus amount under the Company&#8217;s bonus plan for the calendar year in which the termination occurs. The foregoing target bonus amount will not be subject to proration, and the severance amount described in the preceding sentence will be paid in equal monthly installments over an 18-month period (the </font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">&#8220;CIC Severance Period&#8221;</font><font style="letter-spacing:0.2pt;">), subject to standard payroll deductions and withholdings. In the event of a Triggering Event that occurs more than three&#160;months prior to or more than 24&#160;months following a change of control, then Mr.&#160;Masoud will be eligible to receive a severance amount equal to 12&#160;months of his then current base salary, payable in equal monthly installments over a 12-month period (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Non-CIC Severance Period&#8221;</font><font style="letter-spacing:0.2pt;">), subject to standard payroll deductions and withholdings. In addition, upon a Triggering Event that occurs on or within 180&#160;days prior to, or 24&#160;months following, a change of control, all of the unvested shares subject to any stock options granted to Mr.&#160;Masoud that remain outstanding and would otherwise not be vested and exercisable as of the date of termination will be treated as vested and exercisable as of the date of termination. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon the occurrence of a Triggering Event, if Mr.&#160;Masoud timely elects continued coverage under COBRA for himself and his covered dependents under our group health plans following the date of termination, then we will also pay the federal COBRA (or, if applicable, state continuation coverage) premiums </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDICO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">to continue healthcare coverage for Mr.&#160;Masoud and his covered dependents for the CIC Severance Period or Non-CIC Severance Period, as applicable, or, if earlier, until the date when he becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment or the date on which he ceases to be eligible for COBRA or state continuation coverage for any reason. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Douglas Swirsky</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We and Mr.&#160;Swirsky entered into a severance agreement dated March&#160;27, 2023, setting forth the terms of Mr.&#160;Swirsky&#8217;s severance eligibility. Under Mr.&#160;Swirsky&#8217;s severance agreement, if he had been terminated by us other than for &#8220;cause&#8221; &#8203;(as defined in the severance agreement), or if he had resigned for &#8220;good reason&#8221; &#8203;(as defined in the severance agreement), and if such termination or resignation occurred on the date of or within 24&#160;months following a &#8220;change of control&#8221; &#8203;(as defined in the severance agreement), then Mr.&#160;Swirsky would be eligible to receive (i)&#160;payment of his monthly base salary (calculated as his total base salary during the 12&#160;month period prior to his date of termination divided by 12) for the 12&#160;months following his departure (less applicable tax withholdings), (ii)&#160;100% of his &#8220;target bonus&#8221; &#8203;(as defined in the severance agreement) (less applicable tax withholdings) paid in monthly installments over 9&#160;months, (iii)&#160;COBRA premium coverage for up to 9&#160;months, and (iv)&#160;full acceleration of the vesting of the unvested shares subject to his outstanding stock options. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under Mr.&#160;Swirsky&#8217;s severance agreement, if he had been terminated by us other than for &#8220;cause,&#8221; or if he had resigned for &#8220;good reason,&#8221; and if such termination or resignation occurred at any time prior to a &#8220;change of control,&#8221; then Mr.&#160;Swirsky would be eligible to receive (i)&#160;payment of his monthly base salary (calculated as his total base salary during the 12 month period prior to his date of termination divided by 12) for the nine&#160;months following his departure (less any amounts paid to Mr.&#160;Swirsky during such nine month period under our Short Term or Long Term Disability Plan, and less applicable tax withholdings), (ii)&#160;COBRA premium coverage for up to nine&#160;months, and (iii)&#160;if the termination or resignation occurs within 180&#160;days prior to a &#8220;change of control,&#8221; then Mr.&#160;Swirsky would also have received full acceleration of the vesting of the unvested shares subject to his outstanding stock options. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Director Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have historically provided our non-employee directors with an annual cash retainer as well as additional annual retainers for service as chair of the Board and service as chair or member of the Board&#8217;s committees. The fees for committee service are in addition to the annual cash retainer for Board service. Members of committees can receive either a chair or a member retainer for service on the committee, but not both. </font>
        </div>
        <table style="width:416pt;height:137.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:313pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:36.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Annual Cash </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Retainer ($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:313pt;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Board of Directors</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:36.25pt;">
              <font style="letter-spacing:0.2pt;">Chair </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:26.25pt; white-space:nowrap;text-align:center;">80,000</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:313pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36.25pt;">
              <font style="letter-spacing:0.2pt;">Member </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; white-space:nowrap;text-align:center;">40,000</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:313pt;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Audit Committee</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36.25pt;">
              <font style="letter-spacing:0.2pt;">Chair </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; white-space:nowrap;text-align:center;">20,000</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:313pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36.25pt;">
              <font style="letter-spacing:0.2pt;">Member </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; white-space:nowrap;text-align:center;">10,000</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:313pt;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Compensation Committee</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36.25pt;">
              <font style="letter-spacing:0.2pt;">Chair </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; white-space:nowrap;text-align:center;">15,000<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.25pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:313pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36.25pt;">
              <font style="letter-spacing:0.2pt;">Member </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; white-space:nowrap;text-align:center;">7,500<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.25pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:313pt;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Nominating &amp; Corporate Governance Committee</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36.25pt;">
              <font style="letter-spacing:0.2pt;">Chair </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; white-space:nowrap;text-align:center;">10,000</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:313pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36.25pt;">
              <font style="letter-spacing:0.2pt;">Member </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; white-space:nowrap;text-align:center;">5,000</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Annual Retainers for the Compensation Committee Chair and members were $14,000 and $6,000, respectively prior to July&#160;1, 2023. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to annual cash retainers, in accordance with our equity grant policy, our non-employee directors are granted options to purchase shares of our common stock under our 2022 Plan in an amount determined by our Board annually. In June&#160;2023, at the time of our 2023 Annual Meeting, each of our non-employee directors was granted an option to purchase 50,000 shares of our common stock. In March&#160;2023, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;Al-Wakeel and Ms.&#160;Hemrajani were each granted an additional option to purchase 40,000 shares of our common stock. Dr.&#160;Al-Wakeel and Ms.&#160;Hemrajani joined our Board shortly before our U.S. initial public offering in August&#160;2021, and it was determined that the equity awards issued to them at the commencement of their service on the Board was below those of our peer companies listed on Nasdaq and therefore that an upward adjustment was appropriate in the form of a new grant. Our non-employee directors are also reimbursed upon request for out-of-pocket expenses incurred in connection with their attendance at Board meetings. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2023 Director Compensation Table</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth information regarding the compensation earned for service on our Board in 2023 by our non-employee directors. Doug Doerfler, our former President and Chief Executive Officer, was also a member of our Board in 2023 but did not receive any additional compensation for service as a director. Information about compensation for Mr.&#160;Doerfler with respect to 2023 is set forth above under &#8220;2023 Summary Compensation Table.&#8221; </font>
        </div>
        <table style="width:456pt;height:146.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:308.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fees Earned </font>
                <br >
                <font style="letter-spacing:-0.16pt;">or Paid </font>
                <br >
                <font style="letter-spacing:-0.16pt;">in Cash ($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards</font><font style=" position:relative; bottom:3.25pt;line-height:6pt;font-size:5pt;letter-spacing:-0.12pt;">(1)(2)</font><font style="letter-spacing:-0.16pt;"> </font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total ($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:308.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Will Brooke </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">66,750</td>
            <td style="padding:0pt;padding-left:6.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.805pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">110,494</td>
            <td style="padding:0pt;padding-left:2.805pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">177,244</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:308.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Richard Douglas, PhD </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">80,000</td>
            <td style="padding:0pt;padding-left:6.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.805pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">110,494</td>
            <td style="padding:0pt;padding-left:2.805pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">190,494</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:308.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Stanley Erck </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">51,750</td>
            <td style="padding:0pt;padding-left:6.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.805pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">110,494</td>
            <td style="padding:0pt;padding-left:2.805pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">162,244</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:308.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">John Johnston </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:6.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.805pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">110,494</td>
            <td style="padding:0pt;padding-left:2.805pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">160,494</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:308.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Art Mandell </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">60,000</td>
            <td style="padding:0pt;padding-left:6.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.805pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">110,494</td>
            <td style="padding:0pt;padding-left:2.805pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">170,494</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:308.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Yasir Al-Wakeel </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:6.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.805pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">188,527</td>
            <td style="padding:0pt;padding-left:2.805pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">238,527</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:308.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Rekha Hemrajani </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">54,500</td>
            <td style="padding:0pt;padding-left:6.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.805pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">188,527</td>
            <td style="padding:0pt;padding-left:2.805pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">243,027</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:308.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Patrick J. Balthrop, </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">45,000</td>
            <td style="padding:0pt;padding-left:6.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.805pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">110,494</td>
            <td style="padding:0pt;padding-left:2.805pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">155,494</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">This column reflects the full grant date fair value of options granted during the year measured pursuant to ASC 718, the basis for computing stock-based compensation in our financial statements. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in Notes 2 and 4 to our audited financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2023. This amount does not reflect the actual economic value that may be realized by the director upon the exercise of the options or the sale of the underlying shares. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The following table provides information regarding the aggregate number of option awards granted to our non-employee directors that were outstanding as of December&#160;31, 2023: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:416pt;height:128.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Will Brooke </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">215,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Richard Douglas, PhD </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">208,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Stanley Erck </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">378,867</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">John Johnston </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">177,217</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Art Mandell </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">235,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Yasir Al-Wakeel </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">207,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Rekha Hemrajani </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">207,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Patrick J. Balthrop </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">150,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTWRP">&#8203;</a><a name="tRTPA">&#8203;</a><a name="tCRT">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Related-Person Transactions Policy and Procedures</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have adopted a policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of our common stock and any members of the immediate family of any of the foregoing persons are not permitted to enter into a related person transaction with us without the approval or ratification of our Board or Audit Committee. Any request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of any class of our common stock or any member of the immediate family of any of the foregoing persons, in which the amount involved exceeds $120,000 and such person would have a direct or indirect interest, must be presented to our Board or Audit Committee for review, consideration and approval. In approving or rejecting any such proposal, our Board or Audit Committee, as applicable, is to consider the material facts of the transaction, including whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person&#8217;s interest in the transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The related person transactions policy also covers related party transactions under the AIM Rules for Companies published by London Stock Exchange plc (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">AIM Rules</font><font style="letter-spacing:0.2pt;">&#8221;), which contain a different definition of a related party to the definition of a related person set out above for U.S. purposes. The AIM Rules require that any transaction with a related party (pursuant to the definition in the AIM Rules) that exceeds 5% in any of the class tests set out in the AIM Rules, taking into account certain provisions relating to aggregation of transactions, should be announced without delay as soon as the terms of the transaction are agreed, and that the announcement should include certain specified information, including a statement that our directors (with the exception of any director who is involved in the transaction as a related party) consider, having consulted with our nominated adviser for AIM, that the terms of the transaction are fair and reasonable insofar as our stockholders are concerned. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Certain Related-Person Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except as described below, there have been no transactions since January&#160;1, 2022 to which we have been a participant in which the amount involved exceeded or will exceed $120,000, and in which any of our directors, executive officers or holders of more than five&#160;percent of our capital stock, or any members of their immediate family, had or will have a direct or indirect material interest, other than compensation arrangements that are described under &#8220;Executive Compensation&#8221; and &#8220;Director Compensation.&#8221; For a description of severance and change in control arrangements that we have entered into with some of our executive officers, see &#8220;Executive Compensation&#8201;&#8212;&#8201;Potential Payments upon Termination or Change in Control.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Novavax Sublease</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2011, we entered into a Lease Agreement, as subsequently amended or restated (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Lease Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) with Novavax, Inc. (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Novavax</font><font style="letter-spacing:0.2pt;">&#8221;), covering the sublease of approximately 19,000 square feet of office and laboratory space. Richard Douglas, the chairman of our Board, is a member of the board of directors of Novavax, and Stanley Erck, a member of our Board, was the chief executive officer of, and a director of, Novavax until January&#160;2023. We terminated the lease agreement in June&#160;2022. Under the terms of the Lease Agreement, we paid Novavax $296,300 for the fiscal year ended December&#160;31, 2022. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Balthrop Consulting Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;1, 2024, we entered into a Consulting Agreement (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Consulting Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) with Apalachee, pursuant to which Apalachee will provide certain executive advisory and consulting services to the Company. Mr.&#160;Balthrop, a member of our Board, is the founder and principal of Apalachee and the individual primarily responsible for providing services to the Company under the Consulting Agreement. The Consulting Agreement obligates us to pay Apalachee a daily consulting fee of $6,000 for up to 25&#160;days of service during the consulting period. The maximum fee payable to Apalachee under the Consulting Agreement will not exceed $150,000. Since January&#160;1, 2024, pursuant to the Consulting Agreement, we have paid Apalachee approximately $31,000 in total compensation. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tINAG">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:500pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indemnification Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We provide indemnification for our directors and executive officers so that they will be free from undue concern about personal liability in connection with their service to the Company. Under our Bylaws, we are required to indemnify our directors and executive officers to the extent not prohibited under Delaware law. We have also entered into indemnity agreements with certain officers and directors. These agreements provide, among other things, that we will indemnify the officer or director, under the circumstances and to the extent provided for in the agreement, for expenses, damages, judgments, fines and settlements he or she may be required to pay in actions or proceedings which he or she is or may be made a party by reason of his or her position as a director, officer or other agent of the Company, and otherwise to the fullest extent permitted under Delaware law and our Bylaws. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tHOPM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:396pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">HOUSEHOLDING OF PROXY MATERIALS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for Notices of Internet Availability of Proxy Materials or other Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single Notice of Internet Availability of Proxy Materials or other Annual Meeting materials addressed to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially means extra convenience for stockholders and cost savings for companies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This year, a number of brokers with account holders who are MaxCyte, Inc. stockholders will be &#8220;householding&#8221; the Company&#8217;s proxy materials. A single set of Annual Meeting materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be &#8220;householding&#8221; communications to your address, &#8220;householding&#8221; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in &#8220;householding&#8221; and would prefer to receive a separate set of Annual Meeting materials, please notify your broker or MaxCyte. Direct your written request to MaxCyte, Inc., Attn: Corporate Secretary; 9713 Key West Avenue, Suite 400, Rockville, Maryland&#160;20850, Attention: Investor Relations. Stockholders who currently receive multiple copies of the Annual Meeting materials at their addresses and would like to request &#8220;householding&#8221; of their communications should contact their brokers. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tOTMA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:398.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">OTHER MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment. </font>
        </div>
        <div style="margin-left:240pt; margin-top:8pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">By Order of the Board of Directors </font>
        </div>
        <div style="position:relative;margin-left:240pt; margin-top:10pt; width:216pt;">
          <img src="sg_davidsandoval-bw.jpg" alt="[MISSING IMAGE: sg_davidsandoval-bw.jpg]" height="39" width="142" >
        </div>
        <div style="margin-left:240pt; margin-top:13pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">David Sandoval </font>
        </div>
        <div style="margin-left:240pt; margin-top:8pt; width:216pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Senior Vice President, </font>
        </div>
        <table style="width:456pt;margin-top:2pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:228pt;">
              <font style="letter-spacing:0.2pt;">April&#160;26, 2024 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:216pt;">
              <font style="letter-spacing:0.2pt;">General Counsel and </font>
              <br >
              <font style="letter-spacing:0.2pt;">Corporate Secretary</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">A copy of the Company&#8217;s Annual Report to the Securities and Exchange Commission on Form 10-K for the fiscal year ended December&#160;31, 2023 is available without charge upon written request to: Corporate Secretary, MaxCyte, Inc., 9713 Key West Avenue, Suite 400, Rockville, Maryland 20850.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:328pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Appendix&#160;A-1</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">AMENDMENT TO </font>
          <br >
          <font style="letter-spacing:-0.2pt;">MAXCYTE, INC. </font>
          <br >
          <font style="letter-spacing:-0.2pt;">2022 EQUITY INCENTIVE PLAN</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">WHEREAS</font><font style="letter-spacing:0.2pt;">, MaxCyte, Inc., a Delaware corporation (the &#8220;Company&#8221;), has heretofore adopted the MaxCyte, Inc. 2022 Equity Incentive Plan (the &#8220;2022 Plan&#8221;), as amended and restated; and </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">WHEREAS</font><font style="letter-spacing:0.2pt;">, the Company wishes to amend the 2022 Plan to increase the number of shares of common stock of the Company, par value $0.01 per share, available for issuance under the Plan by 2,300,000 shares of Common Stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">NOW, THEREFORE</font><font style="letter-spacing:0.2pt;">, the Plan shall be amended, effective as of the date on which the stockholders of the Company approve such amendment at the 2024 Annual Meeting of Stockholders, as follows: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">1.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Subsection (a)(i) of Section&#160;2 is deleted and replaced with the following: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:40pt; margin-top:8pt; text-align:justify; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to adjustment in accordance with Section&#160;2(c) and any adjustments necessary to implement any Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed the sum of (i)&#160;2,300,000 new shares, plus (ii)&#160;the 7,997,000 shares previously approved under the Plan, plus (iii)&#160;a number of shares of Common Stock equal to the Prior Plan&#8217;s Available Reserve, plus (iv)&#160;a number of shares of Common Stock equal to the number of Prior Plan&#8217;s Returning Shares, if any, as such shares become available from time to time. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:40pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Except as modified herein, the remaining terms of the Plan shall remain unchanged and in full force and effect. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:15pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Appendix&#160;A-2</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MAXCYTE, INC. </font>
          <br >
          <font style="letter-spacing:-0.2pt;">2022 EQUITY INCENTIVE PLAN</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">1.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">GENERAL.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(a)&nbsp;&nbsp;&nbsp;Defined Terms.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Except as otherwise provided, any capitalized term shall have the meaning provided in Section&#160;14 of this Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(b)&nbsp;&nbsp;&nbsp;Successor to and Continuation of Prior Plan.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i)&#160;no additional awards may be granted under the Prior Plan or the Inducement Plan; (ii)&#160;the Prior Plan&#8217;s Available Reserve (plus any Prior Plans&#8217; Returning Shares) will become available for issuance pursuant to Awards granted under this Plan; (iii)&#160;all outstanding awards granted under the Prior Plan will remain subject to the terms of the Prior Plan; and (iv)&#160;all outstanding awards granted under the Inducement Plan will remain subject to the terms of the Inducement Plan. All Awards granted under this Plan will be subject to the terms of this Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(c)&nbsp;&nbsp;&nbsp;Plan&#160;Purpose.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(d)&nbsp;&nbsp;&nbsp;Available Awards.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Plan provides for the grant of the following Awards: (i)&#160;Incentive Stock Options; (ii)&#160;Nonstatutory Stock Options; (iii)&#160;SARs; (iv)&#160;Restricted Stock Awards; (v)&#160;RSU Awards; (vi)&#160;Performance Awards; and (vii)&#160;Other Awards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(e)&nbsp;&nbsp;&nbsp;Adoption Date; Effective Date.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Plan will come into existence on the Adoption Date, but no Award may be granted prior to the Effective Date. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">SHARES SUBJECT TO THE PLAN.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(a)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Share Reserve.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Subject to adjustment in accordance with Section&#160;2(c) and any adjustments as necessary to implement any Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed the sum of: (i)&#160;2,300,000 new shares, plus </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">(ii) the 7,997,000&#160;shares previously approved under the Plan, plus (iii)&#160;a number of shares of Common Stock equal to the Prior Plan&#8217;s Available Reserve, plus (iv)&#160;a number of shares of Common Stock equal to the number of Prior Plan&#8217;s Returning Shares, if any, as such shares become available from time to time.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">1</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Subject to Section&#160;2(c), the number of shares of Common Stock available for issuance under the Plan will be reduced by: (A)&#160;one share for each share of Common Stock issued pursuant to an Appreciation Award granted under the Plan; and (B)&#160;1.14 shares for each share of Common Stock issued pursuant to a Full Value Award granted under the Plan. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Subject to Section&#160;2(c), the number of shares of Common Stock available for issuance under the Plan will be increased by: (A)&#160;one share for each Prior Plans&#8217; Returning Share or 2022 Plan&#160;Returning Share (as defined in Section&#160;2(c)(iii)) subject to an Appreciation Award; and (B)&#160;1.14 shares for each Prior Plans&#8217; Returning Share or 2022 Plan&#160;Returning Share subject to a Full Value Award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(b)&nbsp;&nbsp;&nbsp;Aggregate Incentive Stock Option Limit.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary in Section&#160;2(a) and subject to any adjustments as necessary to implement any Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is 37,200,000 shares. </font>
        </div>
      </div>
      <div style="margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">1</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Marked changes to this section reflect the approval of the amendment to increase the available shares at the 2024 Annual Meeting of Stockholders.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(c)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Share Reserve Operation.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)&nbsp;&nbsp;&nbsp;Limit Applies to Common Stock Issued Pursuant to Awards.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;For clarity, the Share Reserve is a limit on the number of shares of Common Stock that may be issued pursuant to Awards and does not limit the granting of Awards, except that the Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy its obligations to issue shares pursuant to such Awards. Shares may be issued in connection with a merger or acquisition as permitted by, as applicable, Nasdaq Listing Rule&#160;5635(c), NYSE Listed Company Manual Section&#160;303A.08, NYSE American Company Guide Section&#160;711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)&nbsp;&nbsp;&nbsp;Actions that Do Not Constitute Issuance of Common Stock and Do Not Reduce Share Reserve.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The following actions do not result in an issuance of shares under the Plan and accordingly do not reduce the number of shares subject to the Share Reserve and available for issuance under the Plan: (1)&#160;the expiration or termination of any portion of an Award without the shares covered by such portion of the Award having been issued; or (2)&#160;the settlement of any portion of an Award in cash (i.e., the Participant receives cash rather than shares of Common Stock). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iii)&nbsp;&nbsp;&nbsp;Previously Issued Shares of Common Stock Available for Subsequent Issuance.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The following shares of Common Stock (collectively, the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">2022 Plan&#160;Returning Shares</font><font style="letter-spacing:0.2pt;">&#8221;) previously issued pursuant to an Award will become available again for issuance under the Plan: any shares that are forfeited back to or repurchased by the Company because of a failure to meet a contingency or condition required for the vesting of such shares. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iv)&nbsp;&nbsp;&nbsp;Previously Issued Shares of Common Stock Not Available for Subsequent Issuance.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The following shares of Common Stock previously issued pursuant to an Award will not become available again for issuance under the Plan: (1)&#160;any shares that are reacquired or withheld (or not issued) by the Company to satisfy (i)&#160;the exercise or strike price of an Appreciation Award or (ii)&#160;the purchase price of a Full Value Award; (2)&#160;any shares that are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with an Appreciation Award or a Full Value Award; (3)&#160;any shares repurchased by the Company on the open market with the proceeds of (i)&#160;the exercise or strike price of an Appreciation Award or (ii)&#160;the purchase price of a Full Value Award; and (4)&#160;in the event that an SAR is settled in shares of Common Stock, the gross number of shares of Common Stock subject to such award. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">3.&nbsp;&nbsp;&nbsp;ELIGIBILITY AND LIMITATIONS.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(a)&nbsp;&nbsp;&nbsp;Eligible Award Recipients.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Subject to the terms of the Plan, Employees, Directors and Consultants are eligible to receive Awards. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(b)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Specific Award Limitations.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)&nbsp;&nbsp;&nbsp;Limitations on Incentive Stock Option Recipients.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Incentive Stock Options may be granted only to Employees of the Company or a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof (as such terms are defined in Sections&#160;424(e) and (f)&#160;of the Code). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)&nbsp;&nbsp;&nbsp;Incentive Stock Option $100,000 Limitation.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To the extent that the aggregate fair market value (determined at the time of grant) of the shares of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof, as such terms are defined in Sections&#160;424(e) and (f)&#160;of the Code) exceeds $100,000 (or such other limit established in the Code), or any Incentive Stock Options otherwise do not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iii)&nbsp;&nbsp;&nbsp;Limitations on Incentive Stock Options Granted to Ten Percent Stockholders.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;A Ten Percent Stockholder may not be granted an Incentive Stock Option unless (i)&#160;the exercise price of such Option is </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">at least 110% of the Fair Market Value on the date of grant of such Option and (ii)&#160;the Option is not exercisable after the expiration of five&#160;years from the date of grant of such Option. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iv)&nbsp;&nbsp;&nbsp;Limitations on Nonstatutory Stock Options and SARs.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Nonstatutory Stock Options and SARs may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#8220;parent&#8221; of the Company (as such term is defined in Rule&#160;405) unless the stock underlying such Awards is treated as &#8220;service recipient stock&#8221; under Section&#160;409A because the Awards are granted pursuant to a corporate transaction (such as a spin off transaction) or unless such Awards otherwise comply with the distribution requirements of Section&#160;409A. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(c)&nbsp;&nbsp;&nbsp;Aggregate Incentive Stock Option Limit.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is the number of shares specified in Section&#160;2(b). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(d)&nbsp;&nbsp;&nbsp;Non-Employee Director Compensation Limit.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The aggregate value of all compensation granted or paid, as applicable, to any individual for service as a Non-Employee Director with respect to any fiscal year, including Awards granted and cash fees paid by the Company to such Non-Employee Director for his or her service as a Non-Employee Director, will not exceed (i)&#160;$900,000 in total value or (ii)&#160;in the event such Non-Employee Director is first appointed or elected to the Board during such fiscal year, $1,400,000 in total value, in each case calculating the value of any equity awards based on the grant date fair value of such equity awards for financial reporting purposes. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">4.</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">OPTIONS AND STOCK APPRECIATION RIGHTS.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each Option and SAR will have such terms and conditions as determined by the Board. Each Option will be designated in writing as an Incentive Stock Option or Nonstatutory Stock Option at the time of grant; provided, however, that if an Option is not so designated, then such Option will be a Nonstatutory Stock Option, and the shares purchased upon exercise of each type of Option will be separately accounted for. Each SAR will be denominated in shares of Common Stock equivalents. The terms and conditions of separate Options and SARs need not be identical; provided, however, that each Option Agreement and SAR Agreement will conform (through incorporation of provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(a)&nbsp;&nbsp;&nbsp;Term.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Subject to Section&#160;3(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of ten&#160;years from the date of grant of such Award or such shorter period specified in the Award Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(b)&nbsp;&nbsp;&nbsp;Exercise or Strike Price.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Subject to Section&#160;3(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such Award. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value on the date of grant of such Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Transaction and in a manner consistent with the provisions of Sections&#160;409A and, if applicable, 424(a) of the Code. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(c)&nbsp;&nbsp;&nbsp;Exercise Procedure and Payment of Exercise Price for Options.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In order to exercise an Option, the Participant must provide notice of exercise to the Plan&#160;Administrator in accordance with the procedures specified in the Option Agreement or otherwise provided by the Company. The Board has the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. The exercise price of an Option may be paid, to the extent permitted by Applicable Law and as determined by the Board, by one or more of the following methods of payment to the extent set forth in the Option Agreement: </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; text-align:justify; width:416pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;by cash or check, bank draft or money order payable to the Company; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;pursuant to a &#8220;cashless exercise&#8221; program developed under Regulation&#160;T as promulgated by the United States Federal Reserve Board that, prior to the issuance of the Common Stock subject to the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the exercise price to the Company from the sales proceeds; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already owned by the Participant free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1)&#160;at the time of exercise the Common Stock is publicly traded, (2)&#160;any remaining balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (3)&#160;such delivery would not violate any Applicable Law or agreement restricting the redemption of the Common Stock, (4)&#160;any certificated shares are endorsed or accompanied by an executed assignment separate from certificate, and (5)&#160;such shares have been held by the Participant for any minimum period necessary to avoid adverse accounting treatment as a result of such delivery; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iv)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;if the Option is a Nonstatutory Stock Option, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1)&#160;such shares used to pay the exercise price will not be exercisable thereafter and (2)&#160;any remaining balance of the exercise price not satisfied by such net exercise is paid by the Participant in cash or other permitted form of payment; or </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(v)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;in any other form of consideration that may be acceptable to the Board and permissible under Applicable Law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(d)&nbsp;&nbsp;&nbsp;Exercise Procedure and Payment of Appreciation Distribution for SARs.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In order to exercise any SAR, the Participant must provide notice of exercise to the Plan&#160;Administrator in accordance with the SAR Agreement. The appreciation distribution payable to a Participant upon the exercise of a SAR will not be greater than an amount equal to the excess of (i)&#160;the aggregate Fair Market Value on the date of exercise of a number of shares of Common Stock equal to the number of Common Stock equivalents that are vested and being exercised under such SAR, over (ii)&#160;the strike price of such SAR. Such appreciation distribution may be paid to the Participant in the form of Common Stock or cash (or any combination of Common Stock and cash) or in any other form of payment, as determined by the Board and specified in the SAR Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(e)&nbsp;&nbsp;&nbsp;Transferability.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Options and SARs may not be transferred to third party financial institutions for value. The Board may impose such additional limitations on the transferability of an Option or SAR as it determines. In the absence of any such determination by the Board, the following restrictions on the transferability of Options and SARs will apply, provided that except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration and provided, further, that if an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of being transferred: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)&nbsp;&nbsp;&nbsp;Restrictions on Transfer.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;An Option or SAR will not be transferable, except by will or by the laws of descent and distribution, and will be exercisable during the lifetime of the Participant only by the Participant; provided, however, that the Board may permit transfer of an Option or SAR in a manner that is not prohibited by applicable tax and securities laws upon the Participant&#8217;s request, including to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section&#160;671 of the Code and applicable U.S. state law) while such Option or SAR is held in such trust, provided that the Participant and the trustee enter into a transfer and other agreements required by the Company. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)&nbsp;&nbsp;&nbsp;Domestic Relations Orders.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, subject to the execution of transfer documentation in a format acceptable to the Company and subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to a domestic relations order. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(f)&nbsp;&nbsp;&nbsp;Vesting.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Board may impose such restrictions on or conditions to the vesting and/or exercisability of an Option or SAR as determined by the Board. Except as otherwise provided in the applicable Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Options and SARs will cease upon termination of the Participant&#8217;s Continuous Service. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(g)&nbsp;&nbsp;&nbsp;Termination of Continuous Service for Cause.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Except as explicitly otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service is terminated for Cause, the Participant&#8217;s Options and SARs will terminate and be forfeited immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising any portion (including any vested portion) of such Awards on and after the date of such termination of Continuous Service and the Participant will have no further right, title or interest in such forfeited Award, the shares of Common Stock subject to the forfeited Award, or any consideration in respect of the forfeited Award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(h)&nbsp;&nbsp;&nbsp;Post-Termination Exercise Period Following Termination of Continuous Service for Reasons Other than Cause.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Subject to Section&#160;4(i), if a Participant&#8217;s Continuous Service terminates for any reason other than for Cause, the Participant may exercise his or her Option or SAR to the extent vested, but only within the following period of time or, if applicable, such other period of time provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate; provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section&#160;4(a)): </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;three&#160;months following the date of such termination if such termination is a termination without Cause (other than any termination due to the Participant&#8217;s Disability or death); </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;12&#160;months following the date of such termination if such termination is due to the Participant&#8217;s Disability; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;18&#160;months following the date of such termination if such termination is due to the Participant&#8217;s death; or </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iv)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;18&#160;months following the date of the Participant&#8217;s death if such death occurs following the date of such termination but during the period such Award is otherwise exercisable (as provided in (i)&#160;or (ii)&#160;above). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Following the date of such termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise Period (or, if earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the Award will terminate, and the Participant will have no further right, title or interest in terminated Award, the shares of Common Stock subject to the terminated Award, or any consideration in respect of the terminated Award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)&nbsp;&nbsp;&nbsp;Restrictions on Exercise; Extension of Exercisability.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;A Participant may not exercise an Option or SAR at any time that the issuance of shares of Common Stock upon such exercise would violate Applicable Law. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates for any reason other than for Cause and, at any time during the last thirty days of the applicable Post-Termination Exercise Period, the exercise of the Participant&#8217;s Option or SAR would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate Applicable Law (as determined in the sole discretion of the Board), then the applicable Post-Termination Exercise Period will be extended to the last day of the calendar month that commences following the date the Award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period, generally without limitation as to the maximum permitted number of extensions; provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section&#160;4(a)). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(j)&nbsp;&nbsp;&nbsp;Non-Exempt Employees</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;No Option or SAR, whether or not vested, granted to an Employee who is a non-exempt employee for purposes of the United States Fair Labor Standards Act of 1938, as amended, will be first exercisable for any shares of Common Stock until at least six&#160;months following the date of grant of such Award. Notwithstanding the foregoing, in accordance with the provisions of the United States Worker Economic Opportunity Act, any vested portion of such Award may be exercised earlier than six&#160;months following the date of grant of such Award in the event of (i)&#160;such Participant&#8217;s death or Disability, (ii)&#160;a Transaction in which such Award is not assumed, continued or substituted, (iii)&#160;a Change in Control, or (iv)&#160;such Participant&#8217;s retirement (as such term may be defined in the Award Agreement or another applicable agreement or, in the absence of any such definition, in accordance with the Company&#8217;s then current </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">employment policies and guidelines). This Section&#160;4(j) is intended to operate so that any income derived by a non- exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(k)&nbsp;&nbsp;&nbsp;Whole Shares.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Options and SARs may be exercised only with respect to whole shares of Common Stock or their equivalents. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">5.</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(a)&nbsp;&nbsp;&nbsp;Restricted Stock Awards and RSU Awards.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Each Restricted Stock Award and RSU Award will have such terms and conditions as determined by the Board; provided, however, that each Restricted Stock Award Agreement and RSU Award Agreement will conform (through incorporation of the provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions: </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; text-align:justify; width:416pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Form of Award.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:416pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(1)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;RSAs: To the extent consistent with the Company&#8217;s Bylaws, at the Board&#8217;s election, shares of Common Stock subject to a Restricted Stock Award may be (i)&#160;held in book entry form subject to the Company&#8217;s instructions until such shares become vested or any other restrictions lapse, or (ii)&#160;evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board. Unless otherwise determined by the Board, a Participant will have voting and other rights as a stockholder of the Company with respect to any shares subject to a Restricted Stock Award. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:416pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(2)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;RSUs: A RSU Award represents a Participant&#8217;s right to be issued on a future date the number of shares of Common Stock that is equal to the number of restricted stock&#160;units subject to the RSU Award. As a holder of a RSU Award, a Participant is an unsecured creditor of the Company with respect to the Company&#8217;s unfunded obligation, if any, to issue shares of Common Stock in settlement of such Award and nothing contained in the Plan or any RSU Agreement, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between a Participant and the Company or an Affiliate or any other person. A Participant will not have voting or any other rights as a stockholder of the Company with respect to any RSU Award (unless and until shares are actually issued in settlement of a vested RSU Award). </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; text-align:justify; width:416pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Consideration.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:416pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(1)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;RSA: A Restricted Stock Award may be granted in consideration for (A)&#160;cash or check, bank draft or money order payable to the Company, (B)&#160;past services to the Company or an Affiliate, or (C)&#160;any other form of consideration as the Board may determine and permissible under Applicable Law. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:416pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(2)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;RSU: Unless otherwise determined by the Board at the time of grant, a RSU Award will be granted in consideration for the Participant&#8217;s services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than such services) with respect to the grant or vesting of the RSU Award, or the issuance of any shares of Common Stock pursuant to the RSU Award. If, at the time of grant, the Board determines that any consideration must be paid by the Participant (in a form other than the Participant&#8217;s services to the Company or an Affiliate) upon the issuance of any shares of Common Stock in settlement of the RSU Award, such consideration may be paid in any form of consideration as the Board may determine and permissible under Applicable Law. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iii)&nbsp;&nbsp;&nbsp;Vesting.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Board may impose such restrictions on or conditions to the vesting of a Restricted Stock Award or RSU Award as determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Restricted Stock Awards and RSU Awards will cease upon termination of the Participant&#8217;s Continuous Service. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iv)&nbsp;&nbsp;&nbsp;Termination of Continuous Service.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates for any reason, (i)&#160;the Company may receive through a forfeiture condition </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">or a repurchase right any or all of the shares of Common Stock held by the Participant under his or her Restricted Stock Award that have not vested as of the date of such termination as set forth in the Restricted Stock Award Agreement and (ii)&#160;any portion of his or her RSU Award that has not vested will be forfeited upon such termination and the Participant will have no further right, title or interest in the RSU Award, the shares of Common Stock issuable pursuant to the RSU Award, or any consideration in respect of the RSU Award. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(v)&nbsp;&nbsp;&nbsp;Settlement of RSU Awards</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;A RSU Award may be settled by the issuance of shares of Common Stock or cash (or any combination thereof) or in any other form of payment, as determined by the Board and specified in the RSU Award Agreement. At the time of grant, the Board may determine to impose such restrictions or conditions that delay such delivery to a date following the vesting of the RSU Award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(b)&nbsp;&nbsp;&nbsp;Performance Awards</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;With respect to any Performance Award, the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, the other terms and conditions of such Award, and the measure of whether and to what degree such Performance Goals have been attained will be determined by the Board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(c)&nbsp;&nbsp;&nbsp;Other Awards</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Other Awards may be granted either alone or in addition to Awards provided for under Section&#160;4 and the preceding provisions of this Section&#160;5. Subject to the provisions of the Plan, the Board will have sole and complete discretion to determine the persons to whom and the time or times at which such Other Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Awards and all other terms and conditions of such Other Awards. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">6.</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(a)&nbsp;&nbsp;&nbsp;Capitalization Adjustments</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In the event of a Capitalization Adjustment, the Board shall appropriately and proportionately adjust: (i)&#160;the class(es) and maximum number of shares of Common Stock subject to the Plan and the maximum number of shares by which the Share Reserve may annually increase pursuant to Section&#160;2(a), (ii)&#160;the class(es) and maximum number of shares that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section&#160;2(b), and (iii)&#160;the class(es) and number of securities and exercise price, strike price or purchase price of Common Stock subject to outstanding Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. Notwithstanding the foregoing, no fractional shares or rights for fractional shares of Common Stock shall be created in order to implement any Capitalization Adjustment. The Board shall determine an appropriate equivalent benefit, if any, for any fractional shares or rights to fractional shares that might be created by the adjustments referred to in the preceding provisions of this Section. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(b)&nbsp;&nbsp;&nbsp; Dissolution or Liquidation</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Except as otherwise provided in the Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#8217;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#8217;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service, provided, however, that the Board may determine to cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(c)&nbsp;&nbsp;&nbsp;Transactions.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The following provisions will apply to Awards in the event of a Transaction except as set forth in Section&#160;11, and unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or in a director compensation policy or unless otherwise expressly provided by the Board at the time of grant of an Award. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)&nbsp;&nbsp;&nbsp;Awards May Be Assumed.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In the event of a Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar awards for Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Transaction), and any reacquisition or repurchase </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">rights held by the Company in respect of Common Stock issued pursuant to Awards may be assigned by the Company to the successor of the Company (or the successor&#8217;s parent company, if any), in connection with such Transaction. A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of an Award or substitute a similar award for only a portion of an Award, or may choose to assume, continue, or substitute the Awards held by some, but not all Participants. The terms of any assumption, continuation or substitution will be set by the Board. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)&nbsp;&nbsp;&nbsp;Awards Held by Current Participants.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In the event of a Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Transaction (referred to as the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.2pt;">Current Participants</font><font style="letter-spacing:0.2pt;">&#8221;), the vesting of such Awards (and, with respect to Options and SARs, the time when such Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Transaction (contingent upon the effectiveness of the Transaction) as the Board determines (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Transaction), and such Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Transaction). With respect to the vesting of Performance Awards that will accelerate upon the occurrence of a Transaction pursuant to this subsection (ii)&#160;and that have multiple vesting levels depending on the level of performance, unless otherwise provided in the Award Agreement, the vesting of such Performance Awards will accelerate at 100% of the target level upon the occurrence of the Transaction. With respect to the vesting of Awards that will accelerate upon the occurrence of a Transaction pursuant to this subsection (ii)&#160;and are settled in the form of a cash payment, such cash payment will be made no later than 30&#160;days following the occurrence of the Transaction. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iii)&nbsp;&nbsp;&nbsp;Awards Held by Persons other than Current Participants.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In the event of a Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Awards will terminate if not exercised (if applicable) prior to the occurrence of the Transaction; provided, however, that any reacquisition or repurchase rights held by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding the Transaction. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iv)&nbsp;&nbsp;&nbsp;Payment for Awards in Lieu of Exercise.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, in the event an Award will terminate if not exercised prior to the effective time of a Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not exercise such Award but will receive a payment, in such form as may be determined by the Board, equal in value, at the effective time, to the excess, if any, of (1)&#160;the value of the property the Participant would have received upon the exercise of the Award (including, at the discretion of the Board, any unvested portion of such Award), over (2)&#160;any exercise price payable by such holder in connection with such exercise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(d)&nbsp;&nbsp;&nbsp;Appointment of Stockholder Representative.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;As a condition to the receipt of an Award under this Plan, a Participant will be deemed to have agreed that the Award will be subject to the terms of any agreement governing a Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on the Participant&#8217;s behalf with respect to any escrow, indemnities and any contingent consideration. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(e)&nbsp;&nbsp;&nbsp;No Restriction on Right to Undertake Transactions</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The grant of any Award under the Plan and the issuance of shares pursuant to any Award does not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company&#8217;s capital structure or its business, any merger or consolidation of the Company, any issue of stock or of options, rights or options to purchase stock or of bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the Common Stock or the rights thereof or which are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">7.</font>
          <br >
        </div>
        <div style=" margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">ADMINISTRATION.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(a)&nbsp;&nbsp;&nbsp;Administration by Board.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided in subsection (c)&#160;below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(b)&nbsp;&nbsp;&nbsp;Powers of Board.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To determine from time to time: (1)&#160;which of the persons eligible under the Plan will be granted Awards; (2)&#160;when and how each Award will be granted; (3)&#160;what type or combination of types of Award will be granted; (4)&#160;the provisions of each Award granted (which need not be identical), including the time or times when a person will be permitted to receive an issuance of Common Stock or other payment pursuant to an Award; (5)&#160;the number of shares of Common Stock or cash equivalent with respect to which an Award will be granted to each such person; (6)&#160;the Fair Market Value applicable to an Award; and (7)&#160;the terms of any Performance Award that is not valued in whole or in part by reference to, or otherwise based on, the Common Stock, including the amount of cash payment or other property that may be earned and the timing of payment. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it deems necessary or expedient to make the Plan or Award fully effective. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; text-align:justify; width:416pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To settle all controversies regarding the Plan and Awards granted under it. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iv)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest, notwithstanding the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(v)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30&#160;days prior to the consummation of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock or the share price of the Common Stock (including, but not limited to, any Transaction), for reasons of administrative convenience. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(vi)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To suspend or terminate the Plan at any time. Suspension or termination of the Plan will not Materially Impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(vii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To amend the Plan in any respect the Board deems necessary or advisable; provided, however, that stockholder approval will be required for any amendment to the extent required by Applicable Law. Except as provided above, rights under any Award granted before amendment of the Plan will not be Materially Impaired by any amendment of the Plan unless (1)&#160;the Company requests the consent of the affected Participant, and (2)&#160;such Participant consents in writing. </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; text-align:justify; width:416pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(viii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To submit any amendment to the Plan for stockholder approval. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ix)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; provided however, that, a Participant&#8217;s rights under any Award will not be Materially Impaired by any such amendment unless (1)&#160;the Company requests the consent of the affected Participant, and (2)&#160;such Participant consents in writing. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(x)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(xi)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To adopt such procedures and sub-plans as are necessary or appropriate to permit and facilitate participation in the Plan by, or take advantage of specific tax treatment for Awards granted to, Employees, Directors or Consultants who are non-U.S. nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement to ensure or facilitate compliance with the laws of the relevant non-U.S. jurisdiction). </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(c)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Delegation to Committee.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)&nbsp;&nbsp;&nbsp;General.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to another Committee or a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Each Committee may retain the authority to concurrently administer the Plan with the Committee or subcommittee to which it has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously delegated. The Board may retain the authority to concurrently administer the Plan with any Committee and may, at any time, revest in the Board some or all of the powers previously delegated. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)&nbsp;&nbsp;&nbsp;Rule&#160;16b-3 Compliance.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To the extent an Award is intended to qualify for the exemption from Section&#160;16(b) of the Exchange Act that is available under Rule&#160;16b-3 of the Exchange Act, the Award will be granted by the Board or a Committee that consists solely of two or more Non-Employee Directors, as determined under Rule&#160;16b-3(b)(3) of the Exchange Act and thereafter any action establishing or modifying the terms of the Award will be approved by the Board or a Committee meeting such requirements to the extent necessary for such exemption to remain available. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(d)&nbsp;&nbsp;&nbsp;Effect of Board&#8217;s Decision.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;All determinations, interpretations and constructions made by the Board or any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(e)&nbsp;&nbsp;&nbsp;Delegation to an Officer.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Board or any Committee may delegate to one or more Officers the authority to do one or both of the following (i)&#160;designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by Applicable Law, other types of Awards) and, to the extent permitted by Applicable Law, the terms thereof, and (ii)&#160;determine the number of shares of Common Stock to be subject to such Awards granted to such Employees; provided, however, that the resolutions or charter adopted by the Board or any Committee evidencing such delegation will specify the total number of shares of Common Stock that may be subject to the Awards granted by such Officer and that such Officer may not grant an Award to himself or herself. Any such Awards will be granted on the applicable form of Award Agreement most recently approved for use by the Board or the Committee, unless otherwise provided in the resolutions approving the delegation authority. Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) the authority to determine the Fair Market Value. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(f)&nbsp;&nbsp;&nbsp;No Repricing Without Stockholder Approval.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Neither the Board nor any Committee shall have the authority to: (1)&#160;reduce the exercise price (or strike price) of any outstanding Option or SAR; (2)&#160;cancel any outstanding Option or SAR and grant in substitution therefor (A)&#160;a new Option, SAR, Restricted Stock Award, RSU Award or Other Award, under the Plan or another equity plan of the Company, covering the same or a different number of shares of Common Stock, (B)&#160;cash and/or (C)&#160;other valuable consideration (as determined by the Board or any Committee); or (3)&#160;take any other action that is treated as a repricing under generally accepted accounting principles, unless the stockholders of the Company have approved such an action within the prior twelve (12) months. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(g)&nbsp;&nbsp;&nbsp;Minimum Vesting Requirements</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Notwithstanding any other provision of the Plan, no Award may vest (and/or, if applicable, be exercisable) until at least twelve (12) months following the date of grant of the Award; provided, however, that up to five&#160;percent (5%) of the Share Reserve may be subject to Awards that do not meet such vesting (and/or, if applicable, exercisability) requirements. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">8.</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">TAX WITHHOLDING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(a)&nbsp;&nbsp;&nbsp;Withholding Authorization.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;As a condition to acceptance of any Award under the Plan, a Participant authorizes withholding from payroll and any other amounts payable to such Participant, and otherwise agrees to make adequate provision for, any sums required to satisfy any U.S. and/or non-U.S. federal, state or local tax or social insurance contribution withholding obligations of the Company or an Affiliate, if any, which arise in connection with the grant, vesting, exercise, or settlement of such Award, as applicable. Accordingly, a Participant may not be able to exercise an Award even though the Award is vested, and the Company shall have no obligation to issue shares of Common Stock subject to an Award, unless and until such obligations are satisfied. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(b)&nbsp;&nbsp;&nbsp;Satisfaction of Withholding Obligation.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To the extent permitted by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any U.S. and/or non-U.S. federal, state or local tax or social insurance withholding obligation relating to an Award by any of the following means or by a combination of such means: (i)&#160;causing the Participant to tender a cash payment; (ii)&#160;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; (iii)&#160;withholding cash from an Award settled in cash; (iv)&#160;withholding payment from any amounts otherwise payable to the Participant; (v)&#160;by allowing a Participant to effectuate a &#8220;cashless exercise&#8221; pursuant to a program developed under Regulation&#160;T as promulgated by the United States Federal Reserve Board; or (vi)&#160;by such other method as may be set forth in the Award Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(c)&nbsp;&nbsp;&nbsp;No Obligation to Notify or Minimize Taxes; No Liability to Claims.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Except as required by Applicable Law, the Company has no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Award. Furthermore, the Company has no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award and will not be liable to any holder of an Award for any adverse tax consequences to such holder in connection with an Award. As a condition to accepting an Award under the Plan, each Participant (i)&#160;agrees to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation and (ii)&#160;acknowledges that such Participant was advised to consult with his or her own personal tax, financial and other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so. Additionally, each Participant acknowledges any Option or SAR granted under the Plan is exempt from Section&#160;409A only if the exercise or strike price is at least equal to the &#8220;fair market value&#8221; of the Common Stock on the date of grant as determined by the United States Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Award. Additionally, as a condition to accepting an Option or SAR granted under the Plan, each Participant agrees not to make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the United States Internal Revenue Service asserts that such exercise price or strike price is less than the &#8220;fair market value&#8221; of the Common Stock on the date of grant as subsequently determined by the United States Internal Revenue Service. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(d)&nbsp;&nbsp;&nbsp;Withholding Indemnification.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;As a condition to accepting an Award under the Plan, in the event that the amount of the Company&#8217;s and/or its Affiliate&#8217;s withholding obligation in connection with such Award was greater than the amount actually withheld by the Company and/or its Affiliates, each Participant agrees to indemnify and hold the Company and/or its Affiliates harmless from any failure by the Company and/or its Affiliates to withhold the proper amount. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">9.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">MISCELLANEOUS.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(a)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Dividends and Dividend Equivalents.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; text-align:justify; width:416pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Dividends or dividend equivalents may not be paid or credited to Options or SARs. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;With respect to any Award other than an Option or SAR, dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares of Common Stock subject to such Award, as determined by the Board and specified in the applicable Award Agreement; provided, however, that (i)&#160;no dividends or dividend equivalents may be paid or settled </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">with respect to any such shares</font><font style="letter-spacing:0.2pt;"> before </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the date </font><font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">such shares</font><font style="letter-spacing:0.2pt;"> have vested under the terms of such Award Agreement; (ii)&#160;any dividends or dividend equivalents that are credited with respect to any such shares shall be subject to all of the terms and conditions applicable to such shares under the terms of such Award Agreement (including, but not limited to, any vesting conditions); and (iii)&#160;any dividends or dividend equivalents that are credited with respect to any such shares shall be forfeited to the Company on the date, if any, such shares are forfeited to or repurchased by the Company due to a failure to meet any vesting conditions under the terms of such Award Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(b)&nbsp;&nbsp;&nbsp;Source of Shares.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(c)&nbsp;&nbsp;&nbsp;Use of Proceeds from Sales of Common Stock.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(d)&nbsp;&nbsp;&nbsp;Corporate Action Constituting Grant of Awards.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(e)&nbsp;&nbsp;&nbsp;Stockholder Rights.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Award unless and until (i)&#160;such Participant has satisfied all requirements for exercise of the Award pursuant to its terms, if applicable, and (ii)&#160;the issuance of the Common Stock subject to such Award is reflected in the records of the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(f)&nbsp;&nbsp;&nbsp;No Employment or Other Service Rights.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or affect the right of the Company or an Affiliate to terminate at will and without regard to any future vesting opportunity that a Participant may have with respect to any Award (i)&#160;the employment of an Employee with or without notice and with or without cause, (ii)&#160;the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate, or (iii)&#160;the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the U.S. state or non-U.S. jurisdiction in which the Company or the Affiliate is incorporated, as the case may be. Further, nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award will constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or service or confer any right or benefit under the Award or the Plan unless such right or benefit has specifically accrued under the terms of the Award Agreement and/or Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(g)&nbsp;&nbsp;&nbsp;Change in Time Commitment</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board may determine, to the extent permitted by Applicable Law, to (i)&#160;make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii)&#160;in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(h)&nbsp;&nbsp;&nbsp;Execution of Additional Documents.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;As a condition to accepting an Award under the Plan, the Participant agrees to execute any additional documents or instruments necessary or desirable, as determined </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">in the Plan&#160;Administrator&#8217;s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and/or other regulatory requirements, in each case at the Plan&#160;Administrator&#8217;s request. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)&nbsp;&nbsp;&nbsp;Electronic Delivery and Participation</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Any reference herein or in an Award Agreement to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). By accepting any Award, the Participant consents to receive documents by electronic delivery and to participate in the Plan through any on-line electronic system established and maintained by the Plan&#160;Administrator or another third party selected by the Plan&#160;Administrator. The form of delivery of any Common Stock (e.g., a stock certificate or electronic entry evidencing such shares) shall be determined by the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(j)&nbsp;&nbsp;&nbsp;Clawback/Recovery</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law and any clawback policy that the Company otherwise adopts, to the extent applicable and permissible under Applicable Law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a Participant&#8217;s right to voluntarily terminate employment upon a &#8220;resignation for good reason,&#8221; or for a &#8220;constructive termination&#8221; or any similar term under any plan of or agreement with the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(k)&nbsp;&nbsp;&nbsp;Securities Law Compliance.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;A Participant will not be issued any shares in respect of an Award unless either (i)&#160;the shares are registered under the Securities Act; or (ii)&#160;the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act. Each Award also must comply with other Applicable Law governing the Award, and a Participant will not receive such shares if the Company determines that such receipt would not be in material compliance with Applicable Law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(l)&nbsp;&nbsp;&nbsp;Transfer or Assignment of Awards; Issued Shares.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Except as expressly provided in the Plan or the form of Award Agreement, Awards granted under the Plan may not be transferred or assigned by the Participant. After the vested shares subject to an Award have been issued, or in the case of a Restricted Stock Award and similar awards, after the issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of the Trading Policy and Applicable Law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(m)&nbsp;&nbsp;&nbsp;Effect on Other Employee Benefit Plans.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The value of any Award granted under the Plan, as determined upon grant, vesting or settlement, shall not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant&#8217;s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#8217;s or any Affiliate&#8217;s employee benefit plans. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(n)&nbsp;&nbsp;&nbsp;Deferrals.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may also establish programs and procedures for deferral elections to be made by Participants. Deferrals will be made in accordance with the requirements of Section&#160;409A. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(o)&nbsp;&nbsp;&nbsp;Section&#160;409A.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section&#160;409A, and, to the extent not so exempt, in compliance with the requirements of Section&#160;409A. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section&#160;409A, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section&#160;409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes &#8220;deferred compensation&#8221; under Section&#160;409A is a &#8220;specified employee&#8221; for purposes of Section&#160;409A, no distribution or payment of any amount that is due because of a &#8220;separation from service&#8221; &#8203;(as defined in Section&#160;409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six&#160;months and one day following the date of such Participant&#8217;s &#8220;separation from service&#8221; or, if earlier, the date of the Participant&#8217;s death, unless such distribution or payment can be made in a manner that complies with Section&#160;409A, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(p)&nbsp;&nbsp;&nbsp;Choice of Law.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;This Plan and any controversy arising out of or relating to this Plan shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to conflict of law principles that would result in any application of any law other than the law of the State of Delaware. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">10.</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">COVENANTS OF THE COMPANY.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(a)&nbsp;&nbsp;&nbsp;Compliance with Law.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Company will seek to obtain from each regulatory commission or agency, as may be deemed necessary, having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise or vesting of the Awards; provided, however, that this undertaking will not require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary or advisable for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise or vesting of such Awards unless and until such authority is obtained. A Participant is not eligible for the grant of an Award or the subsequent issuance of Common Stock pursuant to the Award if such grant or issuance would be in violation of any Applicable Law. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">11.</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">ADDITIONAL RULES FOR AWARDS SUBJECT TO SECTION 409A.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(a)&nbsp;&nbsp;&nbsp;Application.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Unless the provisions of this Section of the Plan are expressly superseded by the provisions in the form of Award Agreement, the provisions of this Section shall apply and shall supersede anything to the contrary set forth in the Award Agreement for a Non-Exempt Award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(b)&nbsp;&nbsp;&nbsp;Non-Exempt Awards Subject to Non-Exempt Severance Arrangements.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To the extent a Non-Exempt Award is subject to Section&#160;409A due to application of a Non-Exempt Severance Arrangement, the following provisions of this subsection (b)&#160;apply. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If the Non-Exempt Award vests in the ordinary course during the Participant&#8217;s Continuous Service in accordance with the vesting schedule set forth in the Award Agreement, and does not accelerate vesting under the terms of a Non-Exempt Severance Arrangement, in no event will the shares be issued in respect of such Non-Exempt Award any later than the later of: (i)&#160;December&#160;31st of the calendar year that includes the applicable vesting date, or (ii)&#160;the 60th day that follows the applicable vesting date. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If vesting of the Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with the Participant&#8217;s Separation from Service, and such vesting acceleration provisions were in effect as of the date of grant of the Non-Exempt Award and, therefore, are part of the terms of such Non-Exempt Award as of the date of grant, then the shares will be earlier issued in settlement of such Non-Exempt Award upon the Participant&#8217;s Separation from Service in accordance with the terms of the Non-Exempt Severance Arrangement, but in no event later than the 60th day that follows the date of the Participant&#8217;s Separation from Service. However, if at the time the shares would otherwise be issued the Participant is subject to the distribution limitations contained in Section&#160;409A applicable to &#8220;specified employees,&#8221; as defined in Section&#160;409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six&#160;months following the date of such Participant&#8217;s Separation from Service, or, if earlier, the date of the Participant&#8217;s death that occurs within such six month period. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If vesting of a Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with a Participant&#8217;s Separation from Service, and such vesting acceleration provisions were not in effect as of the date of grant of the Non-Exempt Award and, therefore, are not a part of the terms of such Non-Exempt Award on the date of grant, then such acceleration of vesting of the Non-Exempt Award shall not accelerate the issuance date of the shares, but the shares shall instead be issued on the same schedule as set forth in the Grant Notice as if they had vested in the ordinary course during the Participant&#8217;s Continuous Service, notwithstanding the vesting acceleration of the Non-Exempt Award. Such issuance schedule is intended to satisfy the requirements of payment on a specified date or pursuant to a fixed schedule, as provided under United States Treasury Regulations Section&#160;1.409A-3(a)(4). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(c)&nbsp;&nbsp;&nbsp;Treatment of Non-Exempt Awards Upon a Transaction for Employees and Consultants.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The provisions of this subsection (c)&#160;shall apply and shall supersede anything to the contrary set forth in the Plan with respect to the permitted treatment of any Non-Exempt Award in connection with a Transaction if the Participant was either an Employee or Consultant upon the applicable date of grant of the Non-Exempt Award. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)&nbsp;&nbsp;&nbsp;Vested Non-Exempt Awards.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The following provisions shall apply to any Vested Non-Exempt Award in connection with a Transaction: </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:416pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(1)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If the Transaction is also a Section&#160;409A Change in Control, then the Acquiring Entity may not assume, continue or substitute the Vested Non-Exempt Award. Upon the Section&#160;409A Change in Control, the settlement of the Vested Non- Exempt Award will automatically be accelerated and the shares will be immediately issued in respect of the Vested Non-Exempt Award. Alternatively, the Company may instead provide that the Participant will receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section&#160;409A Change in Control. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:416pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(2)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If the Transaction is not also a Section&#160;409A Change in Control, then the Acquiring Entity must either assume, continue or substitute each Vested Non-Exempt Award. The shares to be issued in respect of the Vested Non-Exempt Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Transaction had not occurred. In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of the Fair Market Value of the shares made on the date of the Transaction. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)&nbsp;&nbsp;&nbsp;Unvested Non-Exempt Awards.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The following provisions shall apply to any Unvested Non-Exempt Award unless otherwise determined by the Board pursuant to subsection (e)&#160;of this Section. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:416pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(1)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In the event of a Transaction, the Acquiring Entity shall assume, continue or substitute any Unvested Non-Exempt Award. Unless otherwise determined by the Board, any Unvested Non-Exempt Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Transaction. The shares to be issued in respect of any Unvested Non-Exempt Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Transaction had not occurred. In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made on the date of the Transaction. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:416pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(2)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If the Acquiring Entity will not assume, substitute or continue any Unvested Non-Exempt Award in connection with a Transaction, then such Award shall automatically terminate and be forfeited upon the Transaction with no consideration payable to any Participant in respect of such forfeited Unvested Non-Exempt Award. Notwithstanding the foregoing, to the extent permitted and in compliance with the requirements of Section&#160;409A, the Board may in its discretion determine to elect to accelerate the vesting and settlement of the Unvested Non-Exempt Award upon the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; text-align:justify; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Transaction, or instead substitute a cash payment equal to the Fair Market Value of such shares that would otherwise be issued to the Participant, as further provided in subsection (e)(ii) below. In the absence of such discretionary election by the Board, any Unvested Non-Exempt Award shall be forfeited without payment of any consideration to the affected Participants if the Acquiring Entity will not assume, substitute or continue the Unvested Non-Exempt Awards in connection with the Transaction. </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:416pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(3)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The foregoing treatment shall apply with respect to all Unvested Non-Exempt Awards upon any Transaction, and regardless of whether or not such Transaction is also a Section&#160;409A Change in Control. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(d)&nbsp;&nbsp;&nbsp;Treatment of Non-Exempt Awards Upon a Transaction for Non-Employee Directors.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The following provisions of this subsection (d)&#160;shall apply and shall supersede anything to the contrary that may be set forth in the Plan with respect to the permitted treatment of a Non-Exempt Director Award in connection with a Transaction. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If the Transaction is also a Section&#160;409A Change in Control, then the Acquiring Entity may not assume, continue or substitute the Non-Exempt Director Award. Upon the Section&#160;409A Change in Control, the vesting and settlement of any Non- Exempt Director Award will automatically be accelerated and the shares will be immediately issued to the Participant in respect of the Non-Exempt Director Award. Alternatively, the Company may provide that the Participant will instead receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section&#160;409A Change in Control pursuant to the preceding provision. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If the Transaction is not also a Section&#160;409A Change in Control, then the Acquiring Entity must either assume, continue or substitute the Non-Exempt Director Award. Unless otherwise determined by the Board, the Non-Exempt Director Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Transaction. The shares to be issued in respect of the Non-Exempt Director Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Transaction had not occurred. In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value made on the date of the Transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(e)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If the RSU Award is a Non-Exempt Award, then the provisions in this Section&#160;11(e) shall apply and supersede anything to the contrary that may be set forth in the Plan or the Award Agreement with respect to the permitted treatment of such Non-Exempt Award: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Any exercise by the Board of discretion to accelerate the vesting of a Non-Exempt Award shall not result in any acceleration of the scheduled issuance dates for the shares in respect of the Non-Exempt Award unless earlier issuance of the shares upon the applicable vesting dates would be in compliance with the requirements of Section&#160;409A. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Company explicitly reserves the right to earlier settle any Non-Exempt Award to the extent permitted and in compliance with the requirements of Section&#160;409A, including pursuant to any of the exemptions available in United States Treasury Regulations&#160;Section&#160;1.409A-3(j)(4)(ix). </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To the extent the terms of any Non-Exempt Award provide that it will be settled upon a Change in Control or Transaction, to the extent it is required for compliance with the requirements of Section&#160;409A, the Change in Control or Transaction event triggering settlement must also constitute a Section&#160;409A Change in Control. To the extent the terms of a Non-Exempt Award provides that it will be settled upon a termination of employment or termination of Continuous Service, to the extent it is required for compliance with the requirements of Section&#160;409A, the termination event triggering settlement must also constitute a Separation From Service. However, if at the time the shares would otherwise be issued to a Participant in connection with a &#8220;separation from service&#8221; such Participant is subject to the distribution limitations contained in Section&#160;409A applicable to &#8220;specified employees,&#8221; as defined in Section&#160;409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">six&#160;months following the date of the Participant&#8217;s Separation From Service, or, if earlier, the date of the Participant&#8217;s death that occurs within such six month period. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iv)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The provisions in this subsection (e)&#160;for delivery of the shares in respect of the settlement of a RSU Award that is a Non-Exempt Award are intended to comply with the requirements of Section&#160;409A so that the delivery of the shares to the Participant in respect of such Non-Exempt Award will not trigger the additional tax imposed under Section&#160;409A, and any ambiguities herein will be so interpreted. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">12.</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">SEVERABILITY.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If all or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid. Any Section of the Plan or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">13.</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">TERMINATION OF THE PLAN.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Board may suspend or terminate the Plan at any time. No Incentive Stock Options may be granted after the tenth anniversary of the earlier of: (i)&#160;the Adoption Date, or (ii)&#160;the date the Plan is approved by the Company&#8217;s stockholders. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">14.</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <!--blacklining:none;-->
          <font style="letter-spacing:-0.2pt;">DEFINITIONS.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As used in the Plan, the following definitions apply to the capitalized terms indicated below: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(a)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Acquiring Entity</font><font style="letter-spacing:0.2pt;">&#8221; means the surviving or acquiring corporation (or its parent company) in connection with a Transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(b)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Adoption Date</font><font style="letter-spacing:0.2pt;">&#8221; means the date the Plan is first approved by the Board or Compensation Committee. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(c)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Affiliate</font><font style="letter-spacing:0.2pt;">&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule&#160;405 promulgated under the Securities Act. The Board may determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(d)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Applicable Law</font><font style="letter-spacing:0.2pt;">&#8221; means the Code and any applicable U.S. or non-U.S. securities, federal, state, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of any applicable self-regulating organization such as the Nasdaq Stock Market, New York Stock Exchange, or the Financial Industry Regulatory Authority). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(e)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Appreciation Award</font><font style="letter-spacing:0.2pt;">&#8221; means (i)&#160;a stock option or stock appreciation right granted under the Prior Plan or the Inducement Plan or (ii)&#160;an Option or Stock Appreciation Right, in each case with respect to which the exercise or strike price (per share) is at least 100% of the Fair Market Value of the Common Stock subject to the stock option or stock appreciation right, or Option or Stock Appreciation Right, as applicable, on the date of grant. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(f)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Award</font><font style="letter-spacing:0.2pt;">&#8221; means any right to receive Common Stock, cash or other property granted under the Plan (including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a RSU Award, a SAR, a Performance Award or any Other Award). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(g)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Award Agreement</font><font style="letter-spacing:0.2pt;">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award. The Award Agreement generally consists of the Grant Notice and the agreement containing the written summary of the general terms and conditions applicable to the Award and which is provided to a Participant along with the Grant Notice. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(h)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Board</font><font style="letter-spacing:0.2pt;">&#8221; means the board of directors of the Company (or its designee). Any decision or determination made by the Board shall be a decision or determination that is made in the sole discretion of the Board (or its designee), and such decision or determination shall be final and binding on all Participants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Capitalization Adjustment</font><font style="letter-spacing:0.2pt;">&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(j)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Cause</font><font style="letter-spacing:0.2pt;">&#8221; has the meaning ascribed to such term in any written agreement between the Participant and the Company or an Affiliate defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i)&#160;such Participant&#8217;s actual or attempted commission of, or participation in, a fraud or act of dishonesty against the Company or an Affiliate; (ii)&#160;such Participant&#8217;s intentional, material violation of any contract or agreement between the Participant and the Company or an Affiliate or of any statutory duty owed to the Company or an Affiliate; (iii)&#160;such Participant&#8217;s unauthorized use or disclosure of the Company&#8217;s or any of its Affiliate&#8217;s confidential information or trade secrets; or (iv)&#160;such Participant&#8217;s gross misconduct. The determination that a termination of the Participant&#8217;s Continuous Service is either for Cause or without Cause will be made by the Board with respect to Participants who are executive officers of the Company and by the Company&#8217;s Chief Executive Officer with respect to Participants who are not executive officers of the Company. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or an Affiliate or such Participant for any other purpose. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(k)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Change in Control</font><font style="letter-spacing:0.2pt;">&#8221; or &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Change of Control</font><font style="letter-spacing:0.2pt;">&#8221; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events; provided, however, to the extent necessary to avoid adverse personal income tax consequences to the Participant in connection with an Award, such event or events, as the case may be, also constitute a Section&#160;409A Change in Control: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A)&#160;on account of the acquisition of securities of the Company directly from the Company, (B)&#160;on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#8217;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or (C)&#160;solely because the level of Ownership held by any Exchange Act Person (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Subject Person</font><font style="letter-spacing:0.2pt;">&#8221;) exceeds the designated&#160;percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the&#160;percentage of the then outstanding voting securities Owned by the Subject Person over the designated&#160;percentage threshold, then a Change in Control shall be deemed to occur; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A)&#160;outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B)&#160;more than 50% of the combined outstanding voting power of the parent of the surviving Entity in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; or </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iv)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;individuals who, on the date the Plan is adopted by the Board, are members of the Board (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Incumbent Board</font><font style="letter-spacing:0.2pt;">&#8221;) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the foregoing or any other provision of this Plan, (A)&#160;the term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, and (B)&#160;the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(l)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Code</font><font style="letter-spacing:0.2pt;">&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(m)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Committee</font><font style="letter-spacing:0.2pt;">&#8221; means the Compensation Committee and any other committee of one or more Directors to whom authority has been delegated by the Board or Compensation Committee in accordance with the Plan. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(n)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Common Stock</font><font style="letter-spacing:0.2pt;">&#8221; means the common stock of the Company. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(o)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Company</font><font style="letter-spacing:0.2pt;">&#8221; means MaxCyte, Inc., a Delaware corporation, and any successor thereto. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(p)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Compensation Committee</font><font style="letter-spacing:0.2pt;">&#8221; means the Compensation Committee of the Board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(q)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Consultant</font><font style="letter-spacing:0.2pt;">&#8221; means any person, including an advisor, who is (i)&#160;engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii)&#160;serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(r)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Continuous Service</font><font style="letter-spacing:0.2pt;">&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service; provided, however, that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i)&#160;any leave of absence approved by the Board or chief executive officer, including </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">sick leave, military leave or any other personal leave, or (ii)&#160;transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the Company&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. In addition, to the extent required for exemption from or compliance with Section&#160;409A, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of &#8220;separation from service&#8221; as defined under United States Treasury Regulation&#160;Section&#160;1.409A-1(h) (without regard to any alternative definition thereunder). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(s)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Corporate Transaction</font><font style="letter-spacing:0.2pt;">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;a sale or other disposition of all or substantially all, as determined by the Board, of the consolidated assets of the Company and its Subsidiaries; </font>
        </div>
        <div style="text-indent:40pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;a sale or other disposition of at least 50% of the outstanding securities of the Company; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iv)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(t)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Director</font><font style="letter-spacing:0.2pt;">&#8221; means a member of the Board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(u)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">determine</font><font style="letter-spacing:0.2pt;">&#8221; or &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">determined</font><font style="letter-spacing:0.2pt;">&#8221; means as determined by the Board or the Committee (or its designee) in its sole discretion. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(v)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Disability</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to a Participant, such Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12&#160;months, as provided in Section&#160;22(e)(3) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(w)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Effective Date</font><font style="letter-spacing:0.2pt;">&#8221; means the date on which the Plan is approved by the Company&#8217;s stockholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(x)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Employee</font><font style="letter-spacing:0.2pt;">&#8221; means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(y)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Employer</font><font style="letter-spacing:0.2pt;">&#8221; means the Company or the Affiliate that employs the Participant. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(z)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Entity</font><font style="letter-spacing:0.2pt;">&#8221; means a corporation, partnership, limited liability company or other entity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(aa)&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Exchange Act</font><font style="letter-spacing:0.2pt;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(bb)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Exchange Act Person</font><font style="letter-spacing:0.2pt;">&#8221; means any natural person, Entity or &#8220;group&#8221; &#8203;(within the meaning of Section&#160;13(d) or 14(d) of the Exchange Act), except that &#8220;Exchange Act Person&#8221; will not include (i)&#160;the Company or any Subsidiary of the Company, (ii)&#160;any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii)&#160;an underwriter temporarily holding securities pursuant to a registered public offering of such securities, (iv)&#160;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v)&#160;any natural person, Entity or &#8220;group&#8221; &#8203;(within the meaning of Section&#160;13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(cc)&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Fair Market Value</font><font style="letter-spacing:0.2pt;">&#8221; means, as of any date, unless otherwise determined by the Board, the value of the Common Stock (as determined on a per share or aggregate basis, as applicable) determined as follows: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(i)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists. </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In the absence of such markets for the Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections&#160;409A and 422 of the Code. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(dd)&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Full Value Award</font><font style="letter-spacing:0.2pt;">&#8221; means (i)&#160;a stock award granted under the Prior Plan or the Inducement Plan or (ii)&#160;an Award, in each case that is not an Appreciation Award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ee)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Governmental Body</font><font style="letter-spacing:0.2pt;">&#8221; means any: (i)&#160;nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (ii)&#160;U.S. federal, state, local, municipal, non-U.S. or other government; (iii)&#160;governmental or regulatory body, or quasi-governmental body of any nature (including any governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any Tax authority) or other body exercising similar powers or authority; or (iv)&#160;self-regulatory organization (including the Nasdaq Stock Market, New York Stock Exchange, and the Financial Industry Regulatory Authority). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ff)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Grant Notice</font><font style="letter-spacing:0.2pt;">&#8221; means the notice provided to a Participant that he or she has been granted an Award under the Plan and which includes the name of the Participant, the type of Award, the date of grant of the Award, number of shares of Common Stock subject to the Award or potential cash payment right, (if any), the vesting schedule for the Award (if any) and other key terms applicable to the Award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(gg)&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Incentive Stock Option</font><font style="letter-spacing:0.2pt;">&#8221; means an option granted pursuant to Section&#160;4 of the Plan that is intended to be, and qualifies as, an &#8220;incentive stock option&#8221; within the meaning of Section&#160;422 of the Code. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(hh)&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Inducement Plan</font><font style="letter-spacing:0.2pt;">&#8221; means the MaxCyte, Inc. 2021 Inducement Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ii)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Materially Impair</font><font style="letter-spacing:0.2pt;">&#8221; means any amendment to the terms of the Award that materially adversely affects the Participant&#8217;s rights under the Award. A Participant&#8217;s rights under an Award will not be deemed to have been Materially Impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant&#8217;s rights. For example, the following types of amendments to the terms of an Award do not Materially Impair the Participant&#8217;s rights under the Award: (i)&#160;imposition of reasonable restrictions on the minimum number of shares subject to an Option that may be exercised, (ii)&#160;to maintain the qualified status of the Award as an Incentive Stock Option under Section&#160;422 of the Code; (iii)&#160;to change the terms of an Incentive Stock Option in a manner that disqualifies, impairs or otherwise affects the qualified status of the Award as an Incentive Stock Option under Section&#160;422 of the Code; (iv)&#160;to clarify the manner of exemption from, or to bring the Award into compliance with or qualify it for an exemption from, Section&#160;409A; or (v)&#160;to comply with other Applicable Law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(jj)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Non-Employee Director</font><font style="letter-spacing:0.2pt;">&#8221; means a Director who either (i)&#160;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item&#160;404(a) of Regulation&#160;S-K promulgated pursuant to the Securities Act (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Regulation&#160;S-K</font><font style="letter-spacing:0.2pt;">&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item&#160;404(a) of Regulation&#160;S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item&#160;404(b) of Regulation&#160;S-K; or (ii)&#160;is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule&#160;16b-3. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(kk)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Non-Exempt Award</font><font style="letter-spacing:0.2pt;">&#8221; means any Award that is subject to, and not exempt from, Section&#160;409A, including as the result of (i)&#160;a deferral of the issuance of the shares subject to the Award which is elected by the Participant or imposed by the Company or (ii)&#160;the terms of any Non-Exempt Severance Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ll)&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Non-Exempt Director Award</font><font style="letter-spacing:0.2pt;">&#8221; means a Non-Exempt Award granted to a Participant who was a Director but not an Employee on the applicable grant date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(mm)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Non-Exempt Severance Arrangement</font><font style="letter-spacing:0.2pt;">&#8221; means a severance arrangement or other agreement between the Participant and the Company that provides for acceleration of vesting of an Award and issuance of the shares in respect of such Award upon the Participant&#8217;s termination of employment or separation from service (as such term is defined in Section&#160;409A(a)(2)(A)(i) of the Code (and without regard to any alternative definition thereunder) (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Separation from Service</font><font style="letter-spacing:0.2pt;">&#8221;)) and such severance benefit does not satisfy the requirements for an exemption from application of Section&#160;409A provided under United States Treasury Regulations&#160;Section&#160;1.409A-1(b)(4), 1.409A-1(b)(9) or otherwise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(nn)&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Nonstatutory Stock Option</font><font style="letter-spacing:0.2pt;">&#8221; means any option granted pursuant to Section&#160;4 of the Plan that does not qualify as an Incentive Stock Option. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(oo)&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Officer</font><font style="letter-spacing:0.2pt;">&#8221; means a person who is an officer of the Company within the meaning of Section&#160;16 of the Exchange Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(pp)&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Option</font><font style="letter-spacing:0.2pt;">&#8221; means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(qq)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Option Agreement</font><font style="letter-spacing:0.2pt;">&#8221; means a written agreement between the Company and the Optionholder evidencing the terms and conditions of the Option grant. The Option Agreement includes the Grant Notice for the Option and the agreement containing the written summary of the general terms and conditions applicable to the Option and which is provided to a Participant along with the Grant Notice. Each Option Agreement will be subject to the terms and conditions of the Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(rr)&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Optionholder</font><font style="letter-spacing:0.2pt;">&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ss)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Other Award</font><font style="letter-spacing:0.2pt;">&#8221; means an award valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value at the time of grant), that is not an Incentive Stock Option, Nonstatutory Stock Option, SAR, Restricted Stock Award, RSU Award or Performance Award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(tt)&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Other Award Agreement</font><font style="letter-spacing:0.2pt;">&#8221; means a written agreement between the Company and a holder of an Other Award evidencing the terms and conditions of an Other Award grant. Each Other Award Agreement will be subject to the terms and conditions of the Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(uu)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Own,</font><font style="letter-spacing:0.2pt;">&#8221; &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Owned,</font><font style="letter-spacing:0.2pt;">&#8221; &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Owner,</font><font style="letter-spacing:0.2pt;">&#8221; &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Ownership</font><font style="letter-spacing:0.2pt;">&#8221; means that a person or Entity will be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221; to be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(vv)&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Participant</font><font style="letter-spacing:0.2pt;">&#8221; means an Employee, Director or Consultant to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ww)&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Performance Award</font><font style="letter-spacing:0.2pt;">&#8221; means an Award that may vest or may be exercised or a cash award that may vest or become earned and paid contingent upon the attainment during a Performance Period of certain Performance Goals and which is granted under the terms and conditions of Section&#160;5(b) pursuant to such terms as are approved by the Board. In addition, to the extent permitted by Applicable Law and set forth in the applicable Award Agreement, the Board may determine that cash or other property may be used in payment of Performance Awards. Performance Awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the Common Stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(xx)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Performance Criteria</font><font style="letter-spacing:0.2pt;">&#8221; means the one or more criteria that the Board will select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">establish such Performance Goals may be based on any one of, or combination of, the following as determined by the Board: earnings (including earnings per share and net earnings); earnings before interest, taxes and depreciation; earnings before interest, taxes, depreciation and amortization; net income/loss adjusted for interest expense, interest income, other income/expenses, net provision for/benefit from income taxes, depreciation and amortization, legal settlement expenses and stock-based compensation expenses; other earnings measures; total stockholder return; return on equity or average stockholder&#8217;s equity; return on assets, investment, or capital employed; stock price; margin (including gross margin); income (before or after taxes); operating income; operating income after taxes; pre-tax profit; operating cash flow; sales or revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of working capital levels; economic value added (or an equivalent metric); market share; cash flow; cash flow per share; share price performance; debt reduction; customer satisfaction; stockholders&#8217; equity; capital expenditures; debt levels; operating profit or net operating profit; workforce diversity; growth of net income or operating income; pre-clinical development related compound goals; operations within or below pre-determined annual budget, sales of certain number of instruments, reagents and/or service contracts; financing; regulatory milestones, including approval of a compound; stockholder liquidity; corporate governance and compliance; product commercialization; intellectual property; personnel matters; progress of internal research or clinical programs; progress of partnered programs; partner satisfaction; budget management; clinical achievements; completing phases of a clinical study (including the treatment phase); announcing or presenting preliminary or final data from clinical studies; in each case, whether on particular timelines or generally; timely completion of clinical trials; submission of INDs and NDAs and other regulatory achievements; partner or collaborator achievements; internal controls, including those related to the Sarbanes-Oxley Act of 2002; research progress, including the development of programs; investor relations, analysts and communication; manufacturing achievements (including obtaining particular yields from manufacturing runs and other measurable objectives related to process development activities); strategic partnerships or transactions (including in-licensing and out-licensing of intellectual property; establishing relationships with commercial entities with respect to the marketing, distribution and sale of the Company&#8217;s products (including with group purchasing organizations, distributors and other vendors); supply chain achievements (including establishing relationships with key manufacturers or suppliers of active pharmaceutical ingredients and other component materials and manufacturers of the Company&#8217;s products); co-development, co-marketing, profit sharing, joint venture or other similar arrangements; individual performance goals; corporate development and planning goals; and other measures of performance selected by the Board or Committee. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(yy)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Performance Goals</font><font style="letter-spacing:0.2pt;">&#8221; means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business&#160;units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Board (i)&#160;in the Award Agreement at the time the Award is granted or (ii)&#160;in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Board will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1)&#160;to exclude restructuring and/or other nonrecurring charges; (2)&#160;to exclude exchange rate effects; (3)&#160;to exclude the effects of changes to generally accepted accounting principles; (4)&#160;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&#160;to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles; (6)&#160;to exclude the dilutive effects of acquisitions or joint ventures; (7)&#160;to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture; (8)&#160;to exclude the effect of any change in the outstanding shares of Common Stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9)&#160;to exclude the effects of stock based compensation and the award of bonuses under the Company&#8217;s bonus plans; (10) to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and (11) to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. In addition, the Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Performance Criteria it selects to use for such Performance Period. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Award Agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(zz)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Performance Period</font><font style="letter-spacing:0.2pt;">&#8221; means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to vesting or exercise of an Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(aaa)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Plan</font><font style="letter-spacing:0.2pt;">&#8221; means this MaxCyte, Inc. 2022 Equity Incentive Plan, as amended from time to time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(bbb)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Plan&#160;Administrator</font><font style="letter-spacing:0.2pt;">&#8221; means the person, persons, and/or third-party administrator designated by the Company to administer the day to day operations of the Plan and the Company&#8217;s other equity incentive programs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ccc)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Post-Termination Exercise Period</font><font style="letter-spacing:0.2pt;">&#8221; means the period following termination of a Participant&#8217;s Continuous Service within which an Option or SAR is exercisable, as specified in Section&#160;4(h). </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ddd)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Prior Plan</font><font style="letter-spacing:0.2pt;">&#8221; means the Company&#8217;s Long-Term Incentive Plan, as amended. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(eee)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Prior Plan&#8217;s Available Reserve</font><font style="letter-spacing:0.2pt;">&#8221; means the number of shares available for the grant of new awards under the Prior Plan as of immediately prior to the Effective Date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(fff)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Prior Plans&#8217; Returning Shares</font><font style="letter-spacing:0.2pt;">&#8221; means shares subject to outstanding stock awards granted under the Prior Plan or the Inducement Plan and that following the Effective Date: (A)&#160;are not issued because such stock award or any portion thereof expires or otherwise terminates without all of the shares covered by such stock award having been issued; (B)&#160;are not issued because such stock award or any portion thereof is settled in cash; or (C)&#160;are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ggg)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Restricted Stock Award</font><font style="letter-spacing:0.2pt;">&#8221; or &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">RSA</font><font style="letter-spacing:0.2pt;">&#8221; means an Award of shares of Common Stock which is granted pursuant to the terms and conditions of Section&#160;5(a). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(hhh)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Restricted Stock Award Agreement</font><font style="letter-spacing:0.2pt;">&#8221; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. The Restricted Stock Award Agreement includes the Grant Notice for the Restricted Stock Award and the agreement containing the written summary of the general terms and conditions applicable to the Restricted Stock Award and which is provided to a Participant along with the Grant Notice. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(iii)&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">RSU Award</font><font style="letter-spacing:0.2pt;">&#8221; or &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">RSU</font><font style="letter-spacing:0.2pt;">&#8221; means an Award of restricted stock&#160;units representing the right to receive an issuance of shares of Common Stock which is granted pursuant to the terms and conditions of Section&#160;5(a). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(jjj)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">RSU Award Agreement</font><font style="letter-spacing:0.2pt;">&#8221; means a written agreement between the Company and a holder of a RSU Award evidencing the terms and conditions of a RSU Award. The RSU Award Agreement includes the Grant Notice for the RSU Award and the agreement containing the written summary of the general terms and conditions applicable to the RSU Award and which is provided to a Participant along with the Grant Notice. Each RSU Award Agreement will be subject to the terms and conditions of the Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(kkk)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Rule&#160;16b-3</font><font style="letter-spacing:0.2pt;">&#8221; means Rule&#160;16b-3 promulgated under the Exchange Act or any successor to Rule&#160;16b-3, as in effect from time to time. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(lll)&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Rule&#160;405</font><font style="letter-spacing:0.2pt;">&#8221; means Rule&#160;405 promulgated under the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(mmm)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Section&#160;409A</font><font style="letter-spacing:0.2pt;">&#8221; means Section&#160;409A of the Code and the regulations and other guidance thereunder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(nnn)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Section&#160;409A Change in Control</font><font style="letter-spacing:0.2pt;">&#8221; means a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company&#8217;s assets, as provided in Section&#160;409A(a)(2)(A)(v) of the Code and United States Treasury Regulations&#160;Section&#160;1.409A-3(i)(5) (without regard to any alternative definition thereunder). </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:220pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ooo)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Securities Act</font><font style="letter-spacing:0.2pt;">&#8221; means the Securities Act of 1933, as amended. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ppp)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Share Reserve</font><font style="letter-spacing:0.2pt;">&#8221; means the number of shares available for issuance under the Plan as set forth in Section&#160;2(a). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(qqq)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Stock Appreciation Right</font><font style="letter-spacing:0.2pt;">&#8221; or &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">SAR</font><font style="letter-spacing:0.2pt;">&#8221; means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section&#160;4. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(rrr)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">SAR Agreement</font><font style="letter-spacing:0.2pt;">&#8221; means a written agreement between the Company and a holder of a SAR evidencing the terms and conditions of a SAR grant. The SAR Agreement includes the Grant Notice for the SAR and the agreement containing the written summary of the general terms and conditions applicable to the SAR and which is provided to a Participant along with the Grant Notice. Each SAR Agreement will be subject to the terms and conditions of the Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(sss)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Subsidiary</font><font style="letter-spacing:0.2pt;">&#8221; means, with respect to the Company, (i)&#160;any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&#160;any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(ttt)&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Ten Percent Stockholder</font><font style="letter-spacing:0.2pt;">&#8221; means a person who Owns (or is deemed to Own pursuant to Section&#160;424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(uuu)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Trading Policy</font><font style="letter-spacing:0.2pt;">&#8221; means the Company&#8217;s policy permitting certain individuals to sell Company shares only during certain &#8220;window&#8221; periods and/or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time to time. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(vvv)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Transaction</font><font style="letter-spacing:0.2pt;">&#8221; means a Corporate Transaction or a Change in Control. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(www)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Unvested Non-Exempt Award</font><font style="letter-spacing:0.2pt;">&#8221; means the portion of any Non-Exempt Award that had not vested in accordance with its terms upon or prior to the date of any Transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">(xxx)</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Vested Non-Exempt Award</font><font style="letter-spacing:0.2pt;">&#8221; means the portion of any Non-Exempt Award that had vested in accordance with its terms upon or prior to the date of a Transaction.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A-26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.31pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="position:relative;padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:-8pt;margin-left:0pt;width:595.31pt;">
        <div style="position:relative;z-index:-1;text-align:center; width:595.31pt;">
          <img src="px_24maxcytepage01-bw.jpg" alt="[MISSING IMAGE: px_24maxcytepage01-bw.jpg]" height="961" width="743" >
        </div>
        <div style="margin-top:13pt; text-align:justify; width:595.31pt; line-height:1pt;color:#FFFFFF;font-family:Times New Roman, Times, serif ;font-size:1pt;">
          <font style="letter-spacing:0.02pt;">0000643897_1 R1.0.0.6MAXCYTE, INC.9713 KEY WEST AVENUE, SUITE 400ROCKVILLE, MD 20850SCAN TOVIEW MATERIALS &amp; VOTEVOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode aboveUse the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 11:59 P.M. Eastern Time on June 10, 2024. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALSIf you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future years.VOTE BY PHONE - 1-800-690-6903Use any touch-tone telephone to transmit your voting instructions. Vote by 11:59 P.M. Eastern Time on June 10, 2024. Have your proxy card in hand when you call and then follow the instructions.VOTE BY MAILMark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLYThe Board of Directors recommends you vote FOR the following directors to hold office until the 2027 Annual Meeting:For Withhold For AllAll All ExceptTo withhold authority to vote for anyindividual nominee(s), mark &#8220;For AllExcept&#8221; and write the number(s) of thenominee(s) on the line below.1. Election of Class III DirectorsNominees01) Will Brooke 02) John Johnston 03) Richard DouglasThe Board of Directors recommends you vote FOR proposals 2 and 3. For Against Abstain2. To approve an amendment to the MaxCyte, Inc. 2022 Equity Incentive Plan to increase the shares available for issuance.3. To ratify the selection by the Audit Committee of the Board of Directors of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.NOTE: Such other business as may properly come before the meeting or any adjournment thereof.Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer.Signature [PLEASE SIGN WITHIN BOX]DateSignature (Joint Owners)Date </font>
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.31pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="position:relative;padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:-8pt;margin-left:0pt;width:595.31pt;">
        <div style="position:relative;z-index:-1;margin-top:8pt; text-align:center; width:595.31pt;">
          <img src="px_24maxcytepage02-4c.jpg" alt="[MISSING IMAGE: px_24maxcytepage02-4c.jpg]" height="961" width="743" >
        </div>
        <div style="margin-top:19.5pt; width:595.31pt; line-height:3pt;color:#FFFFFF;font-family:Times New Roman, Times, serif ;font-size:1pt;">
          <font style="letter-spacing:0.02pt;">0000643897_2 R1.0.0.6Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:The Notice and Proxy Statement and Annual Report are available at www.proxyvote.comMAXCYTE, INC.Annual Meeting of StockholdersJune 11, 2024 at 11:00 A.M. ETThis proxy is solicited by the Board of DirectorsThe stockholder hereby appoints Maher Masoud and David Sandoval, or either of them, as proxies, each with the power to appoint his substitute, and hereby authorizes them to represent and to vote, as designated on the reverse side of this ballot, and in their discretion upon such other matters as may be properly brought before the meeting, all of the shares of common stock of MAXCYTE, INC. that the stockholder is entitled to vote at the Annual Meeting of Stockholders to be held at 11:00 AM Eastern Time on June 11, 2024, at 9713 Key West Avenue, Suite 400, Rockville, MD 20850, and any adjournment or postponement thereof.This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors&#39; recommendations.Continued and to be signed on reverse side</font>
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>px_24maxcytepage01-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 px_24maxcytepage01-bw.jpg
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M_\0 HP !  (# 0$! 0            4& P0' @$("0$! 0$
M      $"$   !@$# @,!"0P&!P,+  L  0(#! 4&$1('(1,Q(A0505$RTB.3
M5!8(89'10E)RDK,UE587LC.#E-0V<=,D='57&(&T-[%B0U,T)56UEC@)H=5V
M\7-$IL&"&2<1 0$! 0$                1 2%!_]H # ,!  (1 Q$ /P#]
M_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                 C,BR*CQ*EF9'DL]FKHZ]ONS)TE1
M(:;1J1%J9^Z9F22(NIF>A=0')/\ J_\ LW?Q]$_N\W_#@I_U?_9O_CZ)_=YO
M^' /^K_[-_\ 'T3^[S?\. ?]7_V;_P"/HG]WF_X<!G@_:S^SK8S&($7/H/J9
M+B6FNZW*91O6>A;G'64H26ONJ41 CLR5)6DEH,E)46J5%U(R/W2 ?0
M
M
M
M                 ?F3[>YF7V=K,B,R([*M(R(]-2[VO4!_*ANHMG6TNM0)
M"VEEN0M+2U),C]TC(NH"U5:*:-%HFK/"9LV5"L52;R0E^2R4^O,T;8J4)1HT
M9:+^43UZ@.CV>3\&2*Z8Q7<'6<2P=9=1#E'=6#A,O*29(<-!IT5M/0]#\0'$
M?8ES_P##I7S+GQ0&*16V,1!.RHCS#1GM);K:T)U][51$ _NAQZ9G@.*F9ZF=
M/7ZF?4__ &5L!9
M
M
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MYQ'<P;/F5^GD5=IJU'6^6A&EMUPD[5&?@VZ25>X6X!^@ 0
M
M
M                         !^9/M[_ /V[67_$ZW]<"NB_9F_\ ..O^!Q/
MZ (ZL   #\C?_D0_\%:W_C<?]2\ _2O'G^0,5_X/7_\ =6P%D          '
MYA^V=Q!EO)6-T%YAT9=E8XRY*-^I9ZOO1YI,[EM)_&4@V2\A=5$9Z=2T,N*_
MQ5]M"LLYD3"N9*@Z&\);<1RWV;89R$FDDG)8<(E1SW=346Y*3Z^1/@(H_P!H
MQHL]^UIA^"7:E+QYE=3!5%U,DJ9EO=^1IH?13A*V&KWB+W@'[M575ZZ\ZE<1
ME54;7IC@FV@X_8V[.WV]-NS;Y=NFF@(X-]KG,8W'W!LVDJ4HAOW_ &L>KHS"
M2;0W%4DS?2E"=")!,-J:Z="W$"OS3R[Q38\/\6\.<@U#'I<DIUI<NGR1HXFP
ME.%91NZ9:'\DHG&=3]Y) /U+SAD<',/LO9!E58>L"YI8TY@M=32E]QE>T_NI
MUVG]T@'XN:H;GC#">)?M%8@@TNF[)B7*"U)LY46;):02S+KLDQDJ97^;XZJ
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M<27Y;9J3[^A] 1TP
M
M                                                      ?F3[>_
M_P!NUE_Q.M_7 KHOV9O_   XZ_X'$_H CJP   /R-_\ D0_\%:W_ (W'_4O
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M6
M
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M1%]PB ?3(E$9&6I'T,C\- &K%JZR"XMZ%"8C.N?UCC+2&U*_TFDB,P&V
M      /ROS[_ /<OP;_O#OZ] *_5 ( /+CC;+:W75I;:;2:UK69)2E*2U,S,
M^A$1 /S-RK]J7%GI+_'/&E"GDW*)^Z*Y#0R<NHUUT,G-I*]0DOQB1Y/?60*K
MW 7V5LMQ;(D\BYA>.XU9/O>J+%<<=[+!)4LW/3RED:T*:+7;V4;BT_' ?KP$
M
M
M                                  !^9/M[_P#V[67_ !.M_7 KHOV9
MO_ #CK_@<3^@".K    _(W_Y$/\ P5K?^-Q_U+P#]*\>?Y Q7_@]?_W5L!9
M    '),USK)\.YIP.GDR&SX\S%B55+9-I.]BY8(W65][X7RQ*0TE'AT,P',\
M\YOY#ATG+668U,88H,8O*O%\9-<9MW26TZVBS6LU%Y]5.$E'N$1].O4%;7)?
M+63U7,EMA"N1ZOCW'8%7#FQ)-C6-6"I#\@S):"-QQO33X7C_ -@"TN<GY/AG
M*5]C68V+5AB\?"DY762FXR(Q*>K2[<W0TFH_E#2M[8:CV)T(OND<TQO[0_)D
M[@W);*T[37+D:XKJFF:5&;;2:;WT[L11LZ;3,VENFG4NI)+77J"NT\[9=EN
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M#+W7GU>977J2>B2_%(@1=
M
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M3#9ZI9U,_$M5^^LP1V4
M
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MFD$24)0DM"2DBZ$1%X$ ]@
M
M
M  .5_:(XEE<U\66>"5\]NMLWW8\J#)D$HV.]&<)9)<V$:B2HM2U21F7CH8#\
M%_\ ^O#F_P!V=1_WIW_4@/2/_P >?.3:TN-V%(E:3)25)EO$9&74C(R9]P!W
M/*N+OMOYG@3O'5YD>-KII#"8DZ<VM:9\N.DDEL><[.G7;YU)(C7KU <*_P#]
M>'-_TZC_ +T[_J0&Q!__ !U\ROS6&9UM21(2UD4B23[SJFT>Z9()HMQ^\6I?
MZ2 ?TPH:INBHZRC:<-YJLB,0D.J+12TQVTMDHR+W3).H"0
M
M
M
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MI/W24DR,@&T C3R"E3D",5.:T61+AJLT5VORQPD.DR;VGY)+42?]("2
M
M
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ME39W#S%F>8XA,E3'I;,AM[1@VH"X33,!+/1&B9"R=0>O50&OU6"
M                                                   /QS%Y&S6G
MY+N\DJYLJW<Y(D7^-X#3*6MZN:GT4Z%!BRE(U-+;"4*??>4DO@I/W>H-(RBR
M:Y;P%KC^#DF0Y%+S*[NK6RR.F;D7-S'QBLD' 0\TTVLUM%-DQR0A1>1*5N&
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M:8\E<=3[SR]B7"T<VJVDO7P,$= !
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MA$1$1 )P!KMSH3TM^ U):<G14MN28J5I4ZTA[=VU+01ZI)>Q6TS+KH>G@ V
M&O,G0J]DI-A):BQS6VT3KZTM([CRR;;3N49%N6I1)27NF>A -@    !KR9L&
M(Y&9ER&F'9CG8B-NK2A3SQ)4YL;)1D:E;4*5HGKH1G[@#8 /#P   !K6-C J
M83]C:26H=?&3OD2I"TMM-H]]2E&1$7^D!CMK>JH:]^VNIC-?61B)3\N2M+32
M",R26JE&1:F9DDB]T^A -:VI<=R^J1#NH$:XIWS;DMLR6TOM&I.BVW$DHCT,
MO%*BZD E@&M/L(%7']7926HD7>VSWGUDVCN/N):;3JHR+5:U)2DO=,] &R
M   UFI\"1+D0&)++LZ%VSEQD.)4ZR3Q&;9N((]4[R(S3N+K[@#9T(_$!K1[&
M!+E2X,:2T],@*0B:PA9*<96Z@G$$XDCU2:D*)1:^X>H#6G9!0UC[D:SLXL-]
MF.<YUN2\VT:(J5DT;RMYEH@EJ).X^FIZ )(    !')OZ1=VYC:+!A=^TP4MV
MM2XDY"(ZE;2<4@CU))GX:^(#9B3X,_OG!E,RBC/+C2>PXESMOM=%MKVF>U:=
M?,D^I -:;?4M=8P*B=/8CVMF:RKX3CB4O/\ :+59H1KJ9)(RU/[I>^ D0
M:\R="KHYRK"2U$BDI#9OOK2TV2W5DVA.Y9D6JE*)*2]TS(@&P
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MJ)/74!W.R8LKWBQU/']W+5;/5Q/X]<R#UDO/M$3K/>-]"3T=4DD.;D$>U1^
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MTU(]0[TA:7$)<3\%1$I.I&1Z'U\#Z@CT
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M;9*)!$E))/X6NH#LH(
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MH*2RE"U)2:TIW%HM)DM&J3UZ&8"/B<E8=-FVT-B:[LHCEHMY[D24U7QUU_\
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M/P_\@#YO09),E%HKHD]?$_N /0
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MV.G(<80I?<3H6B]3\_3X6H,K:
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M84<J?';?/T4\T(-U#L'?M,C2:?E#00?I$$
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M=CQOQ_;E4)L\8JY2*#0J5MR&R:(B2TT2RG;HA);2/:1:="]X!:
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MC^X8#Z
M
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MZ6ON@CT
M
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ML<J+UN(4&-=+?77GL133%&A$]6CAZ,DHCU3_ %NA&K9MZ@1U@$
M
M
M
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MT(WP
M
M
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M6#-SBTFOR2FOZO&[:J]6Q(:;7=&79>;E-$:'$DD]RD:$HO!6@$3I<TU9\O\
M\J/9DC::5,)R'7_8SM$12G*A$6WX91U$YKO\?+H!'F/S75'A6>9O,JY#,#!;
M6TIY,=I27G92JI24&XWH2223AJ+HKX/B9Z 18..<OO\ -*4[B\QY%"ATT.5Z
MH]E&MXTJ,Z@E)<;>C:$1D>J5)4GH9=#474$7$
M
M
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ME,]2UTT%9<D^SS;V.6Y3R+5/5C6=N7M9>8;/D=XTM-06&F7XTS1!_)NDE?\
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M)Z :ZT"
M
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MZ]R/@<>XB4#N0P2MYQL%$BD\E2E^L3OC]2U21/%_5&9^<^B=3 6@
M
M
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MUR/4YG,SK!+;#HD9R96M77?DV3;BX+/J8[*$)<6R>]"EF7E-)'KH9>Z BH'
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M3.',H>*.M)%]4CCFZ9EN,_E39,VB(_)KUU KM@(
M
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M!.G&CQ2:425+):UJ6RE?F[9&:= ([2"
M
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M7E%:ERFV'8]*X3L!+Z$.D3IQE%JV;FX_?U!:O0(
M
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M4.1SW+*(W1*X\J4QD/1\@C34M')??7VOEMYJ<;<4A391TH)SIKJ8?HT$
M
M
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M*/RMR5%JD]06+9*R3'8+<%Z;;PHS5GM*M<>DM-IDFLB-/9-2B)S4E)TVZ^)
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M/X'[@#+>V6!V5+7VE]9UR\?.7&FUL]Z6VW%7+B.D^PMMXG$I4:5M[B(E'KH
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MA$ZB.<EI]M;1/NFE*&]R5&6Y1K224^)[B]\!(@
M
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M4BK@9#E-76-O>RF[J@2J!7>E=4E*=JB<WDV9;B*,V9_=#]  @
M
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M#2AU[:2UJ2A/4P(Z<PXIUEMU;9M+6E*E-*-*E),RU-)FDS29EX=#,@1D
M
M
M                                                      &E<5<6
M\J9]+.W>BLHST.3VU;%]J0@VU[5%X'HH]# 5*3Q-B<JNF5;OJ_2SJFMH7]KY
MDOT5,MQR/HK3HO5U6]7XP#%"X?Q*'D)Y$2YCSI2+68S!=>(XC;U\9JG&2$H2
MI7<,S,NXM6S71.U/0%K!"X;HZMBI34W5S!FTT%5-%LF931RE51K);<1Q2V5)
M4VR9%VE;>XG\OJ>HJ<E<?8_,;MVW?4$5W:0;R<:73(_65A1"9-'3RI_V-K<G
M\;S>^"(,N%,0];*EJ>GK;D%<DW$.01,,?6,U*GFV24$HS6I1J2IQ2C1X)T3T
M!:D(G&%%%N:&W5+GR4XPTEJAKWWD+BQ5)A^@-Q&C9.&I3.I*)3AH-1FK;NT,
MB-F!Q_6U.0S;^IL;"$S92E6-C3,O(]G/S7&B96\I"FU+(UDE)J2AQ*346XRU
MU,PCH?$E'5*JUT-I;5#E;71J5:X<I.LN#!6IR.W([K;FXVS6YM6C:O1:BUT,
M%'>(\;>/(HSDRR.AR=$XK''_ %9^SDNVI$4IYIO;O0M:M7/A[4K4I24D9F W
M%\9XY+BV<6Y7*N/;51&Q^V?G/;G9$2(J0I"U*;2WH[K)7JX@B/X.FF@(U8?$
M]"REQ=C8VMS8NRJN6Y9V4ONRC*C>]1#9U0A"2:0X:EJ22-5J6HU&9GJ"CO$&
M&2';)R4U(?;M_;)3V%R%]M:<C*.4Q.A:&1'Z9OMZ'Y.N@(T)W"E%;1H[5O>W
MMA,CQYD K*5-0Y*5!LFFF9$<U=HDI2HF4'O0E+F[4]_F5J6I:+Q9BD-Z*^PF
M2E42P@VS*3?4:2DUE<FK8U+W4=A);D^ZKS C'QS@"<)?RN<Z;*IN37<NVTC[
MS0S%</1A@C7H?0MSBB+RDXXO;T :K7"^%LU<^G04ST=E5N4<G62HU^C>EOS5
M;5:=%]R2YYO>T+W 6K;:8[76\VDL)?<]102U3Z_8LTI[RXST0]Y?C%VWU]/?
MT,$4VLX0PVL1*CD_92ZV16V-"Q72IBW(T2KMW$N2(T=)$1H3JA))49FLDD2=
MVA$1%K';<(8U>0F(5E;73B4U945BZB=VG;&O;<4ZTW+4VA.[MJ6O:I&P]%*)
M6XC,@*G;7C?'+B/>,2#DMN7MA%N7I3#QMOQ[& U':COQED7R:F_2M*+Q(SUU
M(R,R!$K$H50J*5429;]\J0AXG%VZVUF]WDF1MK[32$DV>NW1+?0O< 43%.$Z
MVDPG#Z&382H^2XJEUYK(*UTDR/5SDGZPB4^APG&G#5MVNH/RI3X&DM"U*3^'
ML:LK9-S+FV2Y;B*I-C_M*=LYRA>-^&[(/M[C4E9ZJ)"DI7^,D^@%;MAQI43:
M&?CC%A8U]?9S;"?8>E>;-3YVZW5R6E]YMU)M*-Y6B=OEZ:&6@(F\>QJ#C#+D
M2L?DG7&F,U$@R'E/,1&8<9N*VU')>II0:6B4K4SU6:E&?4!,@
M
M
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MQ6Y*2<\WE UT<$
M
M
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MU:RDQT08WJ9)))28\9LU):01)\-RC^[X$0= !
M
M
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M
M
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MEJ6NQSTY&HSZ]>@"] @
M
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MRMS)*S!IC-5*R:QF093$N"ITZ^1C4B"<J3.CF:U*43;K;D5"S/:I2FU&7FT
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MR<9]UM"W8ZE$M3:U)(S0:DZD9I/IJ70$9@
M
M                                         8)LR-70I%A,7VXD1I;\
MAPDJ6:6VDFI1[4D9GH1>!%J CX=3C<VOB/1*Z*JO<?*XB)].E"2E/*-\I)(4
MDC2Z:EFLUZ$K<9F?4!\<J,7JVF'W84"&Q$-UJ,ZIIEI#1V+A$ZE!F1$GON&G
M<1?#49:ZF P.X-AKTVNL7*" J=4-M,5DCTS1+CLQSU:0V9)\J6SZMI\$_BZ
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M.SI%2%Q4V45^&J4T25.-%(;4V:T$LE)-2=VI;B,@$2YQWA4F@IL9LJ2)9T]
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MW1).*ZK(NBC\=0%A(B21)21$DBT(BZ$1$ ^@
M
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MBU02;]6ZTTV2GWG7FW5MI2^;"]W:2LDFHS(!?@0
M
M
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MO=U ?6Y$=U6QIU"U[4N;4J(SV+^"K0O</3H8#*
M
M
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M'E&,8WR7$3?W,*J58X!B,>M3.DMQSD.FVLB0UW%)WJZET3UZ@C]3 @
M
M
M
M           ^+6EM*EK424)(U*4H]"(BZF9F8"/;D44.(]=,NQ&(,G21(L4*
M:0TYJ1$3BW2T)73IN,P&2)45$*2_/@0(T:9+\TF2PRVVX\>NNJUI(C5UZ]3
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MR ?+&RKZ>$]96LIJ%7QR)3\J0M+;2",R21J4HR(NID0#:
M
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M
M
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MSZ: -*RY4X]JH%5:R<B@KJ[J>BHKYK#Z'V%S%DI6PW&S4E))))[E*,B3[OB
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MIUUU+WP$3D?(V/8]=U..>H9FWUI8QJU=8Q(9]5&3+0XXE]UDU;^V1-^X7ND
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MPZCVY]9?2-^WO2>SO7Z'W?2=SO=K7PV[_-_I 2
M
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M)Y-"Y$7E2"KH3GUHF9">2,29+D]VKEI,E5IQ%M)93W",D..=P_*6I%N\!6_
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M&$K)!&V@M32 OP(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*==#Z@B2
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M$I*4%VV]VQM.G1)$6I@B2
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M?J\@_P!F0[8295/2%)7/*IK'33V(/J5]7>WHI6[P+=M29I21@:Z&"
M
M
M
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M.WKI^*".2%QU]I33_P :8O\ ],0/C@O#^77VE/\ G3%_^F('QP.+QQUCG)=
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M!7^H J=P[@J!AN1P\D9S?,+AV%W=M=<W!S(#G>:6T?=9[2=VTE[D]>BB(_<
MKJH(
M
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MU\ &P1D9$9'J1]2,@
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MD->.JC ?H(B(BT+H1>! @
M                              XZQPW;-\ 3>'G+6.JUE1YT<K1+2RCD
M<V:[*2>PU&KRI<))]?'J"U<<PPZ;DUMA5BS,0PWB]O[6E-N)4HWT^BD1=J=#
MZ*U?UU,$5NKP?DC#:BP9PRUIW9\[(;>[>C6T>0<9R+;25OH:[C"R6VXUN^$2
M%)5[P*F^*\#F8%2VC5I+8E75_;2[^U* R<: S*FD@E-16E&I26DDVGJM1J4K
M<H_A:$1YXMXXB\>T)PWVX<B^=E6,B5;QXZ6GGFYT]Z6A"UF6]6Q+B4>91_!
M5J=PM,G8QGM0=HTQ<Y'DCN6XW:M-F2ZV<VW%]*K56I[D.1O.I'BA1E[H+6S-
MP;DFARBTR_CZRIO5Y0U#5DU1=-2CAIL(3!1RDPW(ZR6DE(2E*VUI/7:1[B,P
M&DCA2T=I&*"UO&YT6]OE9+R,^;)MJM%IV*;A,-F:R:B[F66UH-1F;:--?,H"
MK=@.$S\%G9'7Q9;+F$3YQV>/5:4*0[7.3-7)L<C(]G8-XS=90A*=F]2>I: C
M+Q/A<OCOCO'\*G2FYLJFCG'<E,I4AM9FXM9&25&9ET5H KD_!.0L;RN]R/C"
MTJ40<J=:EW%-D#$AQEB>RRE@Y45R(M"C[J$([K3GB:=266O0K73PA'R++;#+
M>3)J<@GG KJJH<@JEU!L,1$*<E*4F-(3_P"T27%.;-RB2E*"U,]3 K5Q[A6U
MQ^-BU0Q:QSH<-RJ==T4<FW>XW2RV)*&X2EK6HU.-+E+(G#/0T$7N@5@N>%\D
M)G((6,6L"/52,GJ\TQNNF-/J:BSHKB'YK#IMK_J'WFR=0EHD[34OW]0*LN.X
M'ELW,8>?<DVL"=<5$61!Q^IIHSD>!"*::/4/FY(<<==><2VAO4]J4IUT3J>H
M"1R/";6USNFS.LL683E346U6TEUE3YE(LCCJ:>VDI!*2V;&JD&HMWOD"("CP
M'/+3/J;/.19].4S&8DR%5,XZQ)9.5[0)"7%RUR5J/8DD:ML)U(E*-6XP5*\N
M\?6^?4<%.,6Z<?RZHE'*J+E3?=[12&'8<E!EXZ.,/K+I^-M/W $=D?"]7D2<
M$QN0[IQUA;2U>QB6ZV_)E,12B05]]E3:D=A*G%ZI41FHR J!L_L_E'8SNFPZ
M>W68QG%"B!(A2URIKS5Q'-;;<HG7G5J[:F5DAQ.NNJ4F7O 5(RL#Y1RN!30<
MVL:!M%!?4=Y 52L34=QJID&Z^V[ZEUSS+(D=LT^!ZZ@/)X#RS3Y%E[^&WU'6
MTV76)6:Y\R%)F6<)9Q&(I]IHG6V%FGLDI'<Z:GYB,N@"[8[QYCV.<?1^-8Z%
MOX\U <K9'>5J[(1)2HI"W%%IYW5.+6HRTZJZ CFY<5\M2,21Q-.RFI+CA$5%
M0NXCQ'TY$[3-I)OTJDJ6<9+BVB["W]#\OFV;@5;D<45SN2Y7+L"9?Q/):&OQ
MSV.E*DJ;CP2DH41JU\#2^1)TZEH HU;P-E]-QZ]C3&2QK3)V<LC9;"M[-EU3
M;_H'(ZF6Y9-K):E**.DG%(5U_P#T@5:LJPCD7D+BS(,+R^?21\AM5M)AS*MB
M7Z)N.T\R]\HV^XI9KU0LM4JT\ '501RFDX;35\K9%G4B8U)QRV9D*@T)M'_L
M\ZT;B-6#YJ,]#[Z8;>I?=/\ [2M/CGA:?A&$93C<VX19V]ZPJMB6:FU)[-9%
MA%!KV%IU\W8;(]=--=3_ -(%2<WBZQE<787@"+%E$O&%8ZJ3,-"S:>*@<CK<
M)"==2[G9\NOA[H#1H\)Y4P_)LDD8Y.Q^1C&2W[M_)38-32GM%);89<:0;*R;
M/1#!;3,O$^H#:?X>39P.0ZVTL-B,RM47-9,BDI$BNDQXT9N.\E6XM7&7HR74
MZ&1'X>^!4WQ?A5M@7'%9ATVR:F74)$HW;1IHR:5(ER'I'<[:C+713O4M2U^X
M"*[68!R'<YWC>8<B3Z-?U/3-]DJHHLAJ3+<GQU15JDKDK7VFR0HU=EHS(UZ&
M:M"(@5%5'".0XWAF",X_>Q8W(> L2HL*Q=8<=K)D:<K5^-)92M#AMKVMF2DJ
MW(4G<D"L=AQ!GN70\\FYA:T\;(<NHF<<B,5#$GT49F.M]TG7%OK[CBU*?5KH
ME)$1%X@5+YOPN[DV7X7F%7:E72Z"37JOXII4IBRBU;OJ(Y&1*+1UEPU]M1EX
M.*(^G0"F)87RKA=Y;L5D['Y6'7.1S[^1ZEJ:FS;8M)1ONM(-"^UO0DS)*C+0
MS\2 :;''/+5+9YA%Q3(Z:LH,ON)-TY9NPY,FWA*F,,L*)A'=0P:DDRDT*7J6
MO4R/P 7,\&>Q_BY?'N 2DU<B+5*JJ>QDZK4RXILV_4+V$6KFIFYT+3?[F@(I
M#OV;\6I*_&W\#4Y695BTROF0+"5+FOL.HBJ2B2VXRIY2$ID,FXE7;2GJKW@6
MMBRX0D66"9'C'M8H=Y-R.SRK&[F,E25U\N;*<D,ZD9^;1#BV7?<4A:B K"KB
MO/*%''4W#;&G7<85CSF.2DVS4HXKY/-Q$FZUZ=:5EHJ-T)7N& N7'^!SL7F7
MV2Y'9HN<UREYA^YGL,'$BH:AM=J-%C,FMPTM,I-6AJ6:EJ4I2CU/H%9DX+RM
M5YIF%UA-U10JK,)$22[(L8<J7.A+BP6H1FTVV\TTX?R6])+,BU\=2 :K7V>Z
M=3F)4=G+<GX/B4&<IF(I^2Q/E7MF\2WIS[[#B#TVJ=T2DRT4XK\7H!4WB/$R
M,&GYG$QR63.(90TT_%JG5//N1+/L*C2'>ZZM:EI>2EI2MRMVY/O -*UXEN)G
M ]=Q/#LXS=W6PZAAJR=;<5%4]3R8TG52$J2O:LV-O0]2U ><FPWE?.,/L*3)
M)N.QK=N=56-&[7M3CC=RMF(EK1*)U>\TJ[:4I[9D?B D*/ \PM,QJ\[Y+M:^
M5/Q]F4SCM-1QWF(,9R<DFWY+CLAQ;CSJFR[22T2A"35H1FK4!=,68R:/1QF<
MQEQ)V1)-WU<JN97'BJ2;JS:V-N*6HM&S02M5'YM01,
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MU\0&>NJZRHCG$J83$"*;BWC8BM(9;-UU1K6O:@B+<I1FI1^Z8#R=/4FQ.C'
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M2FC' 5'KHS2JIE4:L-#+:3BL+2E*FV#)/R:#2A)&E&A:)+W@&\
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M'Y1??( [B/RB^^0!W$?E%]\@#N(_*+[Y '<1^47WR .XC\HOOD =Q'Y1??(
M[B/RB^^0!W$?E%]\@#N(_*+[Y '<1^47WR .XC\HOOD =Q'Y1??( [B/RB^^
M0!W$?E%]\@#N(_*+[Y '<1^47WR .XC\HOOD =Q'Y1??( [B/RB^^0!W$?E%
M]\@#N(_*+[Y '<1^47WR .XC\HOOD =Q'Y1??( [B/RB^^0!W$?E%]\@#N(_
M*+[Y '<1^47WR .XC\HOOD =Q'Y1??( [B/RB^^0!W$?E%]\@#N(_*+[Y '<
M1^47WR .XC\HOOD =Q'Y1??( [B/RB^^0!W$?E%]\@#N(_*+[Y '<1^47WR
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MN^^1AHM@B@          ALK_ &#+_L_UB1<&/$/V$Q^<Y_3,-$Z(
M
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M,R)9)<)*MJM-4GIU+KX ),
M                        4ECIGBM.GF7^H,5%V$4          $+E?[!E
M_P!G^L2+@\8A^PF/SG/Z9AHG1
M                                     !R7&.%JR%R9F?(62U]79R[B
MPAS\;EJ9[LV"46,EI?G<07;4:RW%VU'X:Z@M4S$N",_J$87A-O95"^-^/[QS
M(:B?%]3[;FN)<D.QVI"%()ELB5)7W30M6XB+0O$P*Z9PI@5IQKQ]"Q.ZD1I5
ME'DSI#K\+?V5%,F.R$Z&XE"C,DK(CU+[G@!KH(( /SS*^SC/L>3,QO9]E&/
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MM*UF.P9NFIPDO1W&XR"4RI*3+56BRZ:!-1L"CN<?W>$>H@1%W4>;%ERZ2 W
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MDB($;0
M        I+/^?%?G+_4&*B["*          "%RO]@R_[/]8D7!XQ#]A,?G.?
MTS#1.B
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M_C"\U_T]\M0372 0
M                  %)9_SXK\Y?Z@Q47810          0N5_L&7_9_K$BX
M/&(?L)C\YS^F8:)T0
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M_> 3M1=T^00DV5'/CV,!2E(3)B.I>;WH/12=R#,M4GT,O< ;X
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M(K"$W5V+DOM;YC#L="&E:-&I&BG&4*Z^[[A-=R!
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MTE.B6R+0B\3U!%P
M<PY;X&P?FAZI>S!<Y"Z9+Z(GH'T,$92C;->_<VO7^K3IX M<V_Z%N$__ %UW
M_?6O\.!3_H6X3_\ 77?]]:_PX%/^A;A/_P!==_WUK_#@4_Z%N$__ %UW_?6O
M\.!3_H6X3_\ 77?]]:_PX%/^A;A/_P!==_WUK_#@51>9OLB\48%Q?DN7T;EL
MJVJ8I/Q2D2FW&MYNH1YDDRDS+17O@M=!^P[_ .!R/^+SO_(T":_2((  "DL_
MY\5^<O\ 4&*B["*          "%RO]@R_P"S_6)%P>,0_83'YSG],PT3H@
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M+*K%-<PO5;=?(><](I25*-6JF21N5X;]VFG@"+4
M                                         .2_:<_\!<X_W%/Z]H%Q
M2/L._P#@<C_B\[_R- :_2((  "DL_P"?%?G+_4&*B["*          "%RO\
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MR4DE$E1H41I41*2I*DFE25$1I41D9:@B6
M                       &"7"AV#!Q9\=J5&4I"U,OH2XV:FU$M!FE1&6J
M5))1>\9:@(^SQ7&+J))@6]-"G09CR94N/(C-.MNR$)2E+JTJ29*61)21+/KH
M1 ,R<?H4LICIJX9,(B*K4-%':)!05Z;HY%MT)H]"U;^#T\ 'U5%2+=2\JMBJ
M>0;"DN&PV:B.&:C8,CVZEVC4KM_DZGIIJ ^%C]"2&FRJXA-L$^EA'IVMK:9A
MF;Y)+;T)TS/N:?"]W4!&LX!@T>G>Q]C&JQNCDK2\_7(AL%&6XC3:M39(VFI.
MA;3TU+0M &O)XZQ.1.K928#3$6N@2Z<JMIIE,!^OG&VM;#S!H-*D$MI"TD6F
MAZ^^8#+%P+&H-Q3V\"(B&BABRHE371D-LPV/7J;4^ZEM""^4439)W:^!JZ>8
MP$@[BV-/WC63/T\)S(F$=MFV7':5,0@B,B)+QIWD1$9D77P,_? ;#5+3,+C.
ML5T5IR&IYR(M#+:5,KE&:GE-F2?*;AF9K-/PO= 8)6,XY.GNVDVHA2;)]A,1
MZ6]':<>7&;<)Y+2EJ29FA+B26E)]"46OB ^66+XW<1I4*UIX4V).=1(FLR([
M3B'GVTI0AQPE)/<M*4))*CZD1%IX ,[=)3,US%.U71D5,;M^G@)9;*.WV%DX
MWL;TVEL4DE)T+H9:D (I*5MTGVZZ*E\E/K)U+#9+)4PR-\]23KJZ9$;A_C>[
MJ T9F%X?8KKW)]!725U"4MU9NQ&5^E;1H:4,ZI\B2VIT2GH6A>\ S7F*XSDR
M6D9'30;=#&ILIGQFI1(U,C/;W4JTU-):Z>.@#Y.Q/%[.RA7-C2P9=M6D2:^<
M_&:<?8)*MR2;6I)FDDJ\R=#Z'U(!CL<,Q"W*,FUH:^:F$^[+B%(BLNDU(D+[
MKKB-R3VJ<7YUF7PE=3Z@-N;04-B^_)L*N)+DR8BZV2\_':=6Y!</<N.M2TF:
MFE'U-L_*9^X RLU%5&F>T(\&.S/].W"]4VTA#WI65*4VSO(B5VTJ4HTHUVD9
MGH0#<
M       ')?M.?^ N<?[BG]>T"XI'V'?_  .1_P 7G?\ D: U^D00  %)9_SX
MK\Y?Z@Q47810          0N5_L&7_9_K$BX/&(?L)C\YS^F8:)T0  !^<\?
MX%SNNP[!L*LK2I=A8#F47(JZ:P4DGI56R[)?<0\A2=J9!KD:)))["(NJC,%K
M%D/V=<FL46L^)/KG[56;6&85L.4[.C1'H5E%;C+C/NQ#0\TZ1()27&MW^@R/
MH*ZEQS@TO$<%DX^]!K*FUFN2Y$AJF=F2(G?E="<-Z:HWW%F1)WK5IJ?@1 .=
M5W"?(.)57&]GB=C3RLSP:MF4TN-:^J362H\\R,U-N-(4ZVMLR+3Y/S>!Z$!7
MBN^SUDD!G'"5<P7Y-=6Y4U;/=MUI#ECE9&K5ALMQ)9:4>G4R/0M=-3T(5CC\
M*<H8NQ4OX;9T+UDO#XF%7Z+9,KLME"W[9<132%&L]%F1M.)2E6FIGUZ"O-K]
MF!R9-P: W<I?Q"GIHF/YG D$M"K6)6/^LC$E*=Q)+OJ4HR-9;4Z$1GH!6C1_
M9GRROX_L*"SOX5AEMA=4DMRV4EU+1U&.)89B1S+;N-:&VU>YIJKQ_& J?E<$
MY)(@9'#*TA$=UG[&;,F9/$2(++K*S95HG7NZ->YY?NE[@KF'%S>0P^8V9K^.
M3+&:_D5X^JLG,6\5['H=H^^:YVY9>R]76]I'V#W.)5H74S!79>1>+\[ML]<S
M; [&JCN7&.NXE=LW3;[I,Q5OJ?3)C$Q\-PC6:>VX:4'XGJ"*B]]G'*G*PX2;
M:O)P^-6N/]3[^WU[4OU'?UV?U.WIX;M?< J8Y#X+O[^9AU[1.5LVSQVF.@L*
MNSDV%=#?9-+9DZT_6F3S:DK2?E-*DJ2>AZ: 4B\0\C8A>4N2\<NXU7S$X\SC
M-Q53&YRJZ*AF2N43\$TJ4ZOS.*U;>6G=XFK4^@K'E/!679&]R=2^UJ]G%,X>
MB759)4E]=A&N()Q30V\V9=E48_3Z*,CW]2Z= *CLMX)Y*Y'J<VL<PM*.%F62
MU=90UK%44M59'AUU@B>XMUQY).K<=41[=$>3PU4!5HY3XJS+,\PIKW%WZNBD
MU[49A&7,O38U_$:;D&Z^PAMC_9Y3#J?*33YI2DU*/KJ G^6<(RW*7\1O,)E0
M&;[%+7VFU&M^^F$^VXPY'6E2HY*62B2YJG0@'/,CX"SFT/,L*@6]4WQ=GM^G
M)KJ1(1)5>QG5NL/R&(Y)+L*2I<=';6M1;$Z]#/0"NFYQ@5GE&;\>Y/"E,,0\
M0FS9<YE[>;KR)<4V$DUM(RU(SZ[M.@#FL+@SD'&CQ[(L;LZ>3EV-7>1V,6)8
ME)372(63*3O2XZTA3J'6R01I-*#+7H?3Q%9*C[.]Y'L,/L;>YBOR(4S++3+#
MC(<92[*RV(<<TP4GNVH:U_\ 2'J?C]P"O?'_  UR=1Y)Q[+RRWHY./\ '$2R
MJZIJL:E-RY,:=&2PEYXW?(3GR;9*0GH6AGN4:M"%2&=\3<A3,LS&YP.QIT5G
M(=2Q2Y&U=HDJ>B%'9<C$_#[!&E9]IU7R;FTM^AF>G0!*4?#MGCV1',A6;3M+
M&P2%@T G264KO0%K-+[A)+823)6OE/74!7&/L]W;];QW46=M%*'BV-W>-73D
M<G3==]LPRBI7&W)(O)X^?3_1[PK7D\*\I9%Q6SQKE-K0);QE-46(2H")Y=]5
M,K:D[#52%))QDDMFE@]4JU62O!(%7[B'CZPPJ%<KN:JGK+6W?;<?.DE6,_NM
MLM[$&_(LS[BU%JK:1)(DETZ@.>8!P/R+C%O@,>YN::3BG'+EVW4E$:DIL)<>
MZC/MDY(-?R:5H6XDMB.FW4]QGH0%2F#\%9'BW\FO5V<%[^6R+]-J3).EZD[I
MI;;78W)+X&[S[]-?< J/QG@;.:K%<$Q*SM*IV'@&6MWM=,CE()V55$N2\XEY
M"DZ)D&Y(T223V$DNJC,"NA<9<;V6&8%:8A:3F795C-MI2940EFEMNS><<1T6
M23W))?7[OWP%*Q'AC/JZ-Q;'R.PJ%?RVFS4H5 ]29RJQZ&4=@S[J"T?W&K>7
MP"+30P*@;#[-F5JKJ25&G5<^]H;S(;-F#*?GP84F'D:TJ-*Y,+;(;=:[:3+8
M1I/J1ZEXBNW\:8H>$X76XZN#7UK\;NK?ATZI#D%#CSRW3[:Y:E.JUW>92_%6
MIZ$70$6T
M
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M1GIKUT ;C;S3IJ)IQ*S3IN))D>FXMQ:Z>^1Z@/8
M
M
M                      .2_:<_\!<X_P!Q3^O:!<4C[#O_ ('(_P"+SO\
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M&X_<O+W,6Q)BDEMUA&]6Q+2-&S3M3U^[KH1>@0
M
M
M                    ')?M.?\ @+G'^XI_7M N*1]AW_P.1_Q>=_Y&@-?I
M$$  !26?\^*_.7^H,5%V$4          $+E?[!E_V?ZQ(N#QB'["8_.<_IF&
MB=$                       5RUX_P6]N6,BNL:J["^B[?3V4J&P])1V_@
M:.+0:O+^+U\ON +&
M
M
M Y+]IS_P%SC_ '%/Z]H%Q2/L._\ @<C_ (O._P#(T!K](@@  *2S_GQ7YR_U
M!BHNPB@          A<K_8,O^S_6)%P>,0_83'YSG],PT3H@
M
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MD>DM\>B9A@,6KJ;^T8I43XEZB>XT_*2XI"C9]&UN3\F>OG =;!
M
M                       !4.4L)<Y&X_O<):FE7.7+!1TS5-]XF]'$KU-!
M*1K\'3X1 (+@GBA[AK!2PUZU3<+*8_,]8A@XQ:/DDMNPUN>&WQW NNF @  *
M2S_GQ7YR_P!08J+L(H          (7*_V#+_ +/]8D7!XQ#]A,?G.?TS#1.B
M
M            #F%Y_P"/V&?_ +-7_P#WNL =/ <WS[_Q'XI_XK:__)9@*Z0"
M    .7Y?_P"./&/_  W)_P"A7@KJ (YQR=_F?BW_ /:A7_R:R ='     <KY
M!_\ &#A__>K_ /\ E#@*ZH".7\S?UW''_P"VM3^JD@N.H @
M
M                          "DL_Y\5^<O]08J+L(H          (7*_V#
M+_L_UB1<'C$/V$Q^<Y_3,-$Z(
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M*AY*_P#V>8\LU><M"V .X@@
M
M  "DL_Y\5^<O]08J+L(H          (7*_V#+_L_UB1<'C$/V$Q^<Y_3,-$Z
M(
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M 0
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MM:'&L7XC\>'+;-2D]V*\XDDNHU2?F2?O'X&1F%F
M
M
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M<IRL*=W7''IR$2B+TZW4J2@V6"V>7<9FH!U $
M
M
M               !26?\^*_.7^H,5%V$4          $+E?[!E_V?ZQ(N#QB
M'["8_.<_IF&B=$
M
M
M                              %)9_SXK\Y?Z@Q47810          0N
M5_L&7_9_K$BX/&(?L)C\YS^F8:)T0      !'W5[28Y 7:Y#91:JK:-*7)LY
MYN,PE2S)*2-;AI21F9Z%U >O;-/[08J?:$;VI*85+C0N\CONQD&25.H;UW*0
M1J(C41:=0&\  (J/DM#+OIN+QK!AW(:YEJ3.K4K(WV67_P"K6M/N$KW $J
M
M
M
M*2S_ )\5^<O]08J+L(H          (7*_P!@R_[/]8D7!XQ#]A,?G.?TS#1.
MB       .*?:DA0K'C:#7V39NU\O(:-B4T1Z&MEV<VA:2/W-4F9 N.%0[?,<
M$SN[Q)F._)S#C#",@CXU9/$EXYM8<F._6/$C;M4IEA1H4@B,C4WM\=05(?S
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MM>@#]1X';-7N$X[<L>M[,ZNBR&SM224\TN,I,E2-A$DW#\5FDM#/J70&5A
M
M
M                                                       4EG_/
MBOSE_J#%1=A%          !"Y7^P9?\ 9_K$BX/&(?L)C\YS^F8:)T0
M !X=99?22'VTNH)1+)*TDHB4D]2/0_=(_ !\[#'>]3VT>HV]OO;2W[-==N[Q
MTUZZ -=BIJHS+T>-!CLQY*C7(:;:0A#BE>)K21$2C/W=0&94.(HU*5';,UM]
ME9FA)FIKKY#Z=4]?#P >%5\!25I5%94EQ*6UD;:3)2&^J$GTZDGW"]P!D.-&
M-;CILH-QY)(>7M+<M!:Z)4>G4BU\# 8(]351(BX$2#'8@.;NY%::0AE6\M%:
MH21)/7W>@#&=%2'#;KCK8IU[*R<:B=AOLH61ZDI*-NTC(_=(@$@
M
M
M                                                 *2S_GQ7YR_U
M!BHNPB@          A<K_8,O^S_6)%P>,0_83'YSG],PT3H@
M
M
M
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MV \DUM2D.(4RM)$:C-*R/:9:$9ZD?N ,D65%G1VYD)]N3$>22V7V5I<;6D_
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M6BE=/!.H"Q'8UZ9R:LY;)6:F^^F$;B>^;1'IO)O7=MUZ:Z: -D
M
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M4$J2Q9K[N36-M7,=B*M%<AI,FLM-_=VK-#3*HAI5U-Q1;.NI'<00
M
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M4I;EJW%:3)-;A;5K[A)UW*+HI7B9>("P
M
M          "DL_Y\5^<O]08J+L(H          (7*_V#+_L_UB1<'C$/V$Q^
M<Y_3,-$Z(
M
M
M                         *2S_GQ7YR_U!BHNPB@          A<K_8,O
M^S_6)%P>,0_83'YSG],PT3H@
M
M
M                                        I+/^?%?G+_4&*B["*
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M6$N; @3XTJ=6K2U8Q6'D..QG'$[TI>0DS-!J3U(E$6I -T
M    :%7=5%XW(=IIS$]J)(=A2EQG$NI:E1U;76EFDST6@^BDGU(!O@
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MJDTGU(R,O$C >@
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M%E5RF9U=*03L67&<2\RZVHM24A:#-*DG[AD8#9   !26?\^*_.7^H,5%V$4
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M.SGU;IUM5:.H.P?:@.K:>=0E/BUN2:FM/_1Z>\8&NS @
M
M                   #\7\',7N'<0WW*=5BF-O>S:[('ZF^90ZYD+TIF6]M
M3)+MI1V$DE6I(>UV(3TZF#6I3^9^<4L&X*MY%3EZIG'\W+'I:6(.ZIMXY-]L
MV^PV24M.&LT)8=)2B,M0'Z%XG9R3ZE5]IE60+R.UNVVK8Y*H[,5N.B8PTLHS
M*&2(NV@]=IJU4>O4P97<  ?GS[3%K&N).'\6NUME=P;J:=QDU31->HGN4]46
MXD=O>C1+LA3?FW%\ ].H+CE]+S!D-!Q%A6,3)]C1R*6]FX?D[D5J''O&V*R*
MX_#0U[2,XK1FWV4+[B]3VF3>IZ@L;N0\D<BT&!4U?<9K8KY+;QNPRN<=4="F
MNVHDK;C*?F2$]MY+>U+1Q81*6L]QZF6T R+E;+X\:]S*#)BP<B=XOQ[($36(
M<7O)FSI:.YHXMM2U-_*&1-K4:2UZ%KU 3\C,.7JA_/</C9G'M;]-)27E);6;
M<"J:CR;*434B,TM23:3W$>6/WMVBS27OF9%>L,EDY7<<.V\?/KJFC,V]]3SK
M"X16$_'FQ&%FI+CS2$Q7S5J49#A$:5)/4BWZ@KJ7VG+Y!TN,\=-P9ELYF=NP
MBTJ:I!NV#]'5J3,GDPDE(\QI0A'PB\JC!,<&G9(;?$-7@LN2_B]A@/(U9%BR
M+II!3*ZHE./RZ^7*8<4I/R;2U>4U&DTM^)D"KT?(G)$C&\IIJ/,V[Z/CV51H
M364-OU5=/LJ=<)4J9%@//MG$5*85H>NWX&OW" 9*#(3R'FOC_*V<[LX]':X8
M<N.BRCPXST[TTUM#L1QI*20;CYI4ZOLI-6J?DSV::!$T/,N2VEZJ-%R&;>8Q
MDN,Y!8$5\W2G\M7,+4TZS#@DM<=H]JD=J69]PM3,O'01\B9OR1/JZ:CQW*TX
MQ7P>)H^:NMP:^"9+GQ'GD&E"5-$EIM?D)9(+31.A$6I@/T[QCD,_+>.<4R>U
MV>T[>IA39IM%M0;[["%N&E/N$:C/I[@,K6  *2S_ )\5^<O]08J+L(H
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MPHB(VVE[=4(/0M4I/3H W@
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M\5^<O]08J+L(H          (7*_V#+_L_P!8D7!XQ#]A,?G.?TS#1.B
M
M
M
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MU<A#9M1N\9EVR?6@SU(_ R 70
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M1EF1N9_6,RX+=-E$RLOZF6Z[))]JSJ404)C2&FB3_L[GHB,W6GB<3NZ)U(C
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M $*\%=0!'..3O\S\6_\ [4*_^360#HX   *2S_GQ7YR_U!BHNPB@
M  A<K_8,O^S_ %B1<'C$/V$Q^<Y_3,-$Z(
M
M
M                       #G.9<;9!>9C#SC$\M7C%U'K'*5[_W>Q9-NQ79
M"9)^5]2=JMZ$]2!6C]0^:/\ FY__ $Y7_P"L 9*7C'+T9E2Y?F><KR1= W,;
MKH::N+7(2JP;2TXI2V5*-71):$ Z@"    .>YMQY?Y!E%9F&*Y6K&+JN@2JI
M;GH&+)#L68\R^HMKZDDDR4PCJ0*C?J'S1_S<_P#Z<K_]8 ]U/&6:?6ZARG,L
M]7D3>.JENP(":F)7)-V;&7%4I;C*E*,B2LS(O? =1!    % S_CVZRN]Q[)L
M;R=>,7F/-SX[+Y0F+%MUJS)@G"4V^:2(R["=ID"HKZA\T?\ -S_^G*__ %@#
M["XRSJ3D-!<9CR"K((&/S%646M33Q(&^2<5^*DU.LK-6A)?7Y?= =3!   4E
MG_/BOSE_J#%1=A%          !"Y7^P9?]G^L2+@\8A^PF/SG/Z9AHG1   &
MO'G09BWFHDEI]R,KMR$-+2M3:_R5DDSVG]PP&P  ,,J7%A,G(FOMQXZ="4Z\
MM+:",ST+52C(NH#%%M*R>XIJ#-8DNH(E+0RZAQ24GX&9),S(@&V   "*L\GQ
MNE@R+2XMX4"MB.E'E2Y,AIIEI]6A$VM:U$25GN+RGUZ@)1*DK2E:%$I"B(TJ
M(]2,C\#(P!2DH2I:U$E"2,U*,]"(B\3,P&*)+B3XK,Z ^W*A24)>CR6%I<:<
M;66Y*T+29DI)D>I&1@,P  \N.-LMK==63;39&I:U&24I2DM3,S/H1$0#Q%E1
MIT9F;">;DPY*$O1Y#*B<:<;<(E)6A23,E)41ZD9>(#* Q/28T=329#R&E/K[
M3"7%$DW'#(U;4ZGU5H1GH7O ,H  P)G0ES'*Y$EI5@RVA]V(2TF\AITU)0M2
M-=Q)4:%$E1EH9D?O ,X  UXD^!/)XX$IF449Y<:0;#B7.V^T>BVU[3/:M/XR
M3ZD V 'AUYIALW7W$M-)TW+69)26IZ%J9]/$![  &C#N:>Q2RNOL(TM$DG3C
MJ8>;=)PF%]MTT&@SW;%>56G@?0P&\ UX\^#+=?9B26GWHJ^W*;:<2M32_':L
MDF9I/[A@-@   &)^3&BI2N4\AE"UI;2IQ1((W'#)*4D9F751GH1>Z R@
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MXQS'Y#;4,DDLY"UI2WM/P/<9Z:& R,O,R6D/QW$NL.%N;=;42D*(_=(RU(R
M>P !KOSH49^-%DR6F94Q2FX;#BTH<>6A!N*2VDS(U&24FHR3X$6H#8 8WWV8
MS+DB2XEF.TDW'77%$A"$)+4U*4>A$1%XF8#VA:7$I6A1*0HB4E23U(R/J1D9
M ,$Z?!K(RIEE*:AQ$J0A4B0XEILE.K)M!&I9D6JE*2E)>Z9D0#8     :SUA
M C2XT"1*9:G3>YZ.,XXE+KW93N<[:#,C5M(]5;2Z%X@-D      8FI,:0IU#
M#R'5L+[;Z4*)1MN:$K:HB/H>AD>A^^ R@   QR)$>)'=E2G4,16$*=??=42&
MT-H+<I2E*T(B(BU,S (\B/+CM2HKJ'XKZ$NL/M*);:VUEN2I*DZD9&1ZD9 ,
M@#7ESH4!#:YTEJ,AYUN.RIY:6R6\\HD-MI-1EJI:C)*4EU,_  ESX$ F3GRF
M8I27D1HYON);[C[IZ(;1N,MRU?BI+J8#W&E1IC)2(CR)#"C4E+K2B6@S0HTJ
M(C29ET,C(_N@,H
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MDF50;N_PK(K*+DK5/?X.["G6%?%)Q#>061,O-]M">WJT;1KCNDG>C=XF:24
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MN1F5]U+^Y"5=]O0D+U(CW)T,^A^)=01E
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M'&677U&MU2$*09)-Q1F:]"\Q^.H"Q(0AM"6VTDE"2)*4I+0B(NA$1$ ]
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M\R;(CMNN5.]Y2D&RQ*<0CN+0:-5)-)*))D9^((L
M
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M-? !(TU+4X[5QJ6BAM5]5#3VXT2.DD-H+4S/0B]TS,U*,^IF>I]0&^
M     #6F5\"Q2RF?&:E)CO-RF$O(2X2'V3W-N))1'HI!^9*O$CZD V0
M
M                          >5MMN?#02M/#<1'_Y0'GT\?_U2/T2 ?4M-
M(/5"$I/WR(B_\@#V     \K;;<^&DE:>&XB/_P H#SZ>/_ZI'Z) /J6FD'JA
M"4G[Y$1 /8    #RM"'"T6DE%[RB(_\ R@//IX__ *I'Z) /J664'N0VE*O?
M(B(P'L   %)9_P ^*_.7^H,5%V$4          $+E?[!E_V?ZQ(N#QB'["8_
M.<_IF&B=$
M
M
M                         %)9_P ^*_.7^H,5%V$4          $+E?[!
ME_V?ZQ(N#QB'["8_.<_IF&B=$ !@F.+9B2'6ST<;;6I)^/5*3,@'XQQ;GOD_
M^7*8&47K2<TLGJ*ZQNX2RP2IM-96C<&6QVTM$WO8<)25=-VU6I>&H-1T;VIR
MOR(KD?+*+-EXK PJWLZ2@HXL.))CON4:2-QZ:X^A2U$^H]-B=-A=2U!%?N<P
MY0R:JXJS*FSF7CK/(\R#5S::+ @OQH;BHR^\\PM]M;A[W&C4E*U'H2O'H W,
MBRG/F.77N.UYIDC,.JJ:9*95!11;)4B7)W)?DS3*.X3!+,B5[B"ZZ>'4/T/4
MWEG89!?4\NCDU]?4*BI@6[ZFSCV)26C<<-@DF:B[*BV*W>Z?0$<IQG+;Z!G5
MM"SV]M8&3(<M7ZW%'HT5%%9U<7>Y&76229-:W&V20MXE/]W=OW(V)+0JQ_SK
MIF:O$;NP@/1JS*<=GY6Z_O2YZ*)61(\MU*TD1&M1ID:%M]U/W0(K^6<A9U+P
M6)DGU:EX^IZVQMZHCQY\=Z78Q9]DPE<19$2"8=6VHD.)69HT7IO/0P%^P7.)
M.5R+^HMZA5'DF-2VX=I7^H1,:TDQVY3#C;Z$H)25MNEJ6TC2K4ONF15('-ZY
MS]7:?5MYO +^V7C]%DIRFU+?F=UR.RM<0D;VV'WFE-MN&LSZI4I*4J!8I;_)
MO)EKBN-W4^J.MLCSLJAJ)63F5^TH[,RPC+B+/1*4);[*$N+6K1S::RTU)("W
MO<\Q(=(;MI3HK<K1?O8J]4S;".Q!:FQF"F..KL%D2"CE'-+A+[>\U&2"1N C
MS&YX5;U=&YC.,NW&07=E9TC=:U-81&1-J&UNNK*89&VY'4A!J0\VD]2,O+N\
MH$27)619539#QQ[!B/2YMC8369E S);CMR=*J2X27GEEM[;*TDX:M#/R^5)G
MH0!CW-$6[M<<H7Z5^%=W%G<45I&4\VXFNL*&.J0\DUD1=Y#B22;:T$6I*(S(
MO "-&7SHA,>G5 I$G)N;.YJ8YV-@S71$NT4HXIH.2M"D]^0HM8[.GF(E>8MH
M$>[;D]S&LAOX,6OL[ZQ=R&LQZ%6K?BM1VY$^I1,2;"C0DT,D1:NFZI:MVY2>
MFB0&![GV#%IV53JINORM5[*Q>153K!B-!8FP&O4ONN6#B21V"9-*TJ[>]2E)
M02-Q@1Y9Y^C3Z_'7JRG:5/O95E7J3-LX\2 W+J'TL.,,S=JVY#CYKWQ21H3J
M"-6J=#("+12\D+O.0+C"(U8VRBD<-J6])FMLSU?(-O)D-P#1O7%6;A-H?)>A
MJ(^G0!H\D<MEQM-:.QK&'Z8RC*=?.SC,3W"DODPKTD%1&X_VM24KS(U+X.ID
M W,6Y)=RG-+_ !:/5(BQL?D/0Y+TB8VBP-;)-[7C@;=Y1GMY]E[>9+).NA:@
M(3,^;'L1M<GC-8M)LZ?#&Z^5D=FU*8:-N)8I-1*89<T-UQ!),S;W)U+\;4R(
MQ&U'Y7N#^M%?9XLFKR+&DU\IR',M8C<1<"U4XEJ0Y,,MC6PV72=1M49&DMIK
MW$ PXGSA7Y-+I(JZI49NUL;>C?L6)+4RO9LJ=DI1(1(022=;D,$XXTZ1%\ T
MF1&!$C_-EA/$2^77J64U7G%58QJI2T>J=AJ>-$=PC^"1O-&AY*3\"41'U 0M
MKSC(QAG)&LMQ236W=%"A6\:J8EL35S:^QE^B0I#C9$E+J'B-"VSZ?!VJ41Z@
M1OR.3LQ3.8QN!@RI>;)KUW-K3^U&&V(D)<AV/&3ZLVS0X](-I1I;)))3H>Y9
M%H9AH'SC(N"@?4+$Y61JG8\SE?RDIBO)N*ZZZR;"C<)?^T$II2207E,]=5$1
M:@1HY#]I+':MAF=50438*:*'E$TIEA%K)7HK%"GF68C#QJ.3)[2%K4T@TI+R
MIW[ED0$2UERC8W-EE&.8W2OE7TE64NPRA4A#!1O7UBYD4VF%)-U;FI$2D^79
MJ2C/W $/C7,[M9@)':UDZTR2FI\5=82;B.]=O9,RRQ'<:4K0B4N5W6G-W@:#
M5X 1?<USF5C5C1X[24ZKW*LA.2JOK^^F&PF/ 0ER0\](6A9(2CN-I(B0HU*4
M1:>)D16[GEZ[@RK*%58:_9S,9K(UMF3!3H[*J\Y;:WDQ63T6F2^3;:W#))I1
MIM\^JB(%C4O.>$PFY]G0XS)O,:J*>NR:UMT26(I-U-HVXZE;33WF<>)MI:^U
MY=2+X1'H1B/<SG/V'%OE93C;M195C%7+K(2YL5PIC%])<APS<>U2W'43S2B?
M)Q1I;3YMRB BR<<<E0^03NXK;#+%EC\EN+-.%+190'2D,I?:<CRVDH2X1I5H
MHMI*0HC(R\#,*!Q?RGD<:JQB'EU7*DU&07-I20,N?F,O..SD3)JV$+C$7<2R
M:&%,MN&>NJ2U223)0"0QC[0M=EUK!K:2I:DE?-6*\:2W91W)3KM<VMY"9T=!
M&N$F0A"E-+6:].A+)*C(@(KG$O(V51<$Q1V?73LCY"SYV7.AQIEJE49<:(A+
MDB5W#;4B&PCN(;3'0VH]=I$74S 7"IYIL\@LZN@I,/D/W[YSDW<1Z='9;K%T
M\]$":EQW11.[5.)6R;9'W$F7P>N@C#COV@J/(\HK::+#9]DW5A,J:N8W81WI
M_?@DZ?=D5R?EF&'>P[VG#,_Q36E)+("-V\SC-(_+YX-$K63Q->.NVCUEWTID
MLN$_VCD$C0S4E!Z([9=3,]VO30!7^,^8K&/C&)1N0*J5!:L,67>1,BD26YCL
M]%1&8<FNO--$:VE+2ZEYO4U&I)]=JN@$3_'/-U?GU[&I/0,PW;*L5=5BHUC&
MLEE';<;0MJ:VQUBR")YI7;5N2>JB)>Y)D!&#+^<)&*6F1MEB4RQQ[$9=?"O;
M9B3'2O?;-QU,E%CK,E/*2J0A+A*4@B+J1GX 1AG<]-4<2WC9/0G4Y55V=?3E
M5N3F51%N7#)R(SBYQI0VVV3:'%/*4GR;#TW:IU$82^T13*IXKY0XJ+R5=2<>
M2R[:1FZCNPXZ9CLDK/0VSC]E;9I43>\UJ)O9NUT$:<7FW)\CR3CYG%:%EVER
M)RYBWC3LQDUMR:=PF7?3OHW(<;;,C=2XC4GD&6FTP(DJ[E&T98J*C&J6PRRY
MO)63*C'8S(D/LM4%IZ1SO/):(DMF;B4L$EM2B+:E6O58#2L_M(5K=!6WU'1.
M342\>D97,9FS&:TF841SLNM-K<2LGI!.$I/;1TZ$9J+<G41>LCY"5CV+45RN
MH=E7^2/0X%10M.)2I=A.;-TFEO+224(;0AQ;CAIZ)0?0ST($5>5SA(KXLR%/
MQ5].:U]Y QR5CK$MAU)OW#1/0WFI2B0A33B3+4U)2I'FW%Y>I8O=A?W-9ARL
M@F5#35TU'0]*J7)[+4=EPS(G$JFNDALD-D9J-S;U(NA:] 10(G.QSZ5J778Z
M=G=.Y*>'HA5UA&E0US#A'.0^W-(DH4QV]-ZMA+0>I;3-.AEB1Q[F5NXL:2KG
MT3];*L;>UQFS<-]MZ/!NJADY"6.YHCNID-(<6TXE)?!T,B,P(GJ#/7<DX\+/
MZZG=0W)8D3:VNE/LQEOQ6W%DPZIUPTMM)>;2E[51^5*NH(IL3GUB;$F1HE(B
M?E#5S#QZ! K+!F;7RI5C&5+;6F>A!)2A#3;JGM6]4&@RT5J6I8@:#/LA<F6*
MLE5:UTM[DF+0L5<>5&>*,TY5QW>PXXXVM*X:U;G=&B0X>XNJ3W$ M</FI<N7
M767U<>3Q[<71XW590F4TXX[,.0J$VZJ&E.]$=R0A32'#7N^"HT$D]0(WZOEZ
M'9U&(VQ53S2<LOIF.,LJ=0:H[D%4Y)NK,BT4E7H5="_*+W@$1%YNLI...946
M&2O8\BSCT=$29L94BPG/6"ZY1);/:33:7$ZDMQ9;BUZ$1:F(S+YIEQ*V<FRQ
M5]K+*V_@XQ*H(\QA\CDVK;3T5UJ29-H4VM#Z#5N))I\VI=.HC7A<VW*Y:6+3
M"7X,:#?1L5R.6FPBOMP["P<9;C&P222J0VHI+"G%:-F@E_!5M,"/5/S_ $MQ
MEL*@8ALG5VEK+HJ^8U81WIYRH1.D;K]<@NZS'<5'=2VZI1G\$U)2E9&!#%N<
M)N2R<?2YB,BOA9A&GNXK(>F,+7*E5C:G5LO-H2?82XA*E-N&I6I%YDIZ 1YP
M#D;D#(N%9>=VU+&3DC4.7(@-M26RCRU,&YHLRT/M$DT[32HSUTU]T!7X7(O)
MEC)XIM#HU/W.0T=K+ET,:>TQ E&EBN=:F/.J0HFT_*+V-DE:DFO3KU,!+R/M
M&4CM7CDFG@,G9Y!6R;<X=S8QJ9F.S"=],XTJ0^2D+>4^2FVT(+16U2C-*2U
MB7K>9EY%;T$#&<;DS*ZVI8&3V%K*?:AM5]9/=>:/N)42U./(-DS[:.BBU\W3
MJ(A:/[2V+V;J),V(F-1RJRRNX,J+-8L):(52UZAPYL1@MT5;C/RC:5*5K\$]
MJ^@$2:.7,E-/H;+#ET]S;TTR[Q)E^>P\F7Z%*%NL2#2DO3/(2\TLTGO1H:B)
M>J3(!O< /7L[BVAN\C7,=MKJ,S9OOSYYV2GCE,-N=UL]")EMS7<F.DM&_ #7
M300
M                                     %)9_P ^*_.7^H,5%V$4
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M7S682>PPT24M[WF&&W7EI2DD$MQ?AXD:O,"-+(.):'(HN6Q)DR8VWF,RML+
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M+H"+6
M                                        "DL_Y\5^<O\ 4&*B["*
M         "%RO]@R_P"S_6)%P>,0_83'YSG],PT3H@
M
M
M                                                          I+
M/^?%?G+_ %!BHNPB@          A<K_8,O\ L_UB1<'C$/V$Q^<Y_3,-$Z(
M
M
M
M               *2S_GQ7YR_P!08J+L(H          (7*_V#+_ +/]8D7!
MXQ#]A,?G.?TS#1.B
M
M
M                                "DL_Y\5^<O\ 4&*B["*
M "%RO]@R_P"S_6)%P>,0_83'YSG],PT3H@
M
M
M                                                  I+/^?%?G+_
M %!BHNPB@          A<K_8,O\ L_UB1<'C$/V$Q^<Y_3,-$Z(
M
M
M
M       *2S_GQ7YR_P!08J+L(H          (7*_V#+_ +/]8D7!XQ#]A,?G
M.?TS#1.B
M
M
M                        "DL_Y\5^<O\ 4&*B["*          "%RO]@R
M_P"S_6)%P>,0_83'YSG],PT3H@
M
M
M                                          I+/^?%?G+_ %!BHNPB
M@          A<K_8,O\ L_UB1<'C$/V$Q^<Y_3,-$Z(
M
M
M                                                           *
M2S_GQ7YR_P!08J+L(H          (7*_V#+_ +/]8D7!XQ#]A,?G.?TS#1.B
M
M
M
M                "DL_Y\5^<O\ 4&*B["*          "%RO]@R_P"S_6)%
MP>,0_83'YSG],PT3H@
M
M
M                                  I+/^?%?G+_ %!BHNPB@
M   A<K_8,O\ L_UB1<'C$/V$Q^<Y_3,-$Z(
M
M
M                                                   *2S_GQ7YR
M_P!08J+L(H          (7*_V#+_ +/]8D7!XQ#]A,?G.?TS#1.B
M
M
M
M        "DL_Y\5^<O\ 4&*B["*          "%RO]@R_P"S_6)%P>,0_83'
MYSG],PT3H@
M
M
M                          I+/^?%?G+_ %!BHNPB@          A<K_8
M,O\ L_UB1<'C$/V$Q^<Y_3,-$Z(
M
M
M                                           *2S_GQ7YR_P!08J+L
M(H          (7*_V#+_ +/]8D7!XQ#]A,?G.?TS#1.B
M
M
M
M"DL_Y\5^<O\ 4&*B["*          "%RO]@R_P"S_6)%P>,0_83'YSG],PT3
MH@
M
M
M                  I+/^?%?G+_ %!BHNPB@          A<K_8,O\ L_UB
M1<'C$/V$Q^<Y_3,-$Z(
M
M
M                                   *2S_GQ7YR_P!08J+L(H
M    (7*_V#+_ +/]8D7!XQ#]A,?G.?TS#1.B
M
M
M                                                    "DL_Y\5^
M<O\ 4&*B["*          "%RO]@R_P"S_6)%P>,0_83'YSG],PT3H@
M
M
M
M          I+/^?%?G+_ %!BHNPB@          A<K_8,O\ L_UB1<'C$/V$
MQ^<Y_3,-$Z(
M
M
M                           *2S_GQ7YR_P!08J+L(H          (7*_
MV#+_ +/]8D7!XQ#]A,?G.?TS#1.B
M
M
M                                            "DL_Y\5^<O\ 4&*B
M["*          "%RO]@R_P"S_6)%P>,0_83'YSG],PT3H@
M
M
M
M  I+/^?%?G+_ %!BHNPB@          A<K_8,O\ L_UB1<'C$/V$Q^<Y_3,-
M$Z(
M
M
M                   *2S_GQ7YR_P!08J+L(H          (7*_V#+_ +/]
M8D7!XQ#]A,?G.?TS#1.B
M
M
M                                    "DL_Y\5^<O\ 4&*B["*
M     "%RO]@R_P"S_6)%P>,0_83'YSG],PT3H@
M
M
M                                                      I+/^?%
M?G+_ %!BHNPB@        #\Y9KS*<:Z@8;:YJ> 2V[*]3=V#U>V4LHD20LZM
M+!2VG6%-2&%)7WDI6:MI)\JE*(BQT/%[R\R3B>-<9"2EV#QN(1+7&7 5,BLS
M%-1IAQE^9DY+*4/]L_@[_>#$U;<0_83'YSG],Q=$Z(
M
M
M                                                          *2
MS_GQ7YR_U!BHNPB@        #F4WE[6?/CTV!Y/D$"KE/PG[:!#BIBJD0W5,
MODQZJ4PXZ3;B%(-2&S(S3Y3,%C9HK0KKBUBR*[?R)3QN=RTF16Z^2:TS%)4R
M]&:0VEMQ@R["D["/5'7KJ&)JSXA^PF/SG/Z9BZ)T0
M
M
M                                                         4EG
M_/BOSE_J#%1=A%         '*[/ +6OM)+6/<H6>,U]M+D3W*13=7,VOS7E/
M/>E7-CN.MI6XM2B3N423,]NA= 5N8Y5-4W%;4%NNL:Q9+>=DQ[MYJ39N2'IR
MW'I$EUE:T+<D+4I\S2K3S^!>!,35KQ#]A,?G.?TS%T3H@
M
M
M
M I+/^?%?G+_4&*B["*         /SG/P>+!MLA3D7!R,VL[.TL)D?)6WJJ7Z
MJ/+DN.QTK<L7FGHYM-*0SL2G8G9Y#TT!70<6H;S&N)HU-D.B+%@W%(AE)<G%
M#BO3%.QH?J72)3WIF5-L=P_A;/>#$U;L0_83'YSG],Q=$Z(
M
M
M
M   *2S_GQ7YR_P!08J+L(H         Y@[S=4G/L8-;BN46Z:N;)K),RMJ5R
M8QR83JF74I<)9:Z*3[WAU!8UL"FUEAPZW(IJE5'6%+L&H]4ZMUQYDF;9]LR=
M[ZE+2XHTFI:#4>Q1FDNA$&)J]XA^PF/SG/Z9BZ)T0
M
M
M                                                         4EG
M_/BOSE_J#%1=A%         'YVF\R9-39'/@UT;#4)OKFTJZUIVS]#+BRJAQ
MR,J9;JT5O2XU$-24MH):?DV]3UU26.G042$<<(.7.K+&6Z:GI$VB9*-6N.O2
MC<7V4$X[T(U&2E&LS4K51]3T#$U/8A^PF/SG/Z9BZ)T0
M
M
M
M4EG_ #XK\Y?Z@Q47810        !59G&7&]A*DSI^'4<J;,6IZ9)?K(CKKSB
MU;E+<6IHS4HSZF:C\0&6WJJNCQ)VJI8,>MJXY)*/"AM(CL-DIXE&2&VR2E.I
MF9GH7B+@V,0_83'YSG],PT3H@
M
M
M                                         I+/^?%?G+_4&*B["*
M        "%RO]@R_[/\ 6)%P>,0_83'YSG],PT3H@
M
M
M                                                         I+/
M^?%?G+_4&*B["*         .7N<VP53[*#5X;E-PW53I-9)FUU<V]&.3"=-I
MTDJ.0DS+5.I:I+4M#\#!8VZ++I.=<:+R67".N??E3(YP5ZDZTF%9.Q4I=29G
MM<VM%W$ZGM5J08FK1B'["8_.<_IF+HG1
M
M
M                                                !26?\^*_.7^H
M,5%V$4         86(D2,X^[&8;9=E.=Z4MM"4*==)*4;UF1%N5M2E.I]="(
MO< <TO;.7%SF?B,4VV,=3CB;8H#33:"]:[9J0MW<E)*U47B6NFO7Q%P73$/V
M$Q^<Y_3,-$Z(
M
M
M                            *2S_ )\5^<O]08J+L(H         XY52
M^:V$6>1TTJ#EE2NYNF$XO:-E4SF(T&TE1F40YS23;61H;29%):Z^/=T!5K>=
MCW>-KR^50O4F0R(Q07V+!MHI[++<KJRI;2W$F@UD:T;5F1D9*#$U-XA^PF/S
MG/Z9BZ)T0
M
M
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MNAD -6$%^9(KV9+3D^&EM<N*E:3>:0_N[:EH(]4DO:K:9EUT/3P,!L@
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M5U#\5]"76'VE$MM;:RW)4E2=2,C(]2,@&0
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M]M.M/M(?86EUAU)+;<09*2I*BU(R,NAD9>!@CV
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M;^"9)(!)0H4.MA1JZO8;BP(;2(\6*RDFVFF6DDA"$)3H24I21$1%X$ S@
M                                      "DL_Y\5^<O]08J+L(H
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MI;2VFI/CJ"/S])XTG74V/[=Q54YA/*]C8J*7&2ZGV'+ANDI_S:_[.XXAK4_
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MB'B??EZ%\%:HJ8#:M>NXEZ^.@)KOP(
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M>[I_Z7;O^Z M(#1.EJCN2R$X;7MPHIP"L-I=\HAN$Z;6[QV;R)6GO@-X
M   &BBFJF[=Z_1#:*[D1VX3T_:7>5&86MQ#6[QVDIQ:M/?,!O
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M?OF W        :-5355&R]'J(;4-F1(?FR$,I)/<DRG#=>=5[ZEK4:E&8#>
M                                              !26?\ /BOSE_J#
M%1=A%         'YIEYAR927%]6<=E97&)HN+-3D]W%53/227ICSDQJ*ZFRA
M>J2U(4ZDC[)^&W<O34%=$PN/31^((ZJ.S=N8TIR1,E6<A@H;SUA+L''YIKC$
ME!,**0MU)L[2[>FWW 35UQ#]A,?G.?TS%T3H@ -><S)D09,>'(.)+=:6W'ED
M@G#9<4DR2YL5T5M/KH?B _/4?[/V86L2Y9R>VB)G6F*/8R]9-RI]E)E6"WV7
MRGOJF;20E:FMQL-%HG7:2C(BT+5BG\6Y[ERLWGY9-J8%CE>+M8Q$9JO4O,QE
MLKE.$XM;Z4*<2I4@SZ)3HGR]=-QA,+P',+BRM;^\?K8MI;X@>,O1H2WWF&IO
MJ)+A.I<=0A2FMKR?%.[77_2 @J[BSD3$([3>(3::0]98M3XQ>*L_5)3'E4C#
MK#<N*3:5]QM27U[F'-FIDD]Y:J(!;<"XW?PBU<6W-1+J6<;H,:A&I)IDG[!3
M+2IUPB+:6\GTF1)/QU 5+&.+.0,:L<#)R13VM)AU4U ;8?>E,*:G/J-$Z:RA
M#*TN.&R?98[BBVI-?AO,!XP7A&=B-Q$C2H=;84E9-GS*V]7-L/:;:)IR%-Z0
MC(XJ'F_4*0;R5=4ZF2249@5EP_BK/JJUX[;OI]0Y0<;-S84!<),@I<^._"7"
M8==2X6QE:4&G>A*ED:M5$KP2 G,FPG.V,NR#(\%DU2FLMJHM5:MW)R"7#>K_
M %"69+'92LG4[)*R6PO9JHB,EEJ8#WC'%4O%;R/(B6"'ZB#A=;AL7N$I,E3U
M8Z^HGUD7E)*DN)Z$>NNH" <X/MYN'X;B,VUCM,T>*6^*6LII#BUJ7;0F(B7F
M"5MU)!M&HR7IJ6@%9\BX[Y(SK%*ZMRQRB9ML=GUUG4-5[DY,68[!;>9?*2YM
M;=90\AW5LF24II7BISP ;M-Q=91$8T\4.LI7:K)7<CLHD*3,L$OH75OUZ3.1
M+23BW_E$:F9)3M3H0#HT'ZQ^V+;VF<+ZO_[/[#*,3OK"^3/U'JC6>SX>G;[?
MXOPNH(E
M
M
M !26?\^*_.7^H,5%V$4         ?G";_- [BZ/C-.7HQ'VM9>H/7&%-G,*:
MZ4TX!6G^T$UW^YL[I[?R/+H"K_AY8^7$C/U;.P5#-V0<P[O7VM[2.>LYWK?
MO4>I[O=V^7=KM\N@8FKGB'["8_.<_IF+HG1
M
M
M                                                   !26?\^*_.
M7^H,5%V$4         ?FJ9B')E]<7MIQVF=1XFNWM$.P?K6Y$.9)8F.MRWH[
M/LV:40GI"'5:)>\3W;4ZZ KHF&.TCG$+#=#7/5,:,Y(B3*Z6]ZN0U8QI[C,X
MG9!*63RSDI=4;VX^YKN]T,35TQ#]A,?G.?TS%T3H@
M
M
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M ![)S7^)8_[L+_$ 'LG-?XEC_NPO\0 >R<U_B6/^["_Q ![)S7^)8_[L+_$
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M&D!;@                               4EG_ #XK\Y?Z@Q47810
M     0N5_L&7_9_K$BX/&(?L)C\YS^F8:)T0  !7J[_.-]_N=;_2E +"
M                                             K^0_M7&?^(N?]RD
M@+           (S(_P#+UM_N4C]4H QS_+U3_N4?]4D!)@
M                 KV"_P"3J3_<VOZ("P@
M                       *S0?YHRW_ 'B'_P!R: 68          5F_P#\
MT8E_O$S_ +DZ LP                               *2S_GQ7YR_U!BH
MNPB@          A<K_8,O^S_ %B1<'C$/V$Q^<Y_3,-$Z(   KU=_G&^_P!S
MK?Z4H!80                                                %?R'
M]JXS_P 1<_[E) 6           1F1_Y>MO\ <I'ZI0!CG^7JG_<H_P"J2 DP
M                               5[!?\G4G^YM?T0%A
M                                    5F@_S1EO^\0_^Y- +,
M    *S?_ .:,2_WB9_W)T!9@                               4EG_/
MBOSE_J#%1=A%          !"Y7^P9?\ 9_K$BX/&(?L)C\YS^F8:)T0  !7J
M[_.-]_N=;_2E +"
M    K^0_M7&?^(N?]RD@+           (S(_\O6W^Y2/U2@#'/\ +U3_ +E'
M_5) 28                               *]@O^3J3_<VOZ("P@
M                                          *S0?YHRW_>(?\ W)H!
M9@         !6;__ #1B7^\3/^Y.@+,
M  "DL_Y\5^<O]08J+L(H          (7*_V#+_L_UB1<'C$/V$Q^<Y_3,-$Z
M(   KU=_G&^_W.M_I2@%A
M          5_(?VKC/\ Q%S_ +E) 6           1F1_P"7K;_<I'ZI0!CG
M^7JG_<H_ZI("3                               !7L%_P G4G^YM?T0
M%A                                                 5F@_S1EO^
M\0_^Y- +,          *S?\ ^:,2_P!XF?\ <G0%F
M            !26?\^*_.7^H,5%V$4          $+E?[!E_V?ZQ(N#QB'["
M8_.<_IF&B=$   42=E^+8IF=JC)KF'4+F0H"XA3GT1S=2TN2E9HWF6XDF9$>
MG@"MC^;G%W\8T_\ ?F/C D/YN<7?QC3_ -^8^,!#^;G%W\8T_P#?F/C 0_FY
MQ=_&-/\ WYCXP$/YN<7?QC3_ -^8^,!#^;G%W\8T_P#?F/C 0_FYQ=_&-/\
MWYCXP$/YN<7?QC3_ -^8^,!#^;G%W\8T_P#?F/C 0_FYQ=_&-/\ WYCXP$/Y
MN<7?QC3_ -^8^,!#^;G%W\8T_P#?F/C 0_FYQ=_&-/\ WYCXP$/YN<7?QC3_
M -^8^,!#^;G%W\8T_P#?F/C 0_FYQ=_&-/\ WYCXP$/YN<7?QC3_ -^8^,!#
M^;G%W\8T_P#?F/C 0_FYQ=_&-/\ WYCXP$/YN<7?QC3_ -^8^,!#^;G%W\8T
M_P#?F/C 0_FYQ=_&-/\ WYCXP$/YN<7?QC3_ -^8^,!#^;G%W\8T_P#?F/C
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M4=FRUE]0IQR(^A"2FL&9J4VHB(B)0*N./$::"J2HM%%#CD9?=)I((D@
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M$!                               4EG_/BOSE_J#%1=A%
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MT=B''9B1D$W&80EIEM/@E"")*2+_ $$0(R@
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MF\4X/XHP>Y:R'%,7BUETPA;;4QE3IK2EU.U9%O6HNI'IX 5T $
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MK_:%KC28Z"2APMJDI6\EQ*^J3TZ J[9UQ_D$NRPJZX[74UDK#')GI*V>PZF
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MS!Q;'Y$9#27YC5?CLZ1+<E=LW$>I4KO$7IT&WIM(TGTV@M2_&>$WDYNFEV,
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MK)ZNJ*=IXDDMR%3QU&J06TU>1U^2\2-=#VI(].H#H((
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MIT?YU'X0#VO4_3H_SJ/P@'M>I^G1_G4?A /:]3].C_.H_" >UZGZ='^=1^$
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MIT?YU'X0#VO4_3H_SJ/P@'M>I^G1_G4?A /:]3].C_.H_" >UZGZ='^=1^$
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MJ9G[YGXF8BM@
M
M
M
M
M
M
M
M
M
M                                                          ?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>px_24maxcytepage02-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 px_24maxcytepage02-4c.jpg
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M_\0 O@ !  ,  P$!              4&!P,$" (! 0$! 0$! 0
M     0(#! 40  $$ @$" P,%# @% P  %P ! @,$!081$@<A,1,B% A!4156
M&&$RDM(C4Y/3=)34M4*TA946-S@Y<3,D5!>!D5)B0R5R@C5E=:&QP>&R<[,T
M)C9V)_%C51$! 0$  @$# @0#" $% 0   !$!00(#(3$28011@2(3<9&A\+'1
M,D)B(Q1RP>%2LN(%_]H # ,!  (1 Q$ /P#W\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M5XYTA:JHC;-AT4CD9"Y7>?GPCEXX:"-;"
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MP$
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M)Y(!]@
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M@]>;<KM&%
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M9U:.K%#$ZU!)4F<D+4CY?#*C7,5>GGA4/C^?-_<[7\?X_P!7JZ?Y<3!Q;
M
M
M
M
M
M
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MMJUG%;EK]_6,XV1^)R+$BM-@E?7D5J.1_LR1JUR>+4\E",F^R5V8_P"RR?\
M>]_]<%I]DKLQ_P!ED_[WO_K@5H7;[MIJO;''6\5J<5B&G=G]ZG;:M36W++T(
MSE'3.<J)PU/! BK[9\.?;#==AO;1GJM^3+Y!S'67P9*Y7C58XVQ-Z8XY&M;[
M+4\D"U"_9*[,?]ED_P"][_ZX%2.!^&7M1K6;Q^P8JID69+%V([=1\F4NRL26
M)W4WJ8^56N3E/%%3A05>M[T+7>X^#_P[M$<\N,2>.ST5K$M5_J1<HWVX7-=Q
M[2^'(1FGV2NS'_99/^][_P"N"T^R5V8_[+)_WO?_ %P*U#2M*P/;_7X-9UN.
M:/$UWR21,L3R69$=,]7NYDE<YR^*_.$9UE?A<[1YK*7LS?IY%U[(V);=ES,I
M=C:LL[UD>J-;*B-3E5X1/(+74^R5V8_[+)_WO?\ UP*G],^'OMKH.PUMHURM
M>BRU1LK(7SY&W9CZ9F+&[F.61S5\'+QRGW05/=P^U>H=T:]"KML-F:'&ODEJ
MI5MSTU1TK4:[J6![>KP:G'/D$4+[)79C_LLG_>]_]<%I]DKLQ_V63_O>_P#K
M@5KF"UW&:[K]+6,8V1N)H5VTZS))'RR)"QO2B+(]5<J\?*J\A&1_9)[,?]ED
M_P"][_ZX+3[)79C_ ++)_P![W_UP*MO;_LEH7;+*6LQJ<%R&[;K^Z3+:O6;;
M%B5[9/!DTCFHO+4\>.?_ '!7UW![*Z'W.R-3*[9!<FMTH%K0+5O6:C$C5ZO\
M6PO:BKROF"JA]DKLQ_V63_O>_P#K@4^R3V8_[+)_WO?_ %P*US+:]C,WKMO5
MK[9'8B[4?0L,9*^.58)&>FJ)(U4<B]/])%Y",C^R3V8_[+)_WO?_ %P6GV2N
MS'_99/\ O>_^N!5[[=]J=.[719"'48;4,>3=$^VEJW/<Y= CD9T^N]_3]^O/
M'G_Z($0FZ_#]VV[@;!/L^R5KTN6L,CBD=7R%NM'TPMZ&\1Q2-:G@GR(%JO\
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ML4T1)U8K^I('MZOO&\<^0%)^R5V8_P"RR?\ >]_]<"B_"3V85./<LG_>]_\
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M^8*U4(
M
M
M
M
M
M
M
M
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MWQ^=SFHB?^J@C2J=VGD:L5['V(K=*PU)(+,#VRQ2,7R<U[55%1?G10CG
M      *'WIWJQVU[7;+NE)C9,AC:J)1:].6):LR,KPN<B^;6OD:YS?E1. 8\
M<_#[\-4'?3&7^Z?='-7[$>4MS,K1UI6I9LRQKTRSS32,D]GJY8UC41?9\^.$
M#6ZVK["W9/\ /9O]]B_APE/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PM
MV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\
M?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L
M+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_
M 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3
M["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F
M_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP
M4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/
M9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX
M<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_
MSV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+
M^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9
M/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]
MB_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PM
MV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\
M?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L
M+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_
M 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3
M["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F
M_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP
M4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/
M9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX
M<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_
MSV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+
M^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9
M/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]
MB_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PM
MV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\
M?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L
M+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_
M 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3
M["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F
M_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP
M4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/
M9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX
M<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_
MSV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+
M^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9
M/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]
MB_AP4^PMV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PM
MV3_/9O\ ?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\
M?8OX<%/L+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP4^PMV3_/9O\ ?8OX<%/L
M+=D_SV;_ 'V+^'!3["W9/\]F_P!]B_AP5ULA\"'9^Q2FAQ^0S5*\]JI!:=8A
MG:Q_R*Z-86]2?.G4G_% 5G/PI[%M?;#O/G/A]V*W[UBU?<;3B17+''>IM]?U
M8.KQ;'/"USW-X\^E?!>>2Z]SAD         8A\7O^GK;_P"SOYE6"XZ'P8_Y
M X+]JR/];D!K?@@
M
M
M      >%,)_N"V/VBY_() UP]UAD         8A\7O\ IZV_^SOYE6"XC_@Q
M_P @<%^U9'^MR UOX0
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ME>HL6*O-(CE1'M8K6\<MZ>I.E$ZN>/ (G
M                                                  >%,)_N"V/V
MBY_('AKA[K#(         Q#XO?\ 3UM_]G?S*L%Q'_!C_D#@OVK(_P!;D!K?
MP@
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M6'6-S_3CL.;#TJY6M:YR.='QU<)U+X!&KA
M                                                  /"F$_W!;'[
M1<_D#PUP]UAD         8A\7O\ IZV_^SOYE6"XC_@Q_P @<%^U9'^MR UO
MX0
M                             (*KINMT]LO[Q#13_%62K14+.1>^21_N
MD"]38HT>Y6QLZO:<D:)U+XNY5$ G0
M                                                   \*83_ '!;
M'[1<_D#PUP]UAD         8A\7O^GK;_P"SOYE6"XC_ (,?\@<%^U9'^MR
MUOX0
M        B=HV&CJ>MY?9\F[IQ^'ISW['CPJLKQK(K4^ZO'"?= PKX=N_&[=Q
MMAR>K=Q\73Q.7EQE38]>939)$D^+M\>TOJ2R\^$D3FJG"\*O*> 7<:+L/?KM
M!JL^1J9_;:=.YBK+:-^HJ2R6([#F]?2D4;'/<B)]\YC5:WR544$3.0[G]O\
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MD^4$:+=[P:!J56C1W?;,=4SCL/!F;#_;BBGKR<1+/ U47E)).?3C15>J?(O
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MK2-EK3L;+#*Q>IKV/3J:Y%3S147E CD
M                                    >%,)_N"V/VBY_('AKA[K#(
M       Q#XO?]/6W_P!G?S*L%Q'_  8_Y X+]JR/];D!K?P@
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M_P"6Y59Y?(&4L
M                  \*83_<%L?M%S^0/#7#W6&0        !B'Q>_Z>MO\
M[._F58+B/^#'_('!?M61_K<@-;^$
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M(^?_ (N5.4_] .P
M                     >%,)_N"V/VBY_('AKA[K#(         Q#XO?]/6
MW_V=_,JP7$?\&/\ D#@OVK(_UN0&M_"
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M/;Y(CF.YXY5$"Q:=\W[6>V^KV=OVJTM?"U5C8Y\3%FD>^=Z,8V-C?%RJJ_\
MMRJ^"!'QV][@ZYW.UF#;=5DEEQ%B26%CK$2PR(^!ZL<BM=]U +!D+U?&4+62
MMJK:E.&2Q.YJ*Y4CB:KW*B)XKX)Y 8_K7Q1=MMMOXVA@ZN<G^E;,5*K;^BK'
MNOJS2I$BNE3EK6HY?:=\@6.EDOBV[48C(+C+T6;BN>L^M&QV*G:LLD3NER1H
M[A7>/S("-2T;=\/W!U^/9,%':BQ\LDD+67Z[ZDW5$[I=^3D3GCGR4(L@
M
M !X4PG^X+8_:+G\@>&N'NL,@        #$/B]_T];?\ V=_,JP7$?\&/^0."
M_:LC_6Y :W\(
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MSID4B=C_ $W>])8Z5A])$Y=U]?L]/'GSX >6*]5WQ(=]\#NN"K+!VJ[92_\
M29U6>FN5R44J2HVNJHG5$R1C/G1&M7R61$0U[.#LTZM(GQ,.R_1[ZN7RJ9'U
MN$_Z5&748C^?Z")ZG'R< U^]D>X^$[4_"[K6T;%#[UEY),E3U?&1M1UZ]+-?
ME5M>'P5R,=(G+U1.$3QX5>E%&^Z-UW&[;\.787<NXN6J^EW(WBW'.VA!'Q%C
M9+CGM@ZV-1W#HO5EE5O''/3'\BJ!0NWFY=K-9[Y]KX-8R-FYA\?AIL5DLG+1
MLQ3V\[DY+"23.9(SU%2225GM+RC&\)SPT#U9\0F>P6"T6)<]GLW@Z]W(5ZD+
M-5X3,7Y7H]4IUW*GLK(B<JO+?O>.?'A28PCM?#F[/=K:>TKKFXZYIF:U=V19
M0SM]KLQ4L)/"SWBM,Q\J1=2*]//Q\>KR3@JR? _J,-70';FW+Y26:W/=QZX:
M6TKL3&C)HW>M'6Z>&S+T<*_J\E7YPFMC[X8+#9#MIMV9NXZO:R^*UW-IC+LT
M+))ZWO%)_JK"]R*K%<C&]2MX7P!B$^'/'TLI\.^HXK)UV6L=>Q<M:W5F:CXI
M8)Y96/8]J^"M<U514^5 :I7:^C4QOQ:]U:&/K1T\?5PN(BK5:\;888HTK4^E
MK&,1&M3CR1$!PY^]FJ;1AM,[S[-)N=O+XS+XN!E+5W?\K%QHK$E5OY1R(CV=
M?WK&<MYZNI?$&,\[JLHN^'#L*W$I'[\[)ZZE)&<>HLJTI/6Z>/'_ )O'7_\
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MW -;^#:]7K=@\;:OV(X(WY&^CI9GMC:KY+*HB<N5$Y55\ FMMW3_ /D[8?\
M[V7?ZN\(\T_"14[S.[<Z?9I9+ L[8I/>ZZ4\%E<NL*7+"2HV1O$7*R]2M^YY
MAK5D^(M53NYV"X^L-C_].F$QZ."
M                                 !X4PG^X+8_:+G\@>&N'NL,@
M    #$/B]_T];?\ V=_,JP7$?\&/^0."_:LC_6Y :W\(
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M3Y0M:%M_;36MWS^J[)F_>/I+3K;[^']"98H_6D6)R^JU$7K3F)OAX?+\X1<
M
M      !X4PG^X+8_:+G\@>&N'NL,@        #$/B]_T];?_ &=_,JP7$?\
M!C_D#@OVK(_UN0&M_"
M              ."[=IXVI-?R-B*I1K,=+8M6'MBACC8G+G/>]41K43S55 _
M*-^CE*<&1QEF*[C[+$EK6Z\C989(W>*.8]BJUR+\Z*!^,R%"6[+C8[4+\C Q
MLDU1LC5F8Q_WKG,1>I$7Y%5 .R         ZT>0Q\UR;'16H9,A7:U]BHV1K
MIHVO\6J]B+U-1?D54 [(    AZNV:M>Q[<O2SF/L8ITRU6WH;4,E=;"+T^DD
MC7JWKY\.GGD"8 ZWTCC_ '_Z+][A^D_3]?W+U&>OZ//3U^GSU=//AU<< =D
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MR./R/K?1]N&W[O(Z"QZ$C)?3F9]\Q_2J]+D^5J^('9
M                                               >%,)_N"V/VBY_
M('AKA[K#(         Q#XO?]/6W_ -G?S*L%Q'_!C_D#@OVK(_UN0&M_"
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M01/GC]&=S&NEB1R/Z'JG*MZDXYX7PY".0
M                            'A3"?[@MC]HN?R!X:X>ZPR         ,
M0^+W_3UM_P#9W\RK!<1_P8_Y X+]JR/];D!K?P@
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M:MOOV:%2"K->E_YD[X(VL=*_E5]IZIU+X_*$2
M                                 /"F$_W!;'[1<_D#PUP]UAD
M    8A\7O^GK;_[._F58+B/^#'_('!?M61_K<@-;^$
M                                          !T,G@L)FUJNS.-JY%:
M,S;5);<$<ZP6&?>RQ^HUW0]/D<WQ [X    CLO@,%GVUV9W%U,FRG,VS4;=@
MCL)%.SE&R1I(UW2].?!R>($B                Z>5Q&*SM";%9NC7R6+L(
MB6*5R)EB"1&N1[>J.1'-7AR(J<IY@=BO7KU*\52I$R"K QL4$$349&R-B=+6
MM:WA$1$3A$0#D
M                                      \*83_<%L?M%S^0/#7#W6&0
M        !B'Q>_Z>MO\ [._F58+B/^#'_('!?M61_K<@-;^$
M
M
M                                       #PIA/]P6Q^T7/Y \-</=8
M9         &(?%[_ *>MO_L[^95@N(_X,?\ ('!?M61_K<@-;^$
M
M
M                                          #PIA/]P6Q^T7/Y \-<
M/=89         &(?%[_IZV_^SOYE6"XC_@Q_R!P7[5D?ZW(#6_A
M
M
M                                           \*83_ '!;'[1<_D#P
MUP]UAD         8A\7O^GK;_P"SOYE6"XC_ (,?\@<%^U9'^MR UOX0
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M%/ #]21CG.8UR*]G'6U%153GQ3E/DY _)9H8&]<\C8F*J-1SW(U.5\$3E?G
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M('AKA[K#(         Q#XO?]/6W_ -G?S*L%Q'_!C_D#@OVK(_UN0&M_"
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MKDG5G7RGR+U 2]>A1JSV;56K%!9NO;)<FBC:R29[&HQKI'-1%<J-1&HKOD\
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MG#T1R>SY^/F!VXL?0@MV;\%6&.]<2-MRTR-K99FPHJ1I(]$Y<C$<J-ZE\.?
M#B;A,,S%+@F8ZJW!K&L"XQ(8TJ>B[GEGH]/1TKSXMXX ^L5B,5@L?!B<)1KX
MW%545M:C3B97KQ-55<J,CC1K6HJJJ^">8'Q]!X5:ER@N-J^XY%\DN0J^A'Z5
MB2?QE=*SIX>Y_P#25R+S\H'U)A\3--[Q-0K23^[OH^J^%CG^Z2*BO@Y5.?3<
MK4Y9]ZO'D!U<!JNKZK#-7U?"4,+!8>DEB+&U8:C)'HG".>D+6HJHGRJ!+@
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MJY[G*ODB(BJH'QC<E0S&.J9;%V&6\9?ACM4[42]4<L$S4>Q[5^5'-5%0#M
M !51$Y7P1/,"/PF;Q&R8JKG,#<BR&(NL]2I<@=UQ2,15;RU?E\45 )
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M)RJKY ?M>Q7N5XK=25D]6=C98)XG(^.2-Z(YKFN:JHK51>45 .4
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M.URY/8<*_,,V['U->N9RILC<#=P25+]14;[I-%/^3D8]'))&YKT=[+FNY\'
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M[0V9,M0V33=KO:ILU7%PX*[>KP5;L-VC67JB]>M:C='ZK'*JLD;PJ(JM\4\
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MY :W\(
M
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MVT2ZE1PN9V'*THZT^97"5&VH\?%><YL#K"ND8[EZ-<Y&Q->[I17<< 2E7?\
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M:MW?U_9]@=K4F,RV R4M5^2Q?T[36BS(48G(U\U97.<O#>IJN9*C)$:J*K.
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M^"VF'<M([CZQB5V'_"WTG4R6#ADB@N2U<O%$Q9JS[#V1]<3H456.<G4U51%
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MJ50-4VC6<YD>[O;[9Z=7U,%@Z6?AR=KU&-]*2_'4; G0KD<[K6)_WJ+QQX\
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ML[!)HF<UV]'CUHLS&QYM<O,YLLS99*T,2WKG3'U,:]9%Z>>/#Y0-A"
M  'A3"?[@MC]HN?R!X:X>ZPR         ,0^+W_3UM_]G?S*L%Q'_!C_ ) X
M+]JR/];D!K?P@         ^7L;(QT;T1S'(K7-7Q147P5% Z>'PV+U_%U<+A
M*D=#$THTAJ4X&]$4<:>36HGD@'>                                $
M?C\%A\5<R.0QU*&M>R\S;.3LQM1)+$S&)&UTCO->EK4:GS(!(   '1S&'Q>P
M8NUA<W4BOXF[&L-NG.U'Q21N\VN1?- .XQC(V-CC1&L8B-:U/!$1/!$0#Z
M1^)P6'P3;C<-2AHMR-N;(WD@:C/6N6EZI9G\>;WJG+E D   ".P6 PVLXV+#
MX"C#CL7"Z1\56NU&1H^9[I9'<)\KGN<Y5^=0)$     *:O:7MBNQ_P"+EU+%
MKL?J^\_2'NL?J>\<]7K<<=/J\^/J<=7/CR!<@                      %
M:VSM[H^]MKMW# 4LRZIS[K);A:^6)'<=2,?]\U'<)U(B\+\H$EBM=P&#K4J>
M&Q=2A5QT3Z]"&M!'$V"&5R.>R-&HG2U[FHYR)]\J<J!)@
M                                     #AK5*M.-T52".O$Y[Y7,B8U
MC5DE<KWN5&HGM.<JN<ORJO(',                        >%,)_N"V/VB
MY_('AKA[K#(         Q#XO?]/6W_V=_,JP7$?\&/\ D#@OVK(_UN0&M_"
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M$7GD"1??HQW8L;):B9D9V/F@J.D:DSXHE1'O:Q5ZE:U7-ZE1/#E .P
M   \*83_ '!;'[1<_D#PUP]UAD         8A\7O^GK;_P"SOYE6"XC_ (,?
M\@<%^U9'^MR UOX0        SCOE0U?*]O[&/V[.LUO&S7**P9B>%MFK%<AL
MLFK^\Q2(L3X72,:DC9N&*G@JIX*%QAVP9RIL_:#+97)X7"2TM8W#%^][-@::
M+B,C3AN4W6;T3'L<[A&?D;'2KV^PJ(]S?(JU;)FNW5;NMI>S[#+C5[.RZY=K
MZED)(XW8.'.NNL6545&^E&]]=O$;W\(O#D;XA%&R56D_4<OG\91D;V'G[CXW
M*6JK('>Y2Z[# QMZRVNC5ZJ+KK6R*UK.E6M<J)P%6;N?D>WNRX3"+V>LX^MD
M9=ZUJO8SN*I-DILR+E>E:5>EK(;"PHK5<UKUX3AKE3R"('(U,'/VH@T#,8CW
M;=,?N> J]R*L[WV)LC;O9!BNR#["HU\L5YG,D;_#I3\FWA&(%6_:-?EP?=G<
ML-VWH,Q&2R':VW)0JXJ)E-DF4AN2PU'HD:,9ZK.I&,<OBB<)Y($5:G=[8YK7
M.T6N]KJU;_R1BLOAI[-:C D.5QT-143+OR*M:U[&*WU&3I*OY5[D^^"OW9HW
MKJ7<V:W!)8U2KW5JVMQKQQOE63 0,QK[?,;$5SF(B-<_C^BBKY 2%:UJ>;[W
M9Z_V7CJ^]6NW65@KY/$0I6ISY=ERLD/IS-:V*22-'1HYS.>GP:Y>4X0B [78
M_6LPWM=0?O&OXO9->N59TU['X-]+9_?X*[V7J5R5]ITG$JK*EJ1\"-D<G7\P
M5J78C5M<FS_<[:I\36DV--ZS->/)RP-=8CBA]/H;$]S>6)^5D^\\^I>>0FI/
MN2L4??'LW8E:JMA;M+E>C5<K43&1JO'"*OBB?^H%'[&Y/7<!N&*T/3;N&WC5
MW8Z];Q^SXZJR'-XB%9F2+7RKV)TN]=ST:QW$<CGL57L^4&ICXAFVZVY]N,QD
M;]'%Z=2DRB6<IFJ3\EAZN4FAB93DM0I- U'*WUFPRO=PQRK\Z Q1,YK^NS]J
ML_\ 1^QX[;<)L&\8-U^'!TW8_$P326J45F.NULTW_,;P^1\<G'4Y?)>0K28-
M8U[$_$8[!XG#TZ6$R.@RNO8RO6BBI3OK9:&.%9(6M2-SF,>YJ<MYZ?#R",HP
M-O5YOA<Q.*P[:S-GQ.4UVMM=2&)L-V"TS.QL:RVU&M?UITNXZ_$+RU+"?X-P
M'Q([E5SD%"AF<[2P5C5DG@C9-:G8V\EN2L_HY5_4J>JK5ZE^7R",@QZ7H.U'
M9O)W+=7':71SVROS=_+T7Y/%5KDEV^S'S7*K7Q+TI(KVLD<]K8Y'-<X*F<SA
M<=_XW[AYO ;/1W#!93.8*WM^.U6@^GC:]*G) E]:\<,UA'OFA:V2RK'^*-7G
MY0+7K.1[9YCXD,#DNV<-%U!=8R,&0R.)K)#2FECGJNCC22-K8Y)(V.3KZ>58
MBM:[Y$0BR]_F:WC\[VTV;:JU-NOTM@=!F,G>@CEABKST+;(VS/>UW3&LKD^^
M]E'<+Y\ Q7K&:[<83O)M64[IR8Z+7LG@L.O;ZYEHF/QSL3'#*MV&JZ1BQHY9
M7-<Z)/;<U6\)P!>_AWHW:';*LR:M/2Q,V0R=G7*-MKF3P86Q<EDI,<U_M-3T
ME1S6KY-5 :R6U@YTW6U\-7NTCM:R>T1;IT/B1:7^$U1<C8J)T\=+?I&)(&I\
MSPKL?2W;'"97O!CN\\523;\EEK4N/KY&!);M[ 2UHH\;%CU<Q5DXX<QK(55S
M).>>%".LE+&ZAD.P>0[NUJM5[,!E,=FK^7@8]K;ONM-U2"S+(Q4]5K6/:Q'K
MSU([CQY B=G@H?XL[LX3N)M6NZQ/FKLCH5V7#NO7+&"DIQ1U)*%IUJNUR1*D
MG1%$USHY6JJ^*A7IJJBZ_P!LH&I[QM:XO!,3Q8K;656M33^@_E4DL=/DO])P
M9>9=(SF-V3N9V>O49-:C;89E&W-?U;&25OHN"SB;#FTKUE97L>Y%9TK"Z*->
MMJN1O ::=\/DVH8_+[[K->*E2W6EM&?EEQ[(&5[K,5)=1\#N$:UWNZM?&L?'
ML>7 33NL[3<'WK[>9[<Z]"MA+6/S=*7(WZ\3H7W?^C=7CDE<Q4Z^&O\ 2ZE^
M=&^:@5QVG:MFIOB+RV9PM6_E62V*\-RS V::.&/!PRL2%SD56*CUZ^8^%YX7
M^BW@*O;N9&'*=H]@VC-XS#X"SV]H0XW.;707*XQN<F;#+:;[4]=L%F6!&<2R
M/]IB/8GBJA6Z=AL3B<1HLC,#L-;8\/;RF1NU+.-JK0QM=+%ASGUJ4'7(C8(Y
M.OHZ7JGCX> 3686</O?=?<.YN>US&X.]J]R&3MY4GSMB[4L,J4&O]^?6]VKS
M-<R2U,Y4?U(O,3>/("+Q,\'<)W8O7]YHQY')X#,9S7MHHVV^O&N2P.,F8BR]
M2</ZUBBG5%]EW/BBIX!4=W)H5,/KGQ-X3$U64L-#+KMFOCZT21UV37*=1\[V
M1L1&HY[DZGJB>?B!J=_5=<TWOKVQKZGB:V&@M878:5Q*,+84FKU6TI(62JQ$
MZ^A[G.17<KU+SYA&*P[3KM'X?]9[73S>GO>(V6M#EM?;"]UBDL.Q>H]]AK6\
M11JV1G3([V7*Y&IRJA4OWUV/&9-W=7!V:VLX"_5KMABJ7\5)?V;.2)28^*U
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MH!!Z#I>.[>ZEC=1Q<TUFMCVO5]NR[KL6)YY'3332.^5TDCW/7_B!9
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M*BKRH'YJ._Z5OM>Q9TW.T\U%4>D=KW.5LCHG.YZ>MOWS4=PO2JIPO'@!8P
M !#:UM6"V^E8R.OV?>ZE6W9QT\G0^/ILTI5AF;Q(UJKTN:J<IX+\@$R
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M:[CA4 G
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MB]*>SSQYJJ^(938
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M)=<E?-3AK67PP3+)%Z2ML,;X2M1/%$=Y+_Q4(GP
M                                   /"F$_W!;'[1<_D#PUP]UAD
M      8A\7O^GK;_ .SOYE6"XC_@Q_R!P7[5D?ZW(#6_A
M
M
M                                     \*83_<%L?M%S^0/#7#W6&0
M       !B'Q>_P"GK;_[._F58+B/^#'_ "!P7[5D?ZW(#6_A
M
M
M                                        \*83_<%L?M%S^0/#7#W6
M&0        !B'Q>_Z>MO_L[^95@N(_X,?\@<%^U9'^MR UOX0
M
M
M                                        /"F$_P!P6Q^T7/Y \-</
M=89         &(?%[_IZV_\ L[^95@N(_P"#'_('!?M61_K<@-;^$
M  'XYS6-5[U1K6IRYR^"(B?*H'S#-#8B;-!(V6%Z=3)&*CFN1?E14\% ^^4_
M]O,           <<UB"LSU+$K(8U5&H^1R,3J<O")RO'BJ^0'(
M ..2Q!"^..65D<DR],+'.1JO<B<\-1?->/F Y           !QQSP2ND9%(U
M[XEZ96M<BJQW'/#D3R7A?E Y  !51/,#@=<IL69'V(VK61'6$5[4]-JIRBOY
M7V45/G YFN:]K7L<CF.1%:Y%Y147R5% ^()X+,:35I630NYZ9(W(]J\+PO"I
MRGF!R        <<,\-AGJUY&RQJJHCXW(YO+5X5.4^90.3E/_;S   .-9X$G
M2LLK$LJWU$AZDZU8B\=73Y\<_*!R            !QMG@>^2)DK'20\>LQ'(
MKF=2<IU)\G*?.!R       XXIX9^OT9&R>FY8Y.AR.Z7M\VKQY*GS &SP/E?
M R5CIXD19(D<BO:CO)7)YIS\@'(   %5$\P   !Q3V:U5K7VIF0L>Y(V.D<C
M$5[O)J*JIRJ_(@'*      #\>]D;'22.1K&HKG.<O"(B>*JJJ!^1RQS1MEA>
MV2)Z(YCV*CFN:ODJ*G@J ?0'&Z>%LK*[I&I/(BN9$KD1[D;YJB>:HG/B!R
M  !RG/'R_,    "*B^0     ?+WLC8Z21R,8U%<YSEX1$3Q5550$<D<K&RQ.
M1\;T1S'M5%:K5\45%3S0#Z  <<L\$'0L\K(DD<D<?6Y&]3W>34Y\U7Y@.0
M         %5$3E?!$\U XUG@2=*RRL2RK?42'J3K5B+QU=/GQS\H"*Q!,Z1L
M,K)'1.Z)6L<CE8_SZ7<>2_<4 EB!9UK)*Q;+6H]T*.3K1BKPCE;Y\<_*!R
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M=BH[9L>K=U=39J\^'UZ;<:ZT[C,BJXRLO$D<BL1J+,GBGL^"JU?N*I(A=/\
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M.P]D]YE?H>V:EGL1BNXFG16ZLJLQZU\)9K9#J]1C:T+E6-&]2\<??*O5[*\
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MG?S*L%Q'_!C_ ) X+]JR/];D!K?P@
M
M
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M$X7P^4L7;5N_/:+=+MW':UM-:Y=H02V[$*LG@7W>!.J22/UXV)(UJ>*K'U>
M(INF_$OK'<C#;K%KUNEAMEP$64EQ7TE)-/5FI4(D='DIO3B8YL"N<BO8G+T1
M%!%GQ7=[7-<[7Z]NO<S:,3&[)P(KLECDG]TM2\NY]UA<SUW<(GM)Z?@O/@@$
MK3[T]K+^I2;U4V>I)JD$\=2QD?RC6PV)G-:R.5CFI)&Y5>W[]J>"\^0(^M5[
MS=KMVRF1PVK;12R61Q3'S78XG.:UL,2HCY6/>UK)(VJJ<R1N<U.?,)#3.\G;
M/N%F+>!TW88<KE:43K$T$<<\:+"QZ1NDC?+&QDK$<Y&JZ-SDY"Q>@@
M
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M*JG2]/#SXY3P3P5/! RG0
M                                                    /"F$_P!P
M6Q^T7/Y \-</=89         &(?%[_IZV_\ L[^95@N(_P"#'_('!?M61_K<
M@-;^$
M
M                                                        #PIA
M/]P6Q^T7/Y \-</=89         &(?%[_IZV_P#L[^95@N(_X,?\@<%^U9'^
MMR UOX0
M
M                                                          /"
MF$_W!;'[1<_D#PUP]UAD         8A\7O\ IZV_^SOYE6"XC_@Q_P @<%^U
M9'^MR UOX0
M
M
M /"F$_W!;'[1<_D#PUP]UAD         8A\7O^GK;_[._F58+B/^#'_('!?M
M61_K<@-;^$
M
M
M #PIA/\ <%L?M%S^0/#7#W6&0        !B'Q>_Z>MO_ +._F58+B/\ @Q_R
M!P7[5D?ZW(#6_A
M
M
M      \*83_<%L?M%S^0/#7#W6&0        !B'Q>_Z>MO\ [._F58+B/^#'
M_('!?M61_K<@-;^$
M
M
M       #PIA/]P6Q^T7/Y \-</=89         &(?%[_ *>MO_L[^95@N(_X
M,?\ ('!?M61_K<@-;^$
M
M
M          #PIA/]P6Q^T7/Y \-</=89         &(?%[_IZV_^SOYE6"XC
M_@Q_R!P7[5D?ZW(#6_A
M
M
M           \*83_ '!;'[1<_D#PUP]UAD         8A\7O^GK;_P"SOYE6
M"XC_ (,?\@<%^U9'^MR UOX0
M
M
M               /"F$_W!;'[1<_D#PUP]UAD         8A\7O^GK;_ .SO
MYE6"XC_@Q_R!P7[5D?ZW(#6_A
M
M
M                 \*83_<%L?M%S^0/#7#W6&0        !B'Q>_P"GK;_[
M._F58+B/^#'_ "!P7[5D?ZW(#6_A
M
M
M                    \*83_<%L?M%S^0/#7#W6&0        !B'Q>_Z>MO
M_L[^95@N(_X,?\@<%^U9'^MR UOX0
M
M
M                    /"F$_P!P6Q^T7/Y \-</=89         &(?%[_IZ
MV_\ L[^95@N(_P"#'_('!?M61_K<@-;^$
M
M
M                        #PIA/]P6Q^T7/Y \-</=89         &(?%[
M_IZV_P#L[^95@N(_X,?\@<%^U9'^MR UOX0
M
M
M                          /"F$_W!;'[1<_D#PUP]UAD         8A\
M7O\ IZV_^SOYE6"XC_@Q_P @<%^U9'^MR UOX0
M
M
M                             /"F$_W!;'[1<_D#PUP]UAD
M8A\7O^GK;_[._F58+B/^#'_('!?M61_K<@-;^$
M
M
M                             #PIA/\ <%L?M%S^0/#7#W6&0
M !B'Q>_Z>MO_ +._F58+B/\ @Q_R!P7[5D?ZW(#6_A
M
M
M                                  \*83_<%L?M%S^0/#7#W6&0
M    !B'Q>_Z>MO\ [._F58+B/^#'_('!?M61_K<@-;^$
M
M
M                                   #PIA/]P6Q^T7/Y \-</=89
M      &(?%[_ *>MO_L[^95@N(_X,?\ ('!?M61_K<@-;^$
M
M
M                                      #PIA/]P6Q^T7/Y \-</=89
M         &(?%[_IZV_^SOYE6"XC_@Q_R!P7[5D?ZW(#6_A
M
M
M                                       \*83_ '!;'[1<_D#PUP]U
MAD         8A\7O^GK;_P"SOYE6"XC_ (,?\@<%^U9'^MR UOX0
M
M
M                                           /"F$_W!;'[1<_D#PU
MP]UAD         8A\7O^GK;_ .SOYE6"XC_@Q_R!P7[5D?ZW(#6_A
M
M
M                                             \*83_<%L?M%S^0/
M#7#W6&0        !B'Q>_P"GK;_[._F58+B/^#'_ "!P7[5D?ZW(#6_A
M
M
M                                                \*83_<%L?M%S
M^0/#7#W6&0        !B'Q>_Z>MO_L[^95@N(_X,?\@<%^U9'^MR UOX0
M
M
M                                                /"F$_P!P6Q^T
M7/Y \-</=89        /.6Z]Y5K9JAIN5W5= MQY+.MS>0FQ\:6TJ5+#UQ;8
M$MQ2P.BL0.:_UFM>KNE&^RYSD0L1G>K.YS9/A S>8V%'/R$RUF,MOK/H.N58
M<U%%6N+6?[4*V86QS^FOWO7\P,]UA^#'_('!?M61_K<@-;^$
M
M
M                                       #PIA/]P6Q^T7/Y \-</=8
M9        ,RN]WN;]^OAM#V?8*&+M3TI\M0IU6U76*<KH9T@]ZM022I'(QS%
M<R-456^RJA8S+OKE$S7PCYW))FY]B=,M;U,I<JQX^RKVYJ)KH9JT3(VQR0*G
MH.;T(O+/'QY!GNF_@Q_R!P7[5D?ZW(#6_A
M
M
M                          \*83_<%L?M%S^0/#7#W6&0       #*\GH
M&5Q^4LQ:]W0R>LX_+6[%^3".CQ=SIGNS.FF]U?=KR2QM?(]SD;U.1JJO3PG@
M%9KWOQ46&^$7/T8\=D<8]'PRV:^;FBLY.2Q-G(Y)K%F6%[V/DL/<Z=5:[CV_
M)/)!GNG_ (,?\@<%^U9'^MR UOX0
M
M
M                   /"F$_W!;'[1<_D#PUP]UAD        \YW]'JT<ML+
M=B[',W;)Y/*9"Y7V6.;%6_>J]NS)+7:^3(S135UBB<R'H:WH;T>PO' 5%=Z<
M#G-:^#_-X;8>&9&!:SF4TLOO)3JS9J*6M3]YE1'3>[0NC@]1?ONCY@9[K%\&
M/^0."_:LC_6Y :W\(
M
M
M        'A3"?[@MC]HN?R!X:X>ZPR        9A+WNQ*W\C1QNJ[1EVXN[9
MQEFYC<2^S66S2E=#*ULB/3GAS?F\O$+&0=U;N,R'P;[!8PV)=@\8EM\5?%2O
MEDFA2'9/35)?7<Y[9'*U7/8KEZ'*K4\$0+RM_P &/^0."_:LC_6Y FM_"
M
M
M                                                !X4PG^X+8_:+
MG\@>&N'NL,@       'G:[WDV;#;'?HXZMIK&Y[,Y3%XV*7)^XVZMK$225G7
M,N[AW6V2*HKFMC8CV_DX^5YY:6.O\0<=AGPH["MN]C,C;E6I-8NX*%*V-DEF
MS$,C_18DDO@BN5'.5ZJYW+E\5X!GNDO@Q_R!P7[5D?ZW(#6_A
M
M
M                                         \*83_<%L?M%S^0/#7#W
M6&0       "JW.V7;?(6K-Z_IV#M7;CW37+,^,J2RS2/=U.?(]T2JYRKXJKE
M\P,N^*G%8O!_#7M.*PM&OC<972@E>E3B97@C1V3KN5&1QHUK>5557A/,+CC^
M#'_('!?M61_K<@-;^$
M
M
M         #PIA/\ <%L?M%S^0/#7#W6&0        !B'Q>_Z>MO_ +._F58+
MB/\ @Q_R!P7[5D?ZW(#6_A
M
M
M              \*83_<%L?M%S^0/#7#W6&0       #*7=U]DH37LYFM2Z.
MV]3(WL6_/T+GOMRLW&7)*4ENW2;"U6UU?$]SG122.C9[3V\<JTK/>_>UOW7X
M4]JV)S:Z,GM^[P/IR>O7D@IY]E:*5DGDY)&1-?RGAX^'@#/=,_!C_D#@OVK(
M_P!;D!K?P@
M
M
M >%,)_N"V/VBY_('AKA[K#(       !UJ>/H8YDL="K%5CGFEM3LA8V-KYYW
M*^61R-1$5SW*KG.\U5>5\0/*_P 44C<!HVWZ!@H*V,TZKK=#*UL/3KQ00QW)
MME@8^1B1M3A'(YW+4]GE>>.0UBY?!C_D#@OVK(_UN0)K?P@
M
M
M                                      >%,)_N"V/VBY_('AKA[K#(
M       !CF*M]ZX&9/8\-:H[9B7YG-0-U?*1IB;T%:CE+5:%E.]$U8WHK(VJ
MB68O'S]7@*J?Q,R5LY\.FS[=;P,V$V&Q6HT;$&0CB2_##%F(%6%SXGR-5BO3
MU&=+U1R*C@8D/@Q_R!P7[5D?ZW(#6_A
M
M
M                       \*83_ '!;'[1<_D#PUP]UAD        \U7L/L
MNR[W'C'9??Z>=EV#))DU@EM8O U=>B=:2I)6E9&E1_L)55GC)(]_4DB??<%<
M7?>SLUGX3=F_Q?ZC\Y6GCIR6IX$J2VH*F=C@KVGPM\(W3PL9,K4\/:\$1.$!
MGNF_@Q_R!P7[5D?ZW(#6_A
M
M
M              \*83_<%L?M%S^0/#7#W6&0       #R_L>F[W8V')3V=?V
M*[IC<KD;>ZXYF9]=<_1FMR/QC,9![Q^3;6B6)9HFNK]3&^E^44*XN\>/S>,^
M#W.T\[!9J66/A=3HWYO>KE7'29R-]*O/+U/ZY(JRQ1N7J7Q3CE?,&>ZS?!C_
M ) X+]JR/];D!K?P@
M
M
M        >%,)_N"V/VBY_('AKA[K#(       !@^0[39')Y1<KM>9R,.IW,M
MFK.Z8N_F9TI6L<RQ._$>DD;T2".)JPJK(WQ^RG3(CN JK=ZL;GL1\(FQ8W8D
ML-N5YV,JQ7IDM6X\?]/,6E'-,USD>]E;TFN=U*OAXKSR#/=8O@Q_R!P7[5D?
MZW(#6_A
M
M                                                           \
M*83_ '!;'[1<_D#PUP]UAD        \E=[^U&KXNGL.SS93&Y'';/<M,:[.Y
MNQC)J63GG7U&59&S+7GCB<V3JJR0H]B-7AZ\=(:Q:OB-QNMXCX5,[1U![)-:
M;%CI,;+'9?>C?#/DZ\J/;/))*Z1KE>KD<KU^YX!,]W<^#'_('!?M61_K<@-;
M^$
M
M                                                     #PIA/\
M<%L?M%S^0/#7#W6&0       #R?L^RY'![Y[SK69QF=JZMDL\Y'VM?SUQ,?+
MFYEFN5Y;.,KS0/=!)RU',5KT3F-_CU.4T[/=[&8[%_!QF8\5E:V;I6U@R3<C
MCXVP47OR.;CMR-K1-5R1PL?*Z../GEK6\+X\A.5H^#'_ "!P7[5D?ZW(#6_A
M
M
M                                                    \*83_<%L
M?M%S^0/#7#W6&0       #S3;W#N9A,QGL9V[3)9C4V9C)NDORZJZY[I9FN3
M27(JLK<E2]Z;%8=*U%]%?+IZG\<A4;W>KX:#X.LX[!Y.7,UK4D=RUD[$"5)I
MLA;SK)[JOK(UB0.2P^5JP]*>GQT_(#E:?@Q_R!P7[5D?ZW(#6_A
M
M
M                                           \*83_ '!;'[1<_D#P
MUP]UAD        \X7?\ R@N8S2]LV[>S4?I;)>\+SK#HUN)=E2ZM!,I_U"1>
MOZG1ZJ]/_P /9X"HCO$FOI\'V>_PVN0=366);:YOGZ6^DESL:WO??)/>/>?5
M]7I]GJYZ?9X!RL_P8_Y X+]JR/\ 6Y :W\(
M
M
M                          'A3"?[@MC]HN?R!X:X>ZPR        >:KF
MH=S,]F,[E.W;;V#U-^7RC):/^*Y*BW+,%R6.W-7A^C;J5$FL,E=PV;S7JZ6\
M\!4;W?EPDGP=YV/ XZ?$UJTD52YCK<WO5B+(UL['#>26PCGI,];+97+-U+ZG
M/5\H,]UH^#'_ "!P7[5D?ZW(#6_A
M
M
M                    \*83_<%L?M%S^0/#7#W6&0       #.LKV/[>Y;)
M7LHZMD*$V4E?9RD&+RV2QM:U-*O,DDL%2Q%&KGJO+W(U%<OBO*A:HGQ08+#Z
MQ\,6QX#7Z46.PU"/&PTZ==O3'&Q,E67P3Y55557*OBJ^*^(,]W[\&/\ D#@O
MVK(_UN0&M_"
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MBLA#':I6HEY9)#*U',<G_%%".Z
M                        \*83_<%L?M%S^0/#7#W6&0        !B'Q>_
MZ>MO_L[^95@N(_X,?\@<%^U9'^MR UOX0
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M&MD17<.:GEY!E<@
M            'A3"?[@MC]HN?R!X:X>ZPR         ,0^+W_3UM_P#9W\RK
M!<1_P8_Y X+]JR/];D!K?P@
M                                                 PN7X5=#5MW&
MT<]LN-T[(SOLWM.HY5T.%E?(O4Y%A]-7]*^'*))\B?,@6MHQ6+Q^#QE/#8FN
MRIB\?#'5I58DX9%#"U&,8U/F1$X".X
M                                                    'A3"?[@M
MC]HN?R!X:X>ZPR         ,0^+W_3UM_P#9W\RK!<1_P8_Y X+]JR/];D!K
M?P@
M
M                                                      >%,)_N
M"V/VBY_('AKA[K#(         Q#XO?\ 3UM_]G?S*L%Q'_!C_D#@OVK(_P!;
MD!K?P@
M
M                                                         >%,
M)_N"V/VBY_('AKA[K#(         Q#XO?]/6W_V=_,JP7$?\&/\ D#@OVK(_
MUN0&M_"
M
M                                                          !X
M4PG^X+8_:+G\@>&N'NL,@        #'?BIQ5W,=@MTJT(UDGBKU[CF)XKZ-*
MW#8E7_[&.-SO_0+B@_!#O&MY'M5#I<5Z-FS8:U:=9QTCD;,^&S*Z9DL;5\7,
M]I6KQY*GCQRG(UZ@"
M
M
M       #K7\A0Q5.;(9.U%2H5VK)8M69&Q0QL3S<Y[U1$1/G50/"':')P=R_
MC5RF\:VCK&OU'9"VEM&JUKJK*2XZ.3VN%1)'/:YJ+X^/EYAKA[X#(
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MUYQWZ>_^J!3[#O>'Z\X[]/?_ %0*?8=[P_7G'?I[_P"J!3[#O>'Z\X[]/?\
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MSCOT]_\ 5 I]AWO#]><=^GO_ *H%/L.]X?KSCOT]_P#5 I]AWO#]><=^GO\
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M;3V<]*+QX-8WE>AC?!.57Q5552;K2 @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
)        #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>sg_davidsandoval-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sg_davidsandoval-bw.jpg
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M_\0 @0 ! 0 " @,!              @&!P0% @,) 0$! 0
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M"@4"@4"@4"@4"@4"@4"@4'!O-ZM&.VN5>[_/8MEGA([LR?,=2PPT@'35:UD
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M"4JZ.EQ.TM6T+6J.$IT^*7=Q<&G3M]O[**IVB% H% H% H% H% H% H% H%
MH% H(6YLBR?)ORDLO",=:Q@. MF=E#S1*=[BPVN2 M(Z*(4S%1K^%96:*N"W
M6Z#:+?$M-L81%ML!EN+#BM#:VTPP@(;0D>P2D "B.30?A 4"D]0>A'W&@D'^
MWX[IA>?P8NHL\;*7S 04Z;4K8:!&I_RI1T]O\:+5?T1Z)LR);H<BX3WD1H,1
MI;\F0ZH(;;::25+6I1Z ) ))H(>L%KN/FSR^]F%];D,^.N$R%1[+;'26A=)J
M0"2H  _J=%O>Z&REL=5*4"KE999C,MQX[:68[*4MM--I"$(0@:)2E(T   T
M%$>= H% H% H% H%!)G-DJ7REY/\9<+-QPO',64G-LA<.JDK4QO+*%I'HD;$
MM]?7O?\ B56=$*!0*"5?*+Q]S/)\IQ_F_AI21RAC*F Y;W%M(3,:C.%;*T%\
MI;[C>Y25I<.CC?3U2 HK-N7N>)_"?#ULR?,H,?\ W/NT9J+#QZ*I3T==Y6T%
M.@*222PRHZJ(5UZ)"M5 T'5^*O",[CZQSN1<[4Y,Y;SO_P"0R"3)'ZT5J0OO
MB+UZA14=[_I\]$Z:(!HBB*!02EY$2)%^\E> <*8CE]N'.DY!( &OP94A04K4
M$:($=9HJK:(4"@\'76F&EO/+2VRVDK<<60E*4I&I))Z  4$7>+$57,7._)7D
M9<&%*MK,@V3%5.+*]B=B6R4Z #5,9#8/M^J?XT5:E$1#E\F9YD<WCCNT/;>#
M>.)29=_N;(44W*>E7:4TAQ*BDA>CC;*@.B XYUU2**MJ/'CQ([42(TAB*PA+
M3##20AM#:!M2E*4Z   : "B/90*!0*!0*!02WSOY5W+&<J/$/"MD.7\K.;D2
M V@R(T)0:4XI(0TK5QY"1N6DD)1^8DZIHKIO'GEKGI?.%[X?YP=BS)ZK.B^,
MB.W':,%92P0TDQT(2I*D/?,*W:+3T5ZZA7M$*!0*!0*!0*!0=7DE^@8MCUVR
M:ZJV6RS0Y%PF*'J&8K2G5Z??HDT$E^ EGGWFT9_S%?D*7>LRO2T"4Z=Q6VQN
M?=4D_8IV0I)_X/NHJR*(4'6Y#=FK#8+K?'R$L6R'(FNJ40E(1&:4X22=0!HF
M@F?P"L-YMO"DN_71U7T^3WJ9<X$8HVI0VD(BK<!]3O6RK[M -*"JJ"4O/#.;
MQ9>.+-QYCI4F\<@W 6Q10K12H;.PNMCH3^HMQI!T_*5#WHK?7$_'MNXJX[Q_
M K:0MJSQ4MR)"1IWY3A+DA[T'XW5+4/L!THC,Z!0*!029Y%^3N56/,8'#/ T
M07ODU]Y NSR8XF-Q K:I+"4Z[>X0=SRUC8TCU^6NPJI;-^[?L]O_ '_L?OOT
MS/[G])N^F^K[:>]VM_RV;]VW=UT]:(YU H%!UF1Y!:L4L-RR6^R$Q;/:H[DR
M;(60D):925'JH@:G30#7J>E!-_A];+QF)S+R*RUI2;_R#/6S9TK)/8LD%7;;
M;;!/1)6G9_!I)]Z*J.B% H%!X//,QV7)$AQ+3#22XZZX0E"$)&I4HGH !U)-
M!#^!H/EOY)3^1+@XI?%'%CS3.+Q0!VY<P.E;3B@KU#BFB^YTUVAI!Z45<=$*
M!02AQ!+/+_E/R%RJTXZ[BN#Q48ACI<)+:I"E?\RXT".@U;=5T]G4ZT55]$*!
M03[YF\C*X]X+O3<*06+[DRD6*V]M6US25J9"DZ=>C"7!J/0D4&6^.'&K/%/#
MN-8L6@W=5QTW&]*'4JN$T!UW4^^S5+0_RH%!J7R"YDOV<Y KQKX)>7)SZZ*+
M&57YDZ1;1;Q\9*%.I"BE8!"75)'P!V)U=4 DK>/#?%&/\,8%;<'Q_P#53&!>
MN-P6D)=F37="Z^O3[3\4)U.U 2G4Z:T1GU H% H% H%!,GEIY$2^-;9%XXX]
M<5)Y=RKML6]N.D.N06)"^TEW:?\ WG5?!A/VZJ/H H,E\9_'BW\(XRY-NRQ<
MN2;^E+^2WA9[JDN*U68S+BOEVTJ)*U>KB_D?RA(8#Q(]'S_S+Y7SF$I3MJQ2
MVQL:COH7N:,@EM#H!'3HN,]T'\:*K2B% H% H% H% H)Q\X\R=Q+Q^O4:*^&
M)N22(UD:.NBU-/J+KZ4CWW,M+2K[C09SXUX<G!>"\'L!"?J/VUN?+*4[?^8N
M1,QP'[2DO;-?NH-JT"@EGS+Y!N+UAMW 6!ZSN2.0W6HRH#/XV;2I9[CBU>B$
MNJ;[9*NG;#BCIMHJ@..\,A<>8+C^$6]9=BV*"S"#QZ%Q;:?FX?O6O<K_ !HC
M)J",//V"_:QQ9R3].M^W8O?%)G;#T >4Q(0/NW?2J&M%6):[E#O-LA7BW.AZ
MWW!AJ7$>'HME] <0H?Q20:(Y= H%!)_._DI?I^2HX+\>&A?.3KBI4:Y7F/M<
MC6M.FCFQS4H[K8ZN.*^#/OJOHDK./&WQMMO!5MGW.Z3Q?^1;]\KY?5!1 25=
MPL,%S5>PK^:UJ^3BM%* T2 1NVY72V6:(N?=YK%O@-_U)4MU##*=?M6X0D?^
M-!IK,?+SQ]PIQ<:;F#%SG(.U4:S(<N)UT)_J,)+0]-.KE!JYW^X!BUPD.,X;
MQYDN0-I/P=0TVWN3M)UVM%\CK17 7Y@<\3%O3;1P!=UV5H(<*W1.4Z&E]=2I
M,,#KUTT%!K+EWR7G\WKLG!F;8^_Q9"NMY@JR>?<W''%MV[4.M MN,LE&Y12O
M58V]$G4)UH/H=9++:\<LUOL%DC(AV>UQVH<"*W^!MAA 0A(_@ *(Y] H% H)
ME\UN5IF%\<,X#C6YW-N0W%6:!'9&YX0W-K<DI .NYSN)81T]5G3J*#:/ W%$
M'ACC&S81&*7)[*#*O4M _KW&0 IY?\!H&T?Y$IH-DT"@GCRRYK>XZQ%K!\/6
MJ5RKG!%KQ^!%4#*81*5V52@D'<#J>VP?=PZC78J@[WB_%<%\6^'(,#*;M"M.
MP?6Y)>)+NU,N[/-A3Q1N.YP@(V-(0G<4H'QUUH-57OS<EY9=UXOX\8'<<XO"
M2=UPE-K8A)0DD%?;1\]GX?DZMKUHKVL\;^;'(:6)^7\CV_C]CN*6FSV-E+K[
M:5$=%K8Z*T'X09*Z#FK\</)#8K9Y$73?H=NL->F[3IKI(]-:"7>1XO/V2\M6
M7B'*Y4;E^Z<>)_>7K3#':;>:4EE]UJ0]LCNN**.T@ZDJ^6T:DF@W7E_F;DN=
M6RV<4\78U,QCFN_RE66XQ[L41T6=X*+:PTMW82[TZ%;:2WU^)5H*"@_'S@&P
M\%XPY%;=%US.[D/Y+D+@/<DOZE00C>2H-(*CM!ZJ.JE=3T(W#0*!0*!0*!08
M5RUR59>(^/[SGE\^<>V-?\M$2H)<DRW2$,LHU(ZJ61KIZ)U5Z"@F_P 0^*\C
MR:]7+R>Y7[<O+<N!>QME2?\ IHCA*2^E!U"-Z$H;C@'XM#U^?0K<7DSS)_LK
MQ?-O]N+;F6W%:;9C41>BBN8_ZN;/5264!3A&FA.U)_%1'#\5N'Y'$'%L:'>E
M=W,,A=-[R)U0.],F2A.U@E74]I "5?Y]Y'K0;OH% H% H% H% H(D\_U"]W?
MB' EZHCWN\/EYW\HU<BQ1]_0/JHJUX\=F*PU%C-I:CL(2TRT@:)0A VI2 /0
M #2B/90:6Y]\CL3X1M(C IO?(-P';L>+1E;Y#CR] A;X1JIMK50TU&Y?HC4Z
MZ!AWC7P=EEJOMTYVYF?5+Y<RI"ML)>A3:X;NW1H $A+A2E*-J3HVV-G\U%4U
M1"@Q'D[CG'>5\)NN"Y.V56VYM;4OHT[T>0CY-/M$] MM6BA['T.H)%!&V(<O
M<J>',E/&/,MAEY#Q=$<4SC&5VYO528ZG2K1"UJV+2 K^@XM+C?X02C;15&X_
MY:^/.10VY;&<P8"EH"UQKGO@O-D_E4'DI!(_RJ-$=NKR4X"2"H\C6'0#4Z36
MB>GW T$D>1_FG#RZ1_MIQ->3:,8FK3'O^>%$@+,=?1Q$5I#?>2@#7>L)WK_"
MG0?)17%X<YRPWC+&Y-C\>^(\@S+(W-C%RRN7'VNS))("5.B*F2IMHJ)+; 6-
MH]25;E$-BN'S\Y2<;;[=HXPL<G]3O)4T)"$@:;5#=,D!1(U_"CU]A0<R!X)(
MR9]5UYJY)ON7W5Y7<=;CN=AE*AT&BI)D*.@^Q*/LTH-R8CXN<"X2N,_9\)@/
M3HPT1,N*57%XJTTWGZE3B0K[TI'W41MJ/&C1&DL1&4,,)_"TTD(0/X!( H,)
MYBY1L7#O']VSF^K3MAMENW1#^.5/=!##"0.IW*'R(_"@*5Z T'S/PS%;GY)Y
M=%Q\-NS^0,FN;E_Y(RN9'W-6BWQE+;8BQ%)6H=M;:@H_AW+[+2=J6U*45]:&
M6FV&FV&D[6FDA"$]3HE(T Z_=1'G0*!0*"(\:@.<X><.1WV[:R\6XI9;8M0:
M>_1:G1UI2R#H.I+_ -0Z1]J "2!I15N40H-4\]<\8KP3B#M\O"T2\@E)4W8+
M"E>U^9(T.FN@)0RD_P!1S30>@U44@A$UJS.9Q[F)YAY6AKS7R7RUIM6&\?LM
M*(LK<DI1'7+: *V75-$?31T N!!U7HMS<DK<.#^,?)',%]A\C^55Z<G--GZJ
MTX''<*(\;N*"NV^E'P:1M2D*::)6KIO<U!!"OK+8;)C=N9M&/6Z-:K7'&UF%
M"91'90/3HAL 41V%!U>37^#BF.7?)[H2+;9H<BX2RG3=V8K2G5Z:^^B>E!\M
M.'N2^0LCRG.'>+K:_.YRY-FNI5=E!(CV6R+<[S[R'==$J4XXA.]2=K:6T[=5
MJ !5;6?P3XQ:XZ<QR_R9,[D"4X9\C.VU%$YJX$ @LA1([*5#JA>JE=25!6A2
M'*X#Y5RW$<J?\<^=)*E9Y;AOQ+)'E*+-\MH!V!+JP"MU(2=%'Y*T4E7ZB#N"
MGZ(4"@4"@4"@AGFM4ORB\D+/P3:75#C[ UF?F,II2D;WTE"9*4K"3HM"5",U
MTZ.*6?2BJPS?.L#X3P8WO(Y+5HQNT,(B6^$WIW'2RWM9BQFM05K*4[4I]@-5
M$)!((G'AS ,J\B,^A>2O,$94''H"DKXVPTJ7L9;96%M3'-0G4;AW$G35U>B^
MC:4)458E$8]GF76_ L,ON9756V#9(3TUSHI6XM()2C1()U4K1/\ C015X<\V
M<O9GS+=[9R!<GIMGRVTOY'"B2%$QXY8D)9;,)!4KM-:=QLMCUVZG4C6BKVHA
M0*!0*!087FW+?&G'/9&;91 LSK[S<9##[H4]W'@5)*FF]RTHT&I6I(2!ZD4$
MI>?H%JN'$7)3#BGX-HNCH(2>Y'5\XTQM2=.A*PPOW^0'W45:2;U:%6=.0&<P
MBQKCIFBXN.)1'$92.X'2XHA(1M.[<3II1$D\A>7>19OD)XQ\6;0O)\F> 2_E
M2FBJ%$&\(4MMMY 04)U&K[Y#8UZ!>H-%99PAXF1\+R9?*G*]X.;\LR5_4F:]
MN<APY!&F]KN *<<2G0(<6E(0--B$Z T13- H% H./.@0;G$=@7*,U,@OIV/Q
M9#:767$^NBD+!!'\103GR[PAXA8?9+AE_(F-6RR17.XO?$=D0GGGE#39%CQ7
M4!:]3T0VWH/4@#4T5(V/\+XUS+/C7^#C\7AK@2"X7$Y)?):U72[ G109?G.%
MM9T2=.V.TUUU+BAH0WTQRIX*\0Q(5GQRT0<DF,M B7 M:+O,4MKH%.2I24@N
M+U)^*]/^$;:#NF?.;%8,+O,\69=%MP3WBXW 8;9"#U*]0X$Z:==:&-B<8^7?
M"7*EVC8]9KP];,BFD(AVN\,F(X\X>@;;<!6RI9/1* YN5[ T1O6@4&/YIF^*
M<=X]*RK,[HS:+%$'ZLI\GY+()2VVA(*G'%:?%" 5'V%! >3L<A>>W(Z!B[*L
M=X:Q-Q<>/=IJ5E)4ZH=Q[MC0.RG$)24L@[6T:!2ANU45;7#W#.$\)8LG&<.B
ME)=*7;I<W]%S)LA*=.X\L =!UV(3HE/L.I)(S.=?++:]YN=RBP@VD+<^I?;9
MVI/H3O4-!0<J+*C38[<N$\W(BO)WM/LJ#C:TGW2I)((_A0>V@4"@C#P!;:?/
M+5X<T5<)>0(0^Z--"E/?<&@'I\G%46K!B7JSSY<B!!N$:5.B?]7%8>;<>:UZ
M?J(2HE/^(HC37/?DYB/"\<62&C_4?)D[8W:<5ADK=[CYVMKD% 44))TVH [B
M^@2-"5 )IO."YKQS@E_\LN;5_NW,\H,HQ*Q3&DNQ+*],<2U'><97JCN,)45M
M,D;6B!NW.'XE;@\,>'(-GQ%CFS)WI%YY+SII<Y^YW'5;T>(^XHI#:EE2E*?
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M2G"RT-RU%1"2&_O+3F[@J\\;SN$L>6O)<F;,5BQ1K&WWX\"9$4E+.C_5"M$
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M+%K5'L>-VV-:;/%3MCP832&&4#[D( &I]S[T'94"@4"@4$8^24ZZ>0/,6/\
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M0*!0*!0*!0*!0*!0*!0*!0=#E7_30?\ ZO\ ZYC_ .Y_I?F_H_\ [_\ \?\
MC0=]0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
/!0*!0*!0*!0*!0*!0?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
